{"id":435,"date":"2022-04-04T11:28:23","date_gmt":"2022-04-04T02:28:23","guid":{"rendered":"https:\/\/sumsuro.jp\/wp_sumsuro\/?page_id=435"},"modified":"2023-10-25T12:16:45","modified_gmt":"2023-10-25T03:16:45","slug":"academic_paper","status":"publish","type":"page","link":"https:\/\/sumsuro.jp\/wp_sumsuro\/performance\/academic_paper\/","title":{"rendered":"\u5b66\u8853\u8ad6\u6587"},"content":{"rendered":"
\n

2022\u5e74<\/em><\/h2>\n
    \n
  1. \u03b3-Glutamylcyclotransferase, a novel regulator of HIF-1\u03b1 expression, triggers aerobic glycolysis.\tTaniguchi K, Kageyama S, Moyama C, Ando S, Ii H, Ashihara E, Horinaka M, Sakai T, Kubota S, Kawauchi A, Nakata S.\tCancer Gene Ther. \tJan;29(1):37-48<\/li>\n
  2. Fluorizoline Blocks the Interaction between Prohibitin-2 and \u03b3-Glutamylcyclotransferase and Induces p21 Waf1\/Cip1 Expression in MCF7 Breast Cancer Cells.\tTakagi H, Moyama C, Taniguchi K, Ando K, Matsuda R, Ando S, Ii H, Kageyama S, Kawauchi A, Chouha N, D\u00e9saubry L, Nakata S.\tMol Pharmacol.\tFeb;101(2):78-86<\/li>\n
  3. Application of the indocyanine green fluorescence imaging method in laparoscopic resection of a solitary retroperitoneal metastasis of renal cell carcinoma: A case report.\tKim CJ, Nishida M, Hanada E, Kageyama S, Narita M, Kawauchi A.\tAsian J Endosc Surg. \tJan;15(1):172-175<\/li>\n
  4. Regeneration of Functional Bladder Using Cell-seeded Amnion and P(LA\/CL) Scaffolds.\tHorii T, Jonin K, Kageyama S, Yoshida T, Kobayashi K, Minato H, Ueda J, Tsujimoto H, Hagiwara A, Ichikawa H, Kawauchi A.\tTissue Eng Part A.\tDec;28(23-24):968-976.<\/li>\n
  5. Administration of Gapmer-type Antisense Oligonucleotides Targeting \u03b3-Glutamylcyclotransferase Suppresses the Growth of A549 Lung Cancer Xenografts.\tIi H, Kasahara Y, Yamaguma H, Kageyama S, Kawauchi A, Obika S, Nakata S.\tAnticancer Res. \t Mar;42(3):1221-1227.<\/li>\n
  6. The \u03b3-Glutamylcyclotransferase Inhibitor Pro-GA Induces an Antiproliferative Effect Through the Generation of Mitochondrial Reactive Oxygen Species.\tIi H, Taniguchi K, Yoshiya T, Nohara Y, Kageyama S, Kawauchi A, Nakata S.\tAnticancer Res. \tSep;42(9):4311-4317.<\/li>\n
  7. Transcriptome analysis of a dog model of congestive heart failure shows that collagen-related 2-oxoglutarate-dependent dioxygenases contribute to heart failure.\tIsono T, Matsumoto T, Suzaki M, Kubota S, Kageyama S, Kawauchi A, Wada A.\tSci Rep.\tDec 29;12(1):22569.<\/li>\n
  8. Androgen receptor axis-targeted agents are not superior to conventional hormonal therapy for treatment of metastatic prostate cancer.\tWada A, Narita M, Nagasawa M, Kusaba T, Kubota S, Yoshida T, Johnin K, Kawauchi A, Kageyama S.\tOncol Lett.\tAug 9;24(4):333.<\/li>\n
  9. Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRAS\u2011activated pancreatic cancer cells.\tTerado T, Kim CJ, Ushio A, Minami K, Tambe Y, Kageyama S, Kawauchi A, Tsunoda T, Shirasawa S, Tanaka H, Inoue H.\tInt J Oncol. \tSep;61(3):108.<\/li>\n
  10. Prognostic nutritional index of early post-pembrolizumab therapy predicts long-term survival in patients with advanced urothelial carcinoma.\tKageyama S, Yoshida T, Kobayashi K, Wada A, Nagasawa M, Kubota S, Kusaba T, Jo F, Nakagawa S, Johnin K, Narita M, Kawauchi A.\tOncol Lett. \tDec 15;25(2):49.<\/li>\n
  11. Population\u2011based prostate\u2011specific antigen screening for prostate cancer may have an indirect effect on early detection through opportunistic testing in Kusatsu City, Shiga, Japan.\tKageyama S, Okinaka Y, Nishizawa K, Yoshida T, Ishitoya S, Shichiri Y, Kim CJ, Iwata T, Yokokawa R, Arai Y, Nishikawa Z, Soga H, Ushida H, Sakano Y, Naya Y, Wada A, Nagasawa M, Yoshida T, Narita M, Kawauchi A.\tMol Clin Oncol.\tNov 23;18(1):3.<\/li>\n
  12. 3D proximal tubule-on-chip model derived from kidney organoids with improved drug uptake.\tAceves JO, Heja S, Kobayashi K, Robinson SS, Miyoshi T, Matsumoto T, Sch\u00e4ffers OJM, Morizane R, & Lewis JA\tSci Rep\t12(1), 14997.<\/li>\n
  13. Live functional assays reveal longitudinal maturation of transepithelial transport in kidney organoids.\tRizki-Safitri A, Gupta N, Hiratsuka K, Kobayashi K, Zhang C, Ida K, Satlin LM,& Morizane R. \tFront Cell Dev Biol\t10, 978888.<\/li>\n
  14. Developments in personalized therapy for metastatic renal cell carcinoma.\tFujiwara R, Kageyama S, Yuasa T.\tExpert Rev Anticancer Ther. \tJun;22(6):647-655.<\/li>\n<\/ol>\n

    2021\u5e74<\/em><\/h2>\n
      \n
    1. Venous malformation of the glans penis: “Every-5-mm” neodymium:yttrium-aluminum-garnet laser irradiation.\tJohnin K, Mori Y, Nakagawa S, Kobayashi K, Kageyama S, Kawauchi A.\tInt J Urol. \t28(11):1189-1191<\/li>\n
    2. Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth.\tRahman NIA, Sato A, Tsevelnorov K, Shimizu A, Komeno M, Ahmat Amin MKB, Molla MR, Soh JEC, Nguyen LKC, Wada A, Kawauchi A, Ogita H.\tCancer Res. \tMay 1;81(9):2318-2331<\/li>\n
    3. Cryptotanshinone, a novel PDK 4 inhibitor, suppresses bladder cancer cell invasiveness via the mTOR\/\u03b2\u2011catenin\/N\u2011cadherin axis\tKim CJ, Terado T, Tambe Y, Mukaisho KI, Kageyama S, Kawauchi A, Inoue H.\tInt J Oncol. \tJul;59(1):40<\/li>\n
    4. Single Short Retention Instillation of Pirarubicin Prevents Intravesical Recurrence of Low-risk Non Muscle Invasive Bladder Cancer.\tKageyama S, Maeda K, Kubota S, Yoshida T, Osafune T, Arai Y, Soga H, Nishikawa Z, Sakano Y, Takimoto K, Kim CJ, Chano T, Kawauchi A.\tIn Vivo. \tMar-Apr;35(2):1141-1145<\/li>\n
    5. Robot-assisted partial nephrectomy versus standard laparoscopic partial nephrectomy for renal hilar tumor: A prospective multi-institutional study\tHinata N, Shiroki R, Tanabe K, Eto M, Takenaka A, Kawakita M, Hara I, Hongo F, Ibuki N, Nasu Y, Teishima J, Kawai N, Kawauchi A, Kondo T, Kawamorita N, Oyama C, Horie S, Shimbo M, Kato M, Kanayama H, Koito Y, Fujisawa M; Japanese Society of Endourology.\tInt J Urol. \tApr;28(4):382-389.<\/li>\n
    6. Differences in the Central Energy Metabolism of Cancer Cells between Conventional 2D and Novel 3D Culture Systems\tIkari R, Mukaisho KI, Kageyama S, Nagasawa M, Kubota S, Nakayama T, Murakami S, Taniura N, Tanaka H, Kushima RP, Kawauchi A.\tInt J Mol Sci. \tFeb 11;22(4):1805<\/li>\n
    7. Effects of Fiber Diameter and Spacing Size of an Artificial Scaffold on the In Vivo Cellular Response and Tissue Remodeling.\tHorii T, Tsujimoto H, Hagiwara A, Isogai N, Sueyoshi Y, Oe Y, Kageyama S, Yoshida T, Kobayashi K, Minato H, Ueda J, Ichikawa H, Kawauchi A.\tACS Appl Bio Mater. \tSep 20;4(9):6924-6936<\/li>\n
    8. Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients\tKoide H, Noda S, Yoshida T, Kageyama S, Teramura K, Kato T, Kawauchi A, Fujimoto N, Terada T.\tIn Vivo. \tSep-Oct;35(5):2969-2974<\/li>\n
    9. Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer: A Case Report\tKubota S, Kageyama S, Nagasawa M, Wada A, Ikari R, Tomita K, Yoshida T, Narita M, Kawauchi A.\tAm J Case Rep.  \tJul 5;22:e930989<\/li>\n
    10. Clinical, pathological, and therapeutic features of newly diagnosed prostate cancer predominantly detected by opportunistic PSA screening: A survey of Shiga Prefecture, Japan\tOkinaka Y, Kageyama S, Nishizawa K, Yoshida T, Ishitoya S, Shichiri Y, Kim CJ, Iwata T, Yokokawa R, Arai Y, Nishikawa Z, Soga H, Ushida H, Sakano Y, Naya Y, Yoshida T, Narita M, Kawauchi A.\tProstate.\tNov;81(15):1172-1178<\/li>\n<\/ol>\n

      2020\u5e74<\/em><\/h2>\n
        \n
      1. Fujiwara R, Inamura K, Yuasa T, Numao N, Yamamoto S, Masuda H, Kawauchi A, Takeuchi K, Yonese J: Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer.. Int J Clin Oncol. 2020 25\uff081\uff09\uff1a151-157.<\/li>\n
      2. Yoshida T, Okinaka Y, Tomita K, Tsuru T, Kageyama S, Narita M, Kawauchi A: Off-clamp tumor excision using soft coagulation in laparoscopic and robotic partial nephrectomy. Asian J Endosc Surg. 2020 13\uff084\uff09\uff1a519-525.<\/li>\n
      3. Nagasawa M, Tomimatsu K, Terada K, Kondo K, Miyazaki K, Miyazaki M, Motooka D, Okuzaki D, Yoshida T, Kageyama S, Kawamoto H, Kawauchi A, Agata Y.: Long non-coding RNA MANCR is a target of BET bromodomain protein BRD4 and plays a critical role in cellular migration and invasion abilities of prostate cancer.. Biochem Biophys Res Commun. 2020. 21;52\uff081\uff09\uff1a128-134.<\/li>\n
      4. Kohno M, Ogawa T, Kojima Y, Sakoda A, Johnin K, Sugita Y, Nakane A, Noguchi M, Moriya K, Hattori M, Hayashi Y, Kubota M: Pediatric congenital hydronephrosis (ureteropelvic junction obstuction):Medical management guide. Int J Urol. 2020 27:369-376.<\/li>\n
      5. Masugi-Tokita M, Tomita K, Kobayashi K, Yoshida T, Kageyama S, Sakamoto H, Kawauchi A: Metabotropic Glutamate Receptor Subtype 7 Is Essential for Ejaculation. Mol Neurobiol. 2020 57\uff0812\uff09\uff1a5208-5218.<\/li>\n
      6. Horii T, Tsujimoto H, Kageyama S, Yoshida T, Kobayashi K, Takamori H, Minato H, Ueda J, Hagiwara A, Ichikawa H, Kawauchi A: The usefulness of reattachability of anti-adhesive cross-linked gelatin film and the required physical and biological properties. Biomed Mater Eng. 2020 31\uff086\uff09\uff1a351-360.<\/li>\n
      7. Kubota S, Yoshida T, Kageyama S, Isono T, Yuasa T, Yonese J, Kushima R, Kawauchi A, Chano T: A risk stratification model based on four novel biomarkers predicts prognosis for patients with renal cell carcinoma. World J Surg Oncol. 2020 18\uff081\uff09\uff1a270.<\/li>\n
      8. Nev\u00e9us T, Fonseca E, Franco I, Kawauchi A, Kovacevic L, Nieuwhof-Leppink A, Raes A, Tekgu\u0308l S, Yang SS, Rittig S: Management and treatment of nocturnal enuresis-an updated standardization document from the International Children’s Continence Society. J Pediatr Urol. 2020 16\uff081\uff09\uff1a10-19.<\/li>\n
      9. \u91d1\u5d0e\u96c5\u7f8e\u3001\u8352\u6728\u4fe1\u4e00\u3001\u6c5f\u53e3 \u8c4a\u3001\u5ca9\u57ce\u79c0\u51fa\u6d19\u3001\u79cb\u5ca1\u6e05\u4e00\u3001\u9580 \u6d69\u5fd7\u3001\u524d\u7530\u54b2\u5f25\u5b50\u3001 \u65b0\u4e95 \u8c4a\u3001\u897f\u5c3e\u5229\u6a39\u3001\u6709\u6751\u54f2\u6717\u3001\u7912\u91ce\u5143\u79c0\u3001\u897f\u6751\u6b63\u5b5d\u3001\u4e00\u8272\u5553\u4e8c\u3001\u66fd\u6211\u5f18\u6a39\u3001\u8c37\u53e3\u6b63\u5c55: \u6ecb\u8cc0\u770c\u306e\u6162\u6027\u900f\u6790\u7642\u6cd5\u306e\u73fe\u6cc1\uff0e\u6ecb\u8cc0\u533b\u5b66. 2020 42\uff1a13-19.<\/li>\n
      10. \u6c38\u6fa4\u8aa0\u4e4b\u3001\u6210\u7530\u5145\u5f18\u3001\u548c\u7530\u6643\u5178\u3001\u5bcc\u7530\u572d\u53f8\u3001\u5409\u7530\u54f2\u4e5f\u3001\u5f71\u5c71 \u9032\u3001\u6cb3\u5185\u660e\u5b8f\uff1a\u5f53\u9662\u306b\u304a\u3051\u308bN1\u524d\u7acb\u817a\u764c\u306b\u5bfe\u3059\u308b\u5c40\u6240\u6cbb\u7642\u306e\u6cbb\u7642\u52b9\u679c. \u6ccc\u5c3f\u5668\u5916\u79d1\uff0e2020 33\uff088\uff09\uff1a1071-1073.<\/li>\n<\/ol>\n

        2019\u5e74<\/em><\/h2>\n
          \n
        1. Kobayashi K, Tsukiyama T, Nakaya M, Kageyama S, Tomita K, Murai R, Yoshida T, Narita M, Kawauchi A, Ema M: A Generation of an OCT3\/4 reporter cynomolgus monkey ES cell line using CRISPR\/Cas9. Stem Cell Res. 2019 37:101439. doi: 10.1016\/j.scr.2019.101439.<\/li>\n
        2. Tsukiyama T, Kobayashi K, Nakaya M, Iwatani C, Seita Y, Tsuchiya H, Matsushita J, Kitajima K, Kawamoto I, Nakagawa T, Fukuda K, Iwakiri T, Izumi H, Itagaki I, Kume S, Maegawa H, Nishinakamura R, Nishio S, Nakamura S, Kawauchi A, Ema M: Monkeys mutant for PKD1 recapitulate human autosomal dominant polycystic kidney disease. Nat Commun. 2019 10(1):5517. doi: 10.1038\/s41467-019-13398-6<\/li>\n
        3. Johnin K, Kobayashi K, Tsuru T, Yoshida T, Kageyama S, Kawauchi A: Pediatric voiding cystourethrography: An essential examination for urologists but a terrible experience for children. Int J Urol. 2019 26(2):160-171.<\/li>\n
        4. Taniguchi K, Ii H, Kageyama S, Takagi H, Chano T, Kawauchi A, Nakata S: Depletion of gamma-glutamylcyclotransferase inhibits cancer cell growth by activating the AMPK-FOXO3a-p21 axis. Biochem Biophys Res Commun. 2019 517(2):238-243.<\/li>\n
        5. Seita Y, Tsukiyama T, Azami T, Kobayashi K, Iwatani C, Tsuchiya H, Nakaya M, Tanabe H, Hitoshi S, Miyoshi H, Nakamura S, Kawauchi A, Ema M: Comprehensive evaluation of ubiquitous promoters suitable for the generation of transgenic cynomolgus monkeys\u2020. Biol Reprod. 2019 100(6):1440-1452.<\/li>\n
        6. Takagi H, Ii H, Kageyama S, Hanada E, Taniguchi K, Yoshiya T, Chano T, Kawauchi A, Nakata S: Blockade of \u03b3-Glutamylcyclotransferase Enhances Docetaxel Growth Inhibition of Prostate Cancer Cells. Anticancer Res. 2019 39(9):4811-4816.<\/li>\n
        7. Hanada E, Kageyama S, Murai R, Kubota S, Ii H, Nakata S, Kita H, Kawauchi A, Chano T: Pro-GA, a Novel Inhibitor of \u03b3-Glutamylcyclotransferase, Suppresses Human Bladder Cancer Cell Growth. Anticancer Res. 2019 39(4):1893-1898.<\/li>\n
        8. Noda S, Yoshida T, Hira D, Murai R, Tomita K, Tsuru T, Kageyama S, Kawauchi A, Ikeda Y, Morita SY, Terada T: Exploratory Investigation of Target Pazopanib Concentration Range for Patients With Renal Cell Carcinoma. Clin Genitourin Cancer. 2019 17(2):e306-e313.<\/li>\n
        9. Wada A, Terashima T, Kageyama S, Yoshida T, Narita M, Kawauchi A, Kojima H: Efficient Prostate Cancer Therapy with Tissue-Specific Homing Peptides Identified by Advanced Phage Display Technology. Mol Ther Oncolytics. 2019 12:138-146.<\/li>\n
        10. Isono T, Chano T, Yoshida T, Makino A, Ishida S, Suzaki M, Kageyama S, Kawauchi A, Yonese J, Yuasa T: ADP-ribosylation factor-like 4C is a predictive biomarker of poor prognosis in patients with renal cell carcinoma. Am J Cancer Res. 2019 9(2):415-423.<\/li>\n
        11. Nagasawa M, Kageyama S, Yoshida T, Okinaka Y, Kubota S, Wada A, Kobayashi K, Tomita K, Murai R, Tsuru T, Johnin K, Narita M, Kawauchi A: Changes in renal function following nedaplatin-containing chemotherapy in patients with urothelial carcinoma unfit for cisplatin. Oncol Lett. 2019 17(2):2551-2556.<\/li>\n
        12. Maeda K, Kageyama S, Osafune T, Masuda Y, Nakagawa S, Miki K, Esumi S, Kakita-Kobayashi M, Yoshida T, Narita M, Kawauchi A: Syndrome of inappropriate antidiuretic hormone secretion as a side effect of chemotherapy for testicular cancer: A case report. IJU Case Rep. 2019 2(6):327-329.<\/li>\n
        13. Tambe Y, Terado T, Kim CJ, Mukaisho K, Yoshida S, Sugihara H, Tanaka H, Chida J, Kido H, Yamaji K, Yamamoto T, Nakano H, Omura S, Inoue H: Antitumor activity of potent pyruvate dehydrogenase kinase 4 inhibitors from plants in pancreatic cancer. Mol Carcinog. 2019 58:1726-1737.<\/li>\n
        14. \u91d1\u3000\u54f2\u5c07\u3001\u897f\u7530\u5c06\u6210\u3001\u82b1\u7530\u82f1\u7d00\u3001\u7aaa\u7530\u6210\u5bff\uff1a\u7d4c\u5c3f\u9053\u7684\u524d\u7acb\u817a\u5207\u9664\u8853\u75c7\u4f8b\u306b\u304a\u3051\u308b\u810a\u690e\u9ebb\u9154\u4e0b\u8180\u80f1\u5bb9\u91cf\u3068\u4e0b\u90e8\u5c3f\u8def\u75c7\u72b6\u306e\u95a2\u4fc2. \u7532\u8cc0\u75c5\u7d00. 2019 22:1-5.<\/li>\n
        15. \u524d\u7530\u822a\u898f\u3001\u9577\u8239\u3000\u5d07\u3001\u76ca\u7530\u826f\u8ce2\u3001\u7af9\u7530\u9686\u4e4b\u3001\u5f71\u5c71\u3000\u9032\u3001\u6210\u7530\u5145\u5f18\u3001\u6cb3\u5185\u660e\u5b8f\uff1a\u30d3\u30ab\u30eb\u30bf\u30df\u30c9\u3068\u9162\u9178\u30ea\u30e5\u30fc\u30d7\u30ed\u30ec\u30ea\u30f3\u306b\u3088\u308b\u8907\u5408\u30a2\u30f3\u30c9\u30ed\u30b2\u30f3\u906e\u65ad\u7642\u6cd5\u4e2d\u306b\u85ac\u5264\u6027\u80ba\u969c\u5bb3\u3092\u304d\u305f\u3057\u305f\u524d\u7acb\u817a\u764c\u306e1\u4f8b. \u65e5\u6ccc\u4f1a\u8a8c. 2019 110(1):36-40.<\/li>\n
        16. \u524d\u7530\u822a\u898f\u3001\u65b0\u4e95\u3000\u8c4a\u3001\u897f\u7530\u5c06\u6210\u3001\u4f50\u85e4\u3000\u4e98\u3001\u5f71\u5c71\u3000\u9032\u3001\u6210\u7530\u5145\u5f18\u3001\u6cb3\u5185\u660e\u5b8f\uff1a\u5c3f\u7ba1\u30b9\u30c6\u30f3\u30c8\u7559\u7f6e\u3067\u8efd\u5feb\u3057\u305f\u5c3f\u7ba1\u5ea7\u9aa8\u30d8\u30eb\u30cb\u30a2\u306e1\u4f8b. \u65e5\u6ccc\u4f1a\u8a8c. 2019 110(2):144-147.<\/li>\n
        17. \u6c38\u6fa4\u8aa0\u4e4b\u3001\u6210\u7530\u5145\u5f18\u3001\u5c0f\u6797\u61b2\u5e02\u3001\u5bcc\u7530\u572d\u53f8\u3001\u6751\u4e95\u4eae\u4ecb\u3001\u6c34\u6d41\u8f1d\u5f66\u3001\u5409\u7530\u54f2\u4e5f\u3001\u5f71\u5c71\u3000\u9032\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u6cb3\u5185\u660e\u5b8f\uff1a\u30ed\u30dc\u30c3\u30c8\u652f\u63f4\u4e0b\u524d\u7acb\u817a\u5168\u6458\u9664\u8853\u306e\u795e\u7d4c\u6e29\u5b58\u304c\u8853\u5f8c\u5c3f\u7981\u5236\u306b\u4e0e\u3048\u308b\u5f71\u97ff\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u6ccc\u5916. 2019 32(8):1057-1060.<\/li>\n
        18. \u5c0f\u6797\u61b2\u5e02\u3001\u4f50\u85e4\u3000\u4e98\u3001\u4e2d\u5ddd\u7fd4\u592a\u3001\u5c71\ufa11\u53cb\u8389\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u6cb3\u5185\u660e\u5b8f\uff1a\u4e21\u5074\u8180\u80f1\u5c3f\u7ba1\u9006\u6d41\u306b\u5bfe\u3059\u308b\u8179\u8154\u93e1\u4e0b\u8180\u80f1\u5185\u624b\u8853\u8853\u5f8c\u306b\u85ac\u5264\u6027\u814e\u969c\u5bb3\u306b\u3088\u308b\u6025\u6027\u814e\u4e0d\u5168\u3092\u5448\u3057\u305f1\u4f8b. \u65e5\u5c0f\u5150\u6ccc\u4f1a\u8a8c. 2019 28(1):34-37.<\/li>\n<\/ol>\n

          2018\u5e74<\/em><\/h2>\n
            \n
          1. Ii H, Yoshiya T, Nakata S, Taniguchi K, Hidaka K, Tsuda S, Mochizuki M, Nishiuchi Y, Tsuda Y, Ito K, Kageyama S, Yoshiki T: A Novel Prodrug of a \u03b3-Glutamylcyclotransferase Inhibitor Suppresses Cancer Cell Proliferation in\u2005vitro and Inhibits Tumor Growth in a Xenograft Mouse Model of Prostate Cancer. ChemMedChem. 2018 13(2):155-163.<\/li>\n
          2. Johnin K, Takahashi K, Kawauchi A: Daikenchuto prevention of postoperative ileus after retroperitoneal lymph node dissection in advanced childhood testicular yolk sac tumor. Tradit Kampo Med. 2018 5(2): DOI: 10.1002\/tkm2.1091.<\/li>\n
          3. Inoue T, Miyazaki J, Ichioka D, Narita S, Kageyama S, Sugimoto M, Mitsuzuka K, Shiraishi Y, Kinoshita H, Wakede H, Nomoto T, Kikuchi E, Matsui Y, Fujie K, Habuchi T, Nishiyama H: A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study. BMC cancer. 2018 18(1):290. doi: 10.1186\/s12885-018-4186-z<\/li>\n
          4. Taniguchi K, Matsumura K, Ii H, Kageyama S, Ashihara E, Chano T, Kawauchi A, Yoshiki T, Nakata S: Depletion of gamma-glutamylcyclotransferase in cancer cells induces autophagy followed by cellular senescence. Am J Cancer Res. 2018 8(4):650-661.<\/li>\n
          5. Taniguchi K, Matsumura K, Kageyama S, Ii H, Ashihara E, Chano T, Kawauchi A, Yoshiki T, Nakata S: Prohibitin-2 is a novel regulator of p21WAF1\/CIP1 induced by depletion of \u03b3-glutamylcyclotransferase. Biochem Biophys Res Commun. 2018 496(1):218-224.<\/li>\n
          6. Kageyama S, Yoshida T, Nagasawa M, Kubota S, Tomita K, Kobayashi K, Murai R, Tsuru T, Hanada E, Johnih K, Narita M, Kawauchi A. The location of the bladder neck in postoperative cystography predicts continence convalescence after radical prostatectomy. BMC Urol. 2018 18(1):52. doi: 10.1186\/s12894-018-0370-3.<\/li>\n
          7. Kageyama S, Ii H, Taniguchi K, Kubota S, Yoshida T, Isono T, Chano T, Yoshiya T, Ito K, Yoshiki T, Kawauchi A, Nakata S: Mechanisms of Tumor Growth Inhibition by Depletion of \u03b3-Glutamylcyclotransferase (GGCT): A Novel Molecular Target for Anticancer Therapy. Int J Mol Sci. 2018 19(7). E2054. doi: 10.3390\/ijms19072054.<\/li>\n
          8. Yoshida T, Kageyama S, Isono T, Yuasa T, Kushima R, Kawauchi A, Chano T: Superoxide dismutase 2 expression can predict prognosis of renal cell carcinoma patients. Cancer Biomark. 2018 22(4):755-761<\/li>\n
          9. Baba M, Kageyama S, Yoshida T, Fujiwara R, Kim CJ, Takimoto K, Nagasawa M, Soga H, Nagatani Y, Nishikawa Z, Kawauchi A: Intravesical bacillus Calmette-Guerin therapy after second transurethral resection for primary T1 bladder cancer. Int J Clin Oncol. 2018 23(5):951-956.<\/li>\n
          10. Murai R, Itoh Y, Kageyama S, Nakayama M, Ishigaki H, Teramoto K, Narita M, Yoshida T, Tomita K, Kobayashi K, Wada A, Nagasawa M, Kubota S, Ogasawara K, Kawauchi A: Prediction of intravesical recurrence of non-muscle-invasive bladder cancer by evaluation of intratumoral Foxp3+ T cells in the primary transurethral resection of bladder tumor specimens. PLoS One. 2018 13(9): e0204745. doi: 10.1371\/journal.pone.0204745.<\/li>\n
          11. Ahmat Amin MKB, Shimizu A, Zankov DP, Sato A, Kurita S, Ito M, Maeda T, Yoshida T, Sakaue T, Higashiyama S, Kawauchi A, Ogita H: Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and Rac1. Oncogene. 2018 37(40):5416-5434.<\/li>\n
          12. Isono T, Chano T, Yoshida T, Kageyama S, Kawauchi A, Yonese J, Yuasa T: Abundance of TRAIL attenuated by HIF2\u03b1 and c-FLIP affects malignancy in renal cell carcinomas\uff0eOncotarget. 2018 9(33):23091-23101.<\/li>\n
          13. Narita M, Kageyama S, Okegawa T, Kinoshita H, Sato F, Nakagawa K, Habuchi T, Hoshi A, Matsubara A, Yoshimura K, Terachi T, Mimata H, Kawauchi A: Urological laparoendoscopic single-site and reduced port surgery: A nationwide survey in Japan. Int J Urol. 2018 25(3):263-268.<\/li>\n
          14. Kim CJ, Terado T, Tambe Y, Mukaisho K, Sugihara H, Kawauchi A, Inoue H: Anti-oncogenic activities of cyclin D1b siRNA on human bladder cancer cells via induction of apoptosis and suppression of cancer cell stemness and invasiveness. Int J Oncol. 2018 52(1):231-240.<\/li>\n
          15. \u725b\u7530\u3000\u535a\uff1a\u533b\u9662\u304b\u3089\u75c5\u9662\u3078\u3000\u75c5\u9662\u304b\u3089\u533b\u9662\u3078\u3000396.\u201c\u814e\u6a5f\u80fd\u4f4e\u4e0b\u306e\u843d\u3068\u3057\u7a74\u201d\u524d\u7acb\u817a\u764c\u306e\u4e21\u5074\u5c3f\u7ba1\u8ee2\u79fb\u304c\u8981\u56e0\u306e\u814e\u5f8c\u6027\u814e\u4e0d\u5168\u306e1\u4f8b. \u5927\u6d25\u5e02\u533b\u5e2b\u4f1a\u8a8c. 2018 41(3):7-10.<\/li>\n
          16. \u6751\u4e95\u4eae\u4ecb\u3001\u5f71\u5c71\u3000\u9032\u3001\u4f0a\u85e4\u3000\u9756\u3001\u77f3\u57a3\u5b8f\u4ec1\u3001\u5bfa\u672c\u548c\u96c4\u3001\u5409\u7530\u54f2\u4e5f\u3001\u5bcc\u7530\u572d\u53f8\u3001\u5c0f\u6797\u61b2\u5e02\u3001\u548c\u7530\u6643\u5178\u3001\u6c38\u6fa4\u8aa0\u4e4b\u3001\u7aaa\u7530\u6210\u5bff\u3001\u5c0f\u7b20\u539f\u4e00\u8aa0\u3001\u6cb3\u5185\u660e\u5b8f\uff1a\u6b63\u6240\u6027\u8180\u80f1\u764c\u30e2\u30c7\u30eb\u30e9\u30c3\u30c8\u3092\u7528\u3044\u305f\uff22\uff23\uff27\u8180\u80f1\u6ce8\u5165\u7642\u6cd5\u306b\u3088\u308b\u5168\u8eab\u6027\u514d\u75ab\u5fdc\u7b54\u304a\u3088\u3073\u5236\u5fa1\u6027\uff34\u7d30\u80de\u306e\u691c\u8a0e. \u6ccc\u5916. 2018 31(4):403-404.<\/li>\n
          17. \u91d1\u3000\u54f2\u5c07\u3001\u7aaa\u7530\u6210\u5bff\u3001\u798f\u5c71\u4f73\u4ee3\u3001\u5927\u6751\u3000\u5be7\u3001\u82b1\u7530\u82f1\u7d00\u3001\u6cb3\u5185\u660e\u5b8f\uff1a\u539f\u767a\u6027\u30a2\u30eb\u30c9\u30b9\u30c6\u30ed\u30f3\u75c7\u3068\u30af\u30c3\u30b7\u30f3\u30b0\u75c7\u5019\u7fa4\u5408\u4f75\u4f8b\u306b\u8179\u8154\u93e1\u4e0b\u526f\u814e\u90e8\u5206\u5207\u9664\u3092\u65bd\u884c\u3057\u305f1\u4f8b. \u6ccc\u7d00. 2018 64(6):265-269.<\/li>\n
          18. \u725b\u7530\u3000\u535a\u3001\u690d\u6751\u7950\u4e00\u3001\u77f3\u6238\u8c37\u3000\u54f2\u3001\u5927\u897f\u88d5\u4e4b\uff1a\u814e\u76c2\u764c\u8853\u5f8c\u306b\u767a\u75c7\u3057\u305f\u6297\u5229\u5c3f\u30db\u30eb\u30e2\u30f3\u4e0d\u9069\u5408\u5206\u6ccc\u75c7\u5019\u7fa4\uff08SIADH)\u306e1\u4f8b. \u6ccc\u5916. 2018 31(11):1561-1565.<\/li>\n<\/ol>\n

            2017\u5e74<\/em><\/h2>\n
              \n
            1. Sato F, Nakagawa K, Kawauchi A, Matsubara A, Okegawa T, Habuchi T, Yoshimura K, Hoshi A, Kinoshita H, Miyajima A, Naitoh Y, Inoue S, Itaya N, Narita S, Hanai K, Okubo K, Yanishi M, Matsuda T, Terachi T, Mimata H: Laparoendoscopic single-site surgeries: A multicenter experience of 469 case in Japan. Int J Urol. 2017 24(1):69-74.<\/li>\n
            2. Chang SJ, Van Laecke E, Bauer SB, von Gontard A, Bagli D, Bower WF, Renson C, Kawauchi A, Yang SS: Treatment of daytime urinary incontinence: A standardization document from the international Children’s Continece. Neurourol Urodyn. 2017 36(1):43-50.<\/li>\n
            3. Kim CJ, Tambe Y, Mukaisyo K, Sugihara H, Kageyama S, Kawauchi A, Inoue H: Periostin suppresses in vivo invasiveness via PDK1\/Akt\/mTOR signaling pathway in a mouse orthotopic model of bladder cancer. Oncolngy letters. 2017 13(6):4276-4284.<\/li>\n
            4. Tomita K, Kageyama S, Hanada E, Yoshida T, Okinaka Y, Kubota S, Nagasawa M, Johnin K, Narita M, Kawauchi A: Indocyanine Grenn Angiography-assisted Laparoendoscopic Single-site Varicocelectomy. Urology. 2017 106:221-225.<\/li>\n
            5. Homma Y, Gotoh M, Kawauchi A, Kojima Y, Masumori N, Nagai A, Saitoh T, Sakai H, Takahashi S, Ukimura O, Yamanishi T, Yokoyama O, Yoshida M, Maeda K: Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol. 2017 24(10):716-729<\/li>\n
            6. Ushida H, Goto H, Ishitoya S, Onishi H: Left Adrenal Tumor Disappeared Outside a Field of Vision During Laparoscopic Surgery: The True Identity Was Gastrointestinal Stromal Tumor. Journal of Endourology case reports. 2017 3(1):102-104.<\/li>\n
            7. Johnin K: Editorial Comment to Pathogenesis of enuresis:Towards a new understanding. Int J Urol. 2017 24(3):183.<\/li>\n
            8. Johnin K: Editorial Comment to A unique defect – persistent posterior cloaca: An example of staged genito-urinary and digestive tract reconstruction with an alternative vaginal creation using the urinary bladder wall. Int J Urol. 2017 24(6):471.<\/li>\n
            9. Johnin K: Editorial Comment to Primary nocturnal enuresis is associated with lower intelligence quotient scores in boys from poorer socioeconomic status families. Int J Urol. 2017 24(3):221-222.<\/li>\n
            10. \u524d\u7530\u822a\u898f\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u5f71\u5c71\u3000\u9032\u3001\u6210\u7530\u5145\u5f18\u3001\u6cb3\u5185\u660e\u5b8f: \u7570\u6240\u6027\u814e\u306b\u767a\u751f\u3057\u305f\u5c3f\u7ba1\u764c\u306e1\u4f8b. \u6ccc\u5c3f\u7d00\u8981 2017 63(2):75-79.<\/li>\n
            11. \u592a\u7530\u88d5\u4e4b\u3001\u5712\u7530\u5bdb\u9053\u3001\u6e05\u6c34\u667a\u6cbb\u3001\u6c34\u6d41\u8f1d\u5f66\u3001\u5409\u7530\u54f2\u4e5f\u3001\u897f\u7530\u5c06\u6210\u3001\u6210\u7530\u5145\u5f18\u3001\u6cb3\u5185\u660e\u5b8f\u3001\u690d\u6728\u667a\u4e4b\u3001\u4e09\u5b85\u3000\u4eab\u3001\u751f\u7530\u5927\u4e8c\u3001\u76ee\u7247\u82f1\u6cbb\u3001\u9060\u85e4\u5584\u88d5\u3001\u8c37\u3000\u771e\u81f3: \u76f4\u8178\u8131\u3092\u5408\u4f75\u3057\u305f\u9aa8\u76e4\u81d3\u5668\u8131\uff08\u81a3\u65ad\u7aef\u8131\u3001\u76f4\u8178\u7624\uff09\u306b\u5bfe\u3057\u3066\u4e00\u671f\u7684\u306b\u8179\u8154\u93e1\u4e0b\u4ed9\u9aa8\u81a3\u56fa\u5b9a\u8853\u304a\u3088\u3073\u76f4\u8178\u56fa\u5b9a\u8853\u3092\u65bd\u884c\u3057\u305f1\u4f8b. \u6ecb\u8cc0\u533b\u79d1\u5927\u5b66\u96d1\u8a8c 2017 30(1):76-80.<\/li>\n
            12. \u5c71\u4e0b\u5bdb\u4eba: \u30d7\u30ed\u30b9\u30bf\u30b0\u30e9\u30f3\u30b8\u30f3\uff251\u9670\u830e\u6d77\u7dbf\u4f53\u81ea\u5df1\u6ce8\u5c04\u5f8c\u306b\u4f75\u767a\u3057\u305f\u9670\u830e\u81bf\u760d\u306e1\u4f8b\uff0e\u6ccc\u5916 2017 30(12):1785-1788.<\/li>\n<\/ol>\n

              2016\u5e74<\/em><\/h2>\n
                \n
              1. Kim CJ, Tambe Y, Mukaisho KI, Sugihara H, Kawauchi A, Inoue H.: Akt-dependent activation of Erk by cyclin D1b contributes to cell invasiveness and tumorigenicity. Oncol Lett. 2016 12(6):4850-6.<\/li>\n
              2. Isono T, Chano T, Yoshida T, Kageyama S, Kawauchi A, Suzaki M, Yuasa T.: Hydroxyl-HIF2-alpha is potential therapeutic target for renal cell carcinomas. Am J Cancer Res. 2016 6(10):2263-2276.<\/li>\n
              3. Matsumura K, Nakata S, Taniguchi K, Ii H, Ashihara E, Kageyama S, Kawauchi A, Yoshiki T.: Depletion of \u03b3-glutamylcyclotransferase inhibits breast cancer cell growth via cellular senescence induction mediated by CDK inhibitor upregulation. BMC Cancer. 2016 22;16(1):784.<\/li>\n
              4. Noda S, Hira D, Kageyama S, Jo F, Wada A, Yoshida T, Kawauchi A, Morita SY, Terada T.: Pharmacokinetic Analysis of a Hemodialyzed Patient Treated With Pazopanib. Clin Genitourin Cancer. 2016 14(4):e453-6.<\/li>\n
              5. Naitoh Y, Oishi M, Kobayashi K, Yamada Y, Nakamura T, Johnin K, Hongo F, Naya Y, Okihara K, Kawauchi A: Transvesical laparoscopic surgery for double renal pelvis and ureter with or without ureterocele. Int J Urol. 2016 23(4):332-6.<\/li>\n
              6. Nakamura T, Kawauchi A, Oishi M, Ueda T, Shiraishi T, Nakanishi H, Kamoi K, Naya Y, Hongo F, Okihara K, Miki T.: Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA\/B non-seminoma germ cell tumors. Int J Clin Oncol. 2016 21(4):791-5.<\/li>\n
              7. Tomita K, Tanaka H, Kageyama S, Nagasawa M, Wada A, Murai R, Kobayashi K, Hanada E, Agata Y, Kawauchi A.: The Effect of D-Aspartate on Spermatogenesis in Mouse Testis. Biol Reprod. 2016 94(2); 30:1-7.<\/li>\n
              8. Yamada Y, Naitoh Y, Kobayashi K, Fujihara A, Johnin K, Hongo F, Naya Y, Kamoi K, Okihara K, Kawauchi A, Miki T.: Laparoendoscopic Single-Site Surgery for Pediatric Urologic Disease. J Endourol. 2016 30(1):24-27.<\/li>\n
              9. Maeda K, Kageyama S, Kubota S, Nagasawa M, Hanada E, Yoshida T, Narita M, Kawauchi A. Laparoscopic off-clamp unsutured partial nephrectomy using soft coagulation for a large renal angiomyolipoma after transarterial embolization for rupture. Videourology<\/strong> 30:No.6, 2016<\/li>\n
              10. Ishitsuka R, Miyazaki J, Ichioka D, Inoue T, Kageyama S, Sugimoto M, Mitsuzuka, K, Matsui Y, Shiraishi Y, Kinoshita H, Wakeda H, Nomoto T, Kikuchi E, Kawai K, Nishiyama H. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients. Clin Exp Nephrol<\/strong>. 2016, in press.<\/li>\n
              11. Matsui Y, Ogawa O, Ishitsuka R, Miyazaki J, Inoue T, Kageyama S, Sugimoto M, Mitsuzuka K, Shiraishi Y, Kinoshita H, Wakeda H, Nomoto T, Kikuchi E, Fujie K, Keino N, Nishiyama H. Current status of systemic chemotherapy for octogenarians with advanced urothelial cancer in Japan: a Japanese multi-institutional study (CURE study). Int J Clin Oncol<\/strong>. 21(6):1142-1149, 2016.<\/li>\n
              12. Kikuchi E, Miyazaki J, Yuge K, Hagiwara M, Ichioka D, Inoue T, Kageyama S, Sugimoto M, Mitsuzuka K, Matsui Y, Yamamoto S, Kinoshita H, Wakeda H, Hanai K, Nishiyama H. Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience. Jpn J Clin Oncol<\/strong>. 46(2):163-9, 2016.<\/li>\n
              13. \u8349\u5834\u62d3\u4eba\u3001\u9577\u8239\u3000\u5d07\u3001\u6c38\u6fa4\u8aa0\u4e4b\u3001\u95a2\u5ca1\u654f\u592b\u3001\u6edd\u672c\u898b\u543e\u3001\u6210\u7530\u5145\u5f18\u3001\u6cb3\u5185\u660e\u5b8f: \u8179\u8154\u93e1\u4e0b\u524d\u7acb\u817a\u5168\u6458\u9664\u8853\u5f8c\u306e\u5c3f\u9053\u76f4\u8178\u763b\u306b\u5bfe\u3057\u3066\u5927\u8178\u5185\u8996\u93e1\u4e0b\u88ab\u8986\u8853\u304c\u594f\u529f\u3057\u305f1\u4f8b. \u65e5\u6ccc\u4f1a\u8a8c 2016;107(1):39-43.<\/li>\n
              14. \u6c38\u6fa4\u8aa0\u4e4b\u3001\u5f71\u5c71\u3000\u9032\u3001\u91d1\u3000\u54f2\u5c07\u3001\u6c34\u6d41\u8f1d\u5f66\u3001\u82b1\u7530\u82f1\u7d00\u3001\u5409\u7530\u54f2\u4e5f\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u6210\u7530\u5145\u5f18\u3001\u77f3\u7530\u5149\u660e\u3001\u6cb3\u5185\u660e\u5b8f: \u75c5\u671fTa\u8180\u80f1\u764c\u306b\u304a\u3051\u308b\u30d4\u30e9\u30eb\u30d3\u30b7\u30f3\u8180\u80f1\u5185\u6ce8\u5165\u7642\u6cd5\u306e\u691c\u8a0e\uff0e\u6ccc\u5916 2016;29(5):511-5.<\/li>\n
              15. \u85e4\u539f\u3000\u907c\u3001\u6210\u7530\u5145\u5f18\u3001\u5f71\u5c71\u3000\u9032\u3001\u6cb3\u5185\u660e\u5b8f\u3001\u4ef2\u5c71\u8cb4\u6c38\u3001\u897f\u5948\u6d25\u5b9f\u3001\u6749\u539f\u6d0b\u884c\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u8ee2\u79fb\u5de3\u306e\u8d77\u6e90\u306b\u82e6\u616e\u3057\u305f\u540c\u6642\u591a\u767a\u8ee2\u79fb\u306e1\u4f8b. \u6ccc\u7d00\u30002016;62(9):473-7.<\/li>\n
              16. \u6c96\u4e2d\u52c7\u8f1d\u3001\u6210\u7530\u5145\u5f18\u3001\u548c\u7530\u6643\u5178\u3001\u5409\u7530\u54f2\u4e5f\u3001\u5f71\u5c71\u3000\u9032\u3001\u6cb3\u5185\u660e\u5b8f\uff1a\u53bb\u52e2\u62b5\u6297\u6027\u524d\u7acb\u817a\u764c\u306b\u5bfe\u3059\u308b\u65b0\u898f\u30db\u30eb\u30e2\u30f3\u5264\u306e\u521d\u671f\u6cbb\u7642\u7d4c\u9a13\uff0e\u6ccc\u5916 2016;29(8):1287-90.<\/li>\n
              17. \u99ac\u5872\u96c5\u4eba\u3001\u5f71\u5c71\u3000\u9032\u3001\u912d\u3000\u88d5\u5348\u3001\u9577\u8c37\u884c\u6d0b\u3001\u6cb3\u5185\u660e\u5b8f. \u7b2c8\u56deBCG\u6ce8\u5165\u7642\u6cd5\u7814\u7a76\u4f1a\u8a18\u9332\u3000Second-TUR\u65bd\u884c\u5f8c\u306eT1\u8180\u80f1\u764c\u306b\u5bfe\u3059\u308bBCG\u5185\u6ce8\u5165\u7642\u6cd5\u306e\u6cbb\u7642\u52b9\u679c. \u6ccc\u5916 2016;29(4):401-3.<\/li>\n
              18. \u99ac\u5872\u96c5\u4eba\u3001\u5bcc\u7530\u572d\u53f8\u3001\u5409\u7530\u54f2\u4e5f\u3001\u5f71\u5c71\u3000\u9032\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u6210\u7530\u5145\u5f18\u3001\u6cb3\u5185\u660e\u5b8f: \u6210\u4eba\u7cbe\u5de3\u306b\u767a\u898b\u3055\u308c\u7cbe\u5de3\u6e29\u5b58\u624b\u8853\u3092\u9078\u629e\u3057\u305f\u5358\u4e00\u578b\u6210\u719f\u5947\u5f62\u816b\u306e1\u4f8b. 2016;107(4):271-5<\/li>\n<\/ol>\n

                2015\u5e74<\/em><\/h2>\n
                  \n
                1. Nagasawa M, Johnin K, Hanada E, Yoshida T, Okamoto K, Okada Y, Ueba T, Taga T, Ohta S, Kawauchi A.: Advanced childhood testicular yolk sac tumor with bone metastasis: a case report. Urology. 2015 Mar;85(3):671-3.<\/li>\n
                2. Naya Y, Kawauchi A, Oishi M, Ueda T, Fujihara A, Naito Y, Nakamura T, Hongo F, Kamoi K, Okihara K, Miki T.: Comparison of diameter-axial-polar nephrometry and RENAL nephrometry score for treatment decision-making in patients with small renal mass. Int J Clin Oncol. 2015 Apr;20(2):358-61.<\/li>\n
                3. Fujiwara R, Kageyama S, Tomita K, Hanada E, Tsuru T, Yoshida T, Narita M, Isono T, Kawauchi A.: Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy : A Case Report. Case Rep Oncol. 2015 Aug 5;8(2):339-44.<\/li>\n
                4. Hongo F, Kawauchi A, Ueda T, Fujihara-Iwata A, Nakamura T, Naya Y, Kamoi K, Okihara K, Miki T.: Laparoscopic off-clamp partial nephrectomy using soft coagulation. Int J Urol. 2015 Aug;22(8):731-4.<\/li>\n
                5. Kita H, Okamoto K, Kushima R, Kawauchi A, Chano T.: Dimethyl sulfoxide induces chemotherapeutic resistance in the treatment of testicular embryonal carcinomas. Oncol Lett. 2015 Aug;10(2):661-666.<\/li>\n
                6. Noda S, Otsuji T, Baba M, Yoshida T, Kageyama S, Okamoto K, Okada Y, Kawauchi A, Onishi H, Hira D, Morita SY, Terada T.: Assessment of Sunitinib-lnduced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. Clin Genitourin Cancer. 2015 Aug;13(4):350-8.<\/li>\n
                7. Ichioka D, Miyazaki J, Inoue T, Kageyama S, Sugimoto M, Mitsuzuka K, Matsui Y, Shiraishi Y, Kinoshita H, Wakeda H, Nomoto T, Kikuchi E, Nishiyama H.: Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes. Jpn J Clin Oncol. 2015 Sep;45(9):867-73.<\/li>\n
                8. Ueda T, Ito S, Shiraishi T, Taniguchi H, Kayukawa N, Nakanishi H, Nakamura T, Naya Y, Hongo F, Kamoi K, Okihara K, Kawauchi A, Miki T.: PAX2 promoted prostate cancer cell invasion through transcriptional requlation of HGF in an in vitro model. Biochim Biophys Acta. 2015 Nov;1852(11):2467-73.<\/li>\n
                9. Yoshiya T, Ii H, Tsuda S, Kageyama S, Yoshiki T, Nishiuchi Y: GGCT fluorogenic probe: Design, synthesis and application to cancer-related cells. Org Biomol Chem 2015;13(11):3182-3185.<\/li>\n
                10. \u4e0a\u4ec1\u6570\u7fa9\uff0c\u6c38\u6fa4\u8aa0\u4e4b\uff0c\u5c0f\u6797\u61b2\u5e02\uff0c\u6c34\u6d41\u8f1d\u5f66\uff0c\u7027\u672c\u5553\u592a\uff0c\u5409\u7530\u54f2\u4e5f\uff0c\u5f71\u5c71\u3000\u9032\uff0c\u6210\u7530\u5145\u5f18\uff0c\u6cb3\u5185\u660e\u5b8f: \u5358\u5b54\u5f0f\u8179\u8154\u93e1\u4e0b\u814e\u76c2\u5f62\u6210\u8853\u306f\uff0c\u814e\u76c2\u5c3f\u7ba1\u79fb\u884c\u90e8\u901a\u8ca8\u50b7\u5bb3\u306e\u6a19\u6e96\u8853\u5f0f\u306b\u306a\u308a\u3046\u308b\u304b\uff1f: \u5358\u4e00\u65bd\u8a2d\u3067\u884c\u308f\u308c\u305f\uff13\u3064\u306e\u8853\u5f0f\uff08\u958b\u653e\u814e\u76c2\u5f62\u6210\u8853\uff0c\u8179\u8154\u93e1\u4e0b\u814e\u76c2\u5f62\u6210\u8853\uff0c\u5358\u5b54\u5f0f\u8179\u8154\u93e1\u4e0b\u814e\u76c2\u5f62\u6210\u8853\uff09\u306e\u6bd4\u8f03\u691c\u8a0e\uff0eJpn J Endourol 2015;28:247-252.<\/li>\n
                11. \u6c38\u6fa4\u8aa0\u4e4b\uff0c\u4e0a\u4ec1\u6570\u7fa9\uff0c\u4f50\u91ce\u592a\u4e00\uff0c\u5c0f\u6797\u61b2\u5e02\uff0c\u5f71\u5c71\u3000\u9032\uff0c\u6210\u7530\u5145\u5f18\uff0c\u5ca1\u672c\u572d\u751f\uff0c\u6cb3\u5185\u660e\u5b8f\uff1a\u5358\u7d14\u6027\u7cbe\u5de3\u56a2\u80de\u306e\u5f62\u614b\u3092\u5448\u3057\u305f\u5c0f\u5150\u6210\u719f\u5947\u5f62\u816b\u306e1\u4f8b\uff0e\u65e5\u6ccc\u4f1a\u8a8c  2015;106(4):289-292.<\/li>\n
                12. \u6c34\u6d41\u8f1d\u5f66\u3001\u8352\u6728 \u52c7\u96c4\u3001\u57ce\u6587\u6cf0\u3001\u912d\u3000\u88d5\u5348\u3001\u5e83\u7530\u7adc\u4e00\u3001\u99ac\u5872\u96c5\u4eba\u3001\u5409\u7530\u54f2\u4e5f\u3001\u6cb3\u5185\u660e\u5b8f\uff1a\u5973\u6027\u9aa8\u76e4\u81d3\u5668\u8131\u60a3\u8005\u306eTVM\u624b\u8853\u306b\u304a\u3051\u308bQOL\u5909\u5316\u306e\u691c\u8a0e\uff1aP-QOL\u306b\u3088\u308b\u691c\u8a0e. \u65e5\u5973\u6027\u9aa8\u76e4\u5e95\u533b\u4f1a\u8a8c.\u30002015;12(1):135-8.<\/li>\n
                13. \u524d\u7530\u822a\u898f\u3001\u548c\u7530\u6643\u5178\u3001\u5f71\u5c71\u3000\u9032\u3001\u7027\u672c\u5553\u592a\u3001\u6210\u7530\u5145\u5f18\u3001\u6cb3\u5185\u660e\u5b8f\uff1a\u5c3f\u9589\u3092\u6765\u305f\u3057\u305f\u5973\u6027\u508d\u5c3f\u9053\u5e73\u6ed1\u7b4b\u816b\u306e1\u4f8b. \u6ccc\u7d00 2015;61(11):455-458.<\/li>\n<\/ol>\n

                  (2015\u5e74 in press)<\/h3>\n
                    \n
                  1. Kim CJ, Tambe Y, Mukaisho K, Sugihara H, Kageyama S, Kawauchi A, Inoue H.: Periostin suppresses in vivo invasiveness via PDK1\/Akt\/mTOR signaling pathway in a mouse orthotopic model of bladder cancer. Oncol Lett 2015; in press<\/li>\n
                  2. Tomita K, Tanaka H, Kageyama S, Nagasawa M, Wada A, Murai R, Kobayashi K, Hanada E, Agata Y, Kawauchi A.: The effect of D-Aspartate on spermatogenesis. Biol Reprod 2015; in press<\/li>\n
                  3. Kikuchi E, Miyazaki J, Yuge K, Hagiwara M, Ichioka D, Inoue T, Kageyama S, Sugimoto M, Mitsuzuka K, Matsui Y, Yamamoto S, Kinoshita H, Wakeda H, Terachi T, Nishiyama H.: Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institution experience Jpn J Clin Oncol 2015; in press<\/li>\n
                  4. Nakamura T, Kawauchi A, Oishi M, Ueda T, Shiraishi T, Nakanishi H, Kamoi K, Naya Y, Hongo F, Okihar K, Miki T.: Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feaside llA\/B non-seminoma germ cell tumors. Int J Clin Oncol 2015; in press<\/li>\n
                  5. Yamada Y, Naitoh Y, Kobayashi K, Fujihara A, Johnin K, Hongo F, Naya Y, Kamoi K,  Kawauchi A, Miki T.: Laparoendoscopic Single-Site Surgery for Pediatric Urologic Disease. J Endourol 2015; in press<\/li>\n<\/ol>\n

                    2014\u5e74<\/em><\/h2>\n
                      \n
                    1. Naitoh Y, Kawauchi A, Kamoi K, Soh J, Hongo F, Okihara K, Miki T.: Nephrolithotomy performed concurrently with laparoendoscopic single-site pyeloplasty. Urology. 2014 Jan;83(1):243-6.<\/li>\n
                    2. Okihara K, Kobayashi K, Iwata T, Naitoh Y, Kamoi K, Kawauchi A, Yamada K, Miki T.: Assessment of permanent brachytherapy combined with androgen deprivation therapy in an intermediate-risk prostate cancer group without a Gleason score of 4 + 3: a single Japanese institutional experience. Int J Urol. 2014 Mar;21(3):271-6.<\/li>\n
                    3. Iwaki H, Kageyama S, Yoshiki T.: Upregulation of tissue and urinary uroplakin mRNA in patients with vesicoureteral reflux. Int J Urol. 2014 Mar;21(3):347<\/li>\n
                    4. Naitoh Y, Kawauchi A, Yamada Y, Fujihara A, Hongo F, Kamoi K, Okihara K, Miki T.: Laparoendoscopic single-site versus conventional laparoscopic pyeloplasty: A matched pair analysis. Int J Urol. 2014;21(8):793-6.<\/li>\n
                    5. Matsuda T, Kanayama H, Ono Y, Kawauchi A, Mizoguchi H, Nakagawa K, Iwamura M, Shigeta M, Habuchi T, Terachi T.: Reliability of laparoscopic skills assessment on video: 8-year results of the Endoscopic Surgical Skill Qualification System in Japan. J Endourol. 2014;28(11):1374-8.<\/li>\n
                    6. Hongo F, Kawauchi A, Ueda T, Fujihara A, Naitoh Y, Nakamura T, Naya Y, Kamoi K, Okihara K, Miki T.: Long-term outcome of hand-assisted laparoscopic radical nephrectomy for T1 renal cell carcinoma. Int J Urol. 2014;21(11):1093-6.<\/li>\n
                    7. Maeda K, Kojima F, Ishida M, Iwai M, Kagotani A, Kawauchi A.: M\u00fcllerianosis and endosalpingiosis of the urinary bladder: report of two cases with review of the literature. Int J Clin Exp Pathol. 2014;15;7(7):4408-14.<\/li>\n
                    8. Ito S, Ueda T, Ueno A, Nakagawa H, Taniguchi H, Hongo F, Kamoi K, Okihara K, Kawauchi A, Miki T.: Paired box 2 upregulates androgen receptor gene expression in androgen-independent prostate cancer. FEBS J. 2014;281(19):4506-18.<\/li>\n
                    9. Hongo F, Kawauchi A, Itoh Y, Fujii H, Naitoh Y, Nakamura T, Naya Y, Kamoi K, Okihara K, Miki T.: Experience of laparoscopic partial nephrectomy using a kidney grasper in selective cases. J Laparoendosc Adv Surg Tech A. 2014;24(11):795-8.<\/li>\n
                    10. Matsuda T, Kanayama H, Ono Y, Kawauchi A, Mizoguchi H, Nakagawa K, Iwamura M, Shigeta M, Habuchi T, Terachi T; Referee Committee of the Endoscopic Surgical Skill Qualification System in Urological Laparoscopy.: Reliability of laparoscopic skills assessment on video: 8-year results of the endoscopic surgical skill qualification system in Japan. J Endourol. 2014;28(11):1374-8.<\/li>\n
                    11. \u5c71\u4e0b\u5bdb\u4eba\u3001\u8352\u6728\u52c7\u96c4\u3001\u5f71\u5c71\u3000\u9032\u3001\u99ac\u5872\u96c5\u4eba\u3001\u4e2d\u91ce\u60a6\u6b21\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u6ecb\u8cc0\u770c\u5185\u306e\u8a3a\u7642\u6240\u306b\u304a\u3051\u308b\u7537\u6027\u5c3f\u9053\u708e\u306e\u8a3a\u7642\u5b9f\u614b\u8abf\u67fb. \u6ccc\u7d00 2014;60(1):7-12.<\/li>\n
                    12. \u7aaa\u7530\u6210\u5bff\u3001\u6751\u4e95\u4eae\u4ecb\u3001\u91d1\u3000\u54f2\u5c07\uff1a\u82e5\u5e74\u6210\u4eba(39\u6b73)\u306b\u767a\u75c7\u3057\u305f\u8180\u80f1\u764c\u306e1\u4f8b. \u6ccc\u5916 2014;27(1):137-40. \u9b3c\u585a\u5343\u8863\u3001\u8cc0\u672c\u654f\u884c\u3001\u677e\u672c\u5bcc\u7f8e\u3001\u5cf6\u7530\u61b2\u6b21\u3001\u5c0f\u6797\u61b2\u5e02\uff1a\u601d\u6625\u671f\u306b\u8180\u80f1\u80cc\u5074\u306e\u56a2\u80de\u6027\u816b\u7624\u306e\u518d\u5897\u5927\u3092\u6765\u3057\u305fHerlyn-Werner-Wunderlich\u75c7\u5019\u7fa4\u306e2\u4f8b. \u65e5\u5c0f\u5150\u6ccc\u4f1a\u8a8c 2014;23(1):18-21.<\/li>\n
                    13. \u725b\u7530\u3000\u535a\u3001\u690d\u6751\u7950\u4e00\u3001\u5f8c\u85e4\u88d5\u6587\u3001\u77f3\u6238\u8c37\u54f2\u3001\u5927\u897f\u88d5\u4e4b\uff1a\u5f53\u65bd\u8a2d\u306b\u304a\u3051\u308b\u7d4c\u76f4\u8178\u7684\u524d\u7acb\u817a\u751f\u691c\u306e\u691c\u8a0e. \u6ccc\u5916 2014;27(10):1721-5.<\/li>\n
                    14. \u6751\u4e95\u4eae\u4ecb\u3001\u7aaa\u7530\u6210\u5bff\u3001\u91d1\u3000\u54f2\u5c07\uff1a\u5c3f\u7ba1\u76ae\u819a\u5ed4\u9020\u8a2d\u8853\u5f8c\u75c7\u4f8b\u306b\u304a\u3051\u308b\u5c3f\u57f9\u990a\u5206\u96e2\u83cc\u306e\u691c\u8a0e. \u6ccc\u7d00 2014;60(12):605-9.<\/li>\n<\/ol>\n

                      2013\u5e74<\/em><\/h2>\n
                        \n
                      1. Kanematsu A, Tanaka S, Johnin K, Kawai S, Nakamura S, Imamura M, Yoshimura K, Higuchi Y, Yamamoto S, Okada Y, Nakai H, and Ogawa O: A multi-center study of pediatric uroflowmetry data using patterning software. J Pediatr Urol. 2013 Feb;9 (1):57-61.<\/li>\n
                      2. Kim CJ, Sano T, Murai R: Evaluations for hydronephrosis after the establishment of tubeless cutaneous ureterostomy. Korean J Urol. 2013 Mar; 54(3):168-71.<\/li>\n
                      3. Yoshida A, Fuchihata Y, Kuraoka S, Osano A, Otsuka A, Ozono S, Takeda M, Masuyama K, Araki I, and Yamada S: Fesoterodine, its active metabolite and tolterodine bind selectively to muscarinic receptors in human bladder mucosa and detrusor muscle. Urology 2013 April; 81(4): 920.e1-5.<\/li>\n
                      4. Yoshida A, Fuchihata Y, Kuraoka S, Osano A, Otsuka A, Ozono S, Takeda M, Masuyama K, Araki I, and Yamada S: Fesoterodine, its active metabolite and tolterodine bind selectively to muscarinic receptors in human bladder mucosa and detrusor muscle. Urology 2013 April; 81(4):920.e1-5.<\/li>\n
                      5. Ushida H, Koizumi S, Katoh K, Okabe H, Okada Y, Okamoto K: Recurrent rhabdomyosarcoma after adjuvant chemotherapy for stage I non-seminomatous germ cell tumor with malignant transformation. Int J Urol. 2013 May; 20(5):544-6.<\/li>\n
                      6. Kim CJ, Kubota S, Murai R: Diagnostic criteria for stomal obstruction of tubeless cutaneous ureterostomy using 99mTc-mercaptoacetyltriglycine (MAG3) diuretic renography. Korean J Urol. 2013 May;54(5):322-6.<\/li>\n
                      7. Li K, Yao J, Chi Y, Sawada N, Araki I, Kitamura M, Takeda M: Eviprostat activates cAMP signaling pathway and suppresses bladder smooth muscle cell proliferation. Int J Mol Sci. 2013 June; 14: 12107-22.<\/li>\n
                      8. Kimura Y, Nakamura T, Kawauchi A, Kawabata G, Hongo F, Miki T.: Post-chemotherapy nerve-sparing laparoscopic retroperitoneal lymph node dissection in stage IIB testicular cancer. Int J Urol. 2013 Aug;20(8):837-41.<\/li>\n
                      9. Rais-Bahrami S, Rizkala ER, Cadeddu JA, Tugcu V, Derweesh IH, Abdel-Karim AM, Kawauchi A, George AK, Autorino R, Bagrodia A, Sonmezay E, Elsalmy S, Liss MA, Harrow BM, Kaouk JH, Richstone L, Stein RJ.: Laparoendoscopic single-site pyeloplasty: outcomes of an international multi-institutional study of 140 patients. Urology. 2013 Aug;82(2):366-72.<\/li>\n
                      10. Ueda T, Ito S, Shiraishi T, Kulkarni P, Ueno A, Nakagawa H, Kimura Y, Hongo F, Kamoi K, Kawauchi A, Miki T.: Hyper-expression of PAX2 in human metastatic prostate tumors and its role as a cancer promoter in an in vitro invasion model. Prostate. 2013 Sep;73(13):1403-12.<\/li>\n
                      11. Johnin K, Takazakura R, Furukawa A, Okamoto K, Murakami Y, Murata K, Okada Y: Magnetic resonance voiding cystourethrography (MRVCUG): A potential alternative to standard VCUG. J Magn Reson Imaging. 2013 Oct; 38(4): 897\u2013904.<\/li>\n
                      12. Anzai Y, Koshida S, Yanagi T, Johnin K, Takeuchi Y.: Neonatal urethral polyps associated with Beckwith-Wiedemann syndrome. Pediatr Int. 2013 Oct;55(5):658-61.<\/li>\n
                      13. Ishida M, Fujiwara R, Tomita K, Yoshida T, Iwai M, Yoshida K, Kagotani A, Kawauchi A, Okabe H.: Sclerosing Sertoli cell tumor of the testis: a case report with review of the literature. Int J Clin Exp Pathol. 2013 Oct 15;6(11):2640-3.<\/li>\n
                      14. Takayama T, Takaoka N, Nagata M, Johnin K, Okada Y, Tanaka S, Kawamura M, Inokuchi T, Ohse M, Kuhara T, Tanioka F, Yamada H, Sugimura H, Ozono S: Ethnic differences in GRHPR mutations in patients with primary hyperoxaluria type 2. Clin Genet. 2013 Oct in press.<\/li>\n
                      15. \u4e8c\u5bae\u65e9\u82d7\u3001\u6589\u85e4\u7965\u4e43\u3001\u5ca1\u5c71\u4e45\u4ee3\u3001\u9060\u85e4\u5584\u88d5\u3001\u68ee\u5ddd\u8302\u5ee3\u3001\u6b63\u6728\u7d00\u4ee3\u5b50\u3001\u9f4b\u85e4\u3044\u305a\u307f\u3001\u8352\u6728\u52c7\u96c4\uff1a\u5ea7\u4f4dMRI\u753b\u50cf\u3092\u7528\u3044\u305fTOT\u624b\u8853\u306b\u3088\u308b\u8180\u80f1\u9838\u90e8\u30fb\u5c3f\u9053\u8ef8\u306e\u5f62\u614b\u7684\u5909\u5316\u306b\u95a2\u3059\u308b\u691c\u8a0e\u3000\u65e5\u5973\u6027\u9aa8\u76e4\u5e95\u533b\u4f1a\u8a8c\u30002013; 10(1):46-51.<\/li>\n
                      16. \u6cb3\u91ce\u76f4\u660e\u3001\u90b5\u3000\u5553\u5168\u3001\u6d25\u5ddd\u62d3\u4e5f\u3001\u6751\u7530\u559c\u4ee3\u53f2\u3001\u91ce\u9593\u548c\u592b\u3001\u672c\u591a\u6075\u7406\u5b50\u3001\u6a4b\u672c\u60e0\u6b21\u3001\u8fd1\u85e4\u5eb7\u96c4\u3001\u725b\u7530\u3000\u535a\u3001\u5ca1\u672c\u572d\u751f\u3001\u5ca1\u7530\u88d5\u4f5c\uff1aStage C\u524d\u7acb\u817a\u764c\u306b\u5bfe\u3059\u308b\u5185\u5206\u6ccc\u30db\u30eb\u30e2\u30f3\u7642\u6cd5\u4f75\u7528\u5f37\u5ea6\u5909\u8abf\u653e\u5c04\u7dda\u6cbb\u7642(IMRT)\u306e\u4e2d\u671f\u6cbb\u7642\u6210\u7e3e. \u6ecb\u8cc0\u533b\u5927\u8a8c 2013; 26(1):6-12.<\/li>\n
                      17. \u5c0f\u6797\u82f1\u6a39\u3001\u7fbd\u6839\u7530\u7834\u3001\u5409\u826f\u3000\u8061\u3001\u5bae\u672c\u9054\u4e5f\u3001\u6fa4\u7530\u667a\u53f2\u3001\u571f\u7530\u5b5d\u4e4b\u3001\u8352\u6728\u52c7\u96c4\u3001\u6b66\u7530\u6b63\u4e4b\uff1aTVM\u30e1\u30c3\u30b7\u30e5\u306e\u5927\u304d\u3055\u306b\u95a2\u3059\u308b\u691c\u8a0e\u3000\u65e5\u5973\u6027\u9aa8\u76e4\u5e95\u533b\u4f1a\u8a8c 2013;10(1)216-8.<\/li>\n
                      18. \u4eca\u6751\u6b63\u660e\u3001\u5409\u6751\u8015\u6cbb\u3001\u5c0f\u5ddd\u3000\u4fee\u3001\u517c\u677e\u660e\u5f18\u3001\u4e0a\u4ec1\u6570\u7fa9\uff1a\u6210\u4eba\u8a9e\u3068\u5c0f\u5150\u8a9e\u306eDysfunctional voiding symptom score(DVSS)\u975e\u516c\u5f0f\u8a8d\u8a3c\u548c\u8a33\u7248\u306e\u8a66\u7528\u3068\u610f\u7fa9. \u65e5\u5c0f\u5150\u6ccc\u4f1a\u8a8c 2013;22(1):69-43.<\/li>\n
                      19. \u6751\u4e95\u4eae\u4ecb\u3001\u7aaa\u7530\u6210\u5bff\u3001\u4e95\u672c\u52dd\u6cbb\u3001\u5742\u672c\u3000\u529b\u3001\u91d1\u3000\u54f2\u5c07\uff1a\u5c3f\u7ba1\u76ae\u819a\u763b\u8853\u5f8c\u306b\u767a\u751f\u3057\u305f\u5c3f\u7ba1\u52d5\u8108\u763b\u306b\u5bfe\u3057\u3066\u8840\u7ba1\u5185\u30b9\u30c6\u30f3\u30c8\u30b0\u30e9\u30d5\u30c8\u6cbb\u7642\u3092\u7e70\u308a\u8fd4\u3057\u305f1\u4f8b. \u6ccc\u7d00\u30002013; 58(10): 647-50.<\/li>\n
                      20. \u9ad8\u5c71\u9054\u4e5f\u3001\u9ad8\u5ca1\u76f4\u592e\u3001\u6c38\u7530\u4ec1\u592b\u3001\u9ea6\u8c37\u58ee\u4e00\u3001\u5927\u5712\u8aa0\u4e00\u90ce\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u539f\u767a\u6027\u9ad8\u84da\u9178\u5c3f\u75c72\u578b\u306e\u8cac\u4efb\u907a\u4f1d\u5b50\u3067\u3042\u308bGRHPR\u907a\u4f1d\u5b50\u306e\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u306b\u304a\u3051\u308b\u5730\u57df\u5206\u5e03\u3068\u4eba\u7a2e\u5dee\u3068\u306e\u95a2\u4fc2.\u65e5\u5c3f\u7d50\u77f3\u8a8c 2013;11(2):109-11.<\/li>\n
                      21. \u6751\u4e95\u4eae\u4ecb\u3001\u725b\u7530\u3000\u535a\u3001\u9577\u8239\u3000\u5d07\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u5f71\u5c71\u3000\u9032\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u5916\u50b7\u6027\u5c3f\u7ba1\u72ed\u7a84\u306b\u5bfe\u3057\u866b\u5782\u5c3f\u7ba1\u7f6e\u63db\u8853\u3092\u65bd\u884c\u3057\u305f1\u4f8b.\u3000\u65e5\u6ccc\u4f1a\u8a8c 2013;104(5):667-70.<\/li>\n
                      22. \u91d1\u3000\u54f2\u5c07\u3001\u7aaa\u7530\u6210\u5bff\u3001\u6751\u4e95\u4eae\u4ecb\uff1a\u4e0b\u90e8\u5c3f\u8def\u75c7\u72b6\u306e\u521d\u671f\u8a55\u4fa1\u3067\u65bd\u884c\u3057\u305f\u5c3f\u6d41\u91cf\u6e2c\u5b9a\u691c\u67fb\u3001\u56fd\u969b\u524d\u7acb\u817a\u75c7\u72b6\u30b9\u30b3\u30a2\u3001\u524d\u7acb\u817a\u5bb9\u7a4d\u3001\u6b8b\u5c3f\u91cf\u304b\u3089\u307f\u305f\u7d4c\u5c3f\u9053\u7684\u524d\u7acb\u817a\u5207\u9664\u8853\u65bd\u884c\u75c7\u4f8b\u306e\u691c\u8a0e. \u6ccc\u5916\u30002013; 26(12) 1815-8.<\/li>\n
                      23. \u5317\u6751\u6d69\u4e8c\u3001\u7be0\u7530\u5eb7\u592b\u3001\u4e09\u795e\u4e00\u54c9\u3001\u6c96\u539f\u5b8f\u6cbb\u3001\u6cb3\u5185\u660e\u5b8f\u3001\u4e09\u6728\u6052\u6cbb\uff1a\u9ad8\u3044\u524d\u7acb\u817a\u304c\u3093\u691c\u8a3a\u66b4\u9732\u7387\u3092\u6709\u3059\u308b\u5730\u57df\u3067\u898b\u3064\u304b\u308b\u524d\u7acb\u817a\u764c\u306e\u7279\u5fb4. \u65e5\u672c\u304c\u3093\u691c\u8a3a\u30fb\u8a3a\u65ad\u5b66\u4f1a\u8a8c 2013;21(2):169-71.<\/li>\n<\/ol>\n

                        2012\u5e74<\/em><\/h2>\n
                          \n
                        1. Kobayashi H, Sawada N, Kira S, Miyamoto T, Haneda Y, Zakoji H, Tsuchida T, Araki I, Takeda M: Intraoperative fluoroscopic monitoring during TVM surgery: safer procedure even for beginners. Open Journal of Urology. 2012 2(2):72-4.<\/li>\n
                        2. Ushida H, Chano T, Minami K, Kita H, Kawakami T, Okabe H, Okada Y, Okamoto K: Therapeutic potential of SOX2 inhibition for embryonal carcinoma. J Urol. 2012 May;187(5):1876-81.<\/li>\n
                        3. Ushida H, Kawakami T, Minami K, Chano T, Okabe H, Okada Y, Okamoto K: Methylation profile of DNA repetitive elements in human testicular germ cell tumor. Mol Carcinog. 2012 Sep;51(9):711-22.<\/li>\n
                        4. Noda S, Kageyama S, Tsuru T, Kubota S, Yoshida T, Okamoto K, Okada Y, Morita SY, Terada T: Pharmacokinetic\/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated with 25 mg of Sunitinib. Case Rep Oncol. 2012 Sep;5(3):627-32.<\/li>\n
                        5. \u7aaa\u7530\u6210\u5bff\u3001\u8352\u6728\u52c7\u96c4\u3001\u4f0a\u72e9\u3000\u4eae\u3001\u524d\u6fa4\u5353\u4e5f\u3001\u5409\u7530\u54f2\u4e5f\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u5409\u826f\u3000\u8061\u3001\u7fbd\u6839\u7530\u7834\u3001\u5c0f\u6797\u82f1\u6a39\u3001\u6b66\u7530\u6b63\u4e4b\uff1aTOT\u30b9\u30ea\u30f3\u30b0\u624b\u8853\u306e\u6cbb\u7642\u6210\u7e3e\u306b\u5bfe\u3059\u308b\u9aa8\u76e4\u81d3\u5668\u8131\u4fee\u5fa9\u8853\uff08TVM\u624b\u8853\uff09\u540c\u6642\u65bd\u8853\u306e\u5f71\u97ff\uff0e\u65e5\u5973\u6027\u9aa8\u76e4\u5e95\u533b\u4f1a\u8a8c. 2012; 9(1): 109-12.<\/li>\n
                        6. \u4e8c\u5bae\u65e9\u82d7\u3001\u9f4b\u85e4\u3044\u305a\u307f\u3001\u9060\u85e4\u5584\u88d5\u3001\u68ee\u5ddd\u8302\u5ee3\u3001\u8352\u6728\u52c7\u96c4\u3001\u6b63\u6728\u7d00\u4ee3\u5b50\u3001\u6589\u85e4\u7965\u4e43\u3001\u5ca1\u5c71\u4e45\u4ee3\uff1a\u7e26\u578b\u30aa\u30fc\u30d7\u30f3MR\u3092\u7528\u3044\u305f\u8180\u80f1\u981a\u90e8\u4f4d\u7f6e\u306e\u8a55\u4fa1\u306b\u5f71\u97ff\u3092\u4e0e\u3048\u308b\u8981\u56e0\u306e\u691c\u8a0e\uff0e\u65e5\u5973\u6027\u9aa8\u76e4\u5e95\u533b\u4f1a\u8a8c. 2012; 9(1): 60-3.<\/li>\n
                        7. \u5c0f\u6797\u82f1\u6a39\u3001\u6fa4\u7530\u667a\u53f2\u3001\u4eca\u4e95\u4f51\u6a39\u3001\u5409\u826f\u3000\u8061\u3001\u5bae\u672c\u9054\u4e5f\u3001\u7fbd\u6839\u7530\u7834\u3001\u571f\u7530\u5b5d\u4e4b\u3001\u8352\u6728\u52c7\u96c4\u3001\u6b66\u7530\u6b63\u4e4b\uff1a\u900f\u8996\u4e0bTVM\u624b\u8853\u306e\u691c\u8a0e\uff0e\u65e5\u5973\u6027\u9aa8\u76e4\u5e95\u533b\u4f1a\u8a8c. 2012; 9(1): 68-71.<\/li>\n
                        8. \u5409\u826f\u3000\u8061\u3001\u7fbd\u6839\u7530\u7834\u3001\u5c0f\u6797\u82f1\u6a39\u3001\u6b66\u7530\u6b63\u4e4b\u3001\u8352\u6728\u52c7\u96c4\uff1aTOT\u624b\u8853\u306b\u304a\u3051\u308b\u8853\u524d\u5f8c\u306e\u6392\u5c3f\u72b6\u614b\u306e\u5909\u5316\u306b\u95a2\u3059\u308b\u691c\u8a0e\uff0e\u3000\u65e5\u5973\u6027\u9aa8\u76e4\u5e95\u533b\u4f1a\u8a8c. 2012; 9(1): 118-21.<\/li>\n
                        9. \u5f71\u5c71\u3000\u9032\u3001\u5ca9\u57ce\u79c0\u51fa\u6d19\u3001\u82b1\u7530\u82f1\u7d00\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u98ef\u5c45\u5b8f\u7f8e\u3001\u5409\u8cb4\u9054\u5bdb\uff1a\u5c3f\u4e2d\u30a6\u30ed\u30d7\u30e9\u30ad\u30f3mRNA\u6e2c\u5b9a\u306b\u3088\u308b\u4f4e\u4fb5\u8972\u306a\u5148\u5929\u6027\u8180\u80f1\u5c3f\u7ba1\u9006\u6d41\u75c7\u691c\u67fb\u6cd5\u306e\u958b\u767a\uff0e\u814e\u81d3\uff0e2012; 35(2): 117-22.<\/li>\n
                        10. \u6210\u7530\u5145\u5f18\u3001\u5f71\u5c71\u3000\u9032\u3001\u5409\u7530\u54f2\u4e5f\u3001\u82b1\u7530\u82f1\u7d00\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u8179\u8154\u93e1\u4e0b\u524d\u7acb\u817a\u5168\u6458\u9664\u8853\u306b\u304a\u3051\u308b\u5f8c\u58c1\u88dc\u5f37\u306e\u5de5\u592b\uff0eAudio-Visual Journal of JUA\uff0e2012; 18(3): 18-14\uff0e<\/li>\n
                        11. \u6210\u7530\u5145\u5f18\u3001\u5f71\u5c71\u3000\u9032\u3001\u5409\u7530\u54f2\u4e5f\u3001\u82b1\u7530\u82f1\u7d00\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u814e\u51b7\u5374\u306b\u3088\u308b\u5f8c\u8179\u819c\u93e1\u4e0b\u814e\u90e8\u5206\u5207\u9664\u8853\uff0dice slush\u633f\u5165\u6cd5\u306e\u5de5\u592b\uff0d\uff0eAudio-Visual Journal of JUA\uff0e2012; 18(4): 18-22.<\/li>\n
                        12. \u4f50\u91ce\u592a\u4e00\u3001\u5bcc\u7530\u572d\u53f8\u3001\u7027\u672c\u5553\u592a\u3001\u91d1\u3000\u54f2\u5c07\uff1a\u5c3f\u7ba1\u76ae\u819a\u763b\u9020\u8a2d\u8853\u5f8c\u30ab\u30c6\u30fc\u30c6\u30eb\u4ea4\u63db\u306b\u4f34\u3044\u767a\u75c7\u3057\u305f\u8178\u8170\u7b4b\u81bf\u760d\u306e1\u4f8b.\u3000\u6ccc\u7d00.\u30002012; 58(7): 341-4.<\/li>\n
                        13. \u7aaa\u7530\u6210\u5bff\u3001\u5f71\u5c71\u3000\u9032\u3001\u6210\u7530\u5145\u5f18\u3001\u524d\u6fa4\u5353\u4e5f\u3001\u8352\u6728\u52c7\u96c4\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u814e\u7d30\u80de\u764c\u5c0f\u8178\u8ee2\u79fb\u306e1\u4f8b\uff0e\u3000\u6ccc\u7d00.\u30002012; 58(8): 431-4.<\/li>\n
                        14. \u7aaa\u7530\u6210\u5bff\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u5409\u7530\u54f2\u4e5f\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u9ad8\u5c71\u9054\u4e5f\u3001\u4e45\u539f\u3068\u307f\u5b50\uff1a\u96e3\u6cbb\u6027\u306e\u5c3f\u8def\u7d50\u77f3\u3092\u5448\u3057\u305f\u539f\u767a\u6027\u9ad8\u30b7\u30e5\u30a6\u9178\u5c3f\u75c72\u578b\u306e1\u4f8b.\u3000\u65e5\u5c3f\u7d50\u77f3\u8a8c2012; 10(2):78-82.<\/li>\n<\/ol>\n

                          2011\u5e74<\/em><\/h2>\n
                            \n
                          1. Ushida H, Murai R, Narita M, Kojima F, Okada Y: Leiomyosarcoma involving the inferior vena cava in an elderly patient with reference to its operative modalities: a case report. \u6ecb\u8cc0\u533b\u5927\u8a8c 2011 24(1):1-12.<\/li>\n
                          2. Seki M, Ogoda M, Kuraoka S, Otsuka A, Ozono S, Takeda M, Masuyama K, Araki I, Yamada S: Muscarinic receptor binding of imidafenacin in the human bladder mucosa and detrusor and parotid gland. LUTS: Lower Urinary Tract Symptoms 2011 3(2):64-8.<\/li>\n
                          3. Uejima D, Nishijo K, Kajita Y, Ishibe T, Aoyama T, Kageyama S, Iwaki H, Nakamura T, Iida H, Yoshiki T, Toguchida J: Involvement of cancer biomarker C7orf24 in the growth of human osteosarcoma. Anticancer Res. 2011 Apr;31(4):1297-305.<\/li>\n
                          4. Kim CJ, Sakamoto K, Tambe Y, Inoue H: Opposite regulation of epithelial-to-mesenchymal transition and cell invasiveness by periostin between prostate and bladder cancer cells. Int J Oncol. 2011 Jun;38(6):1759-66.<\/li>\n
                          5. Kim CJ, Sano T, Takimoto K: Miliary tuberculosis following transrectal ultrasonography (TRUS)-guided prostate biopsy. Korean J Urol. 2011 Jun;52(6):425-7.<\/li>\n
                          6. Takeda M, Homma Y, Araki I, Kakizaki H, Yamanishi T, Yokota T, Gotoh M, Igawa Y, Seki N, Takei M, Yoshida M, Sugaya K, Nishizawa O; Japanese Naftopidil Neurogenic Lower Urinary Tract Dysfunction Study Group: Predictive factors for the effect of the \u03b11-D\/A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunction. BJU Int. 2011 Jul;108(1):100-7.<\/li>\n
                          7. Yoshida A, Seki M, Nasrin S, Otsuka A, Ozono S, Takeda M, Masuyama K, Araki I, Ehlert FJ, Yamada S: Characterization of muscarinic receptors in the human bladder mucosa: direct quantification of subtypes using 4-DAMP mustard. Urology. 2011 Sep;78(3):721.e7-721.e12.<\/li>\n
                          8. Kanematsu A, Johnin K, Yoshimura K, Imamura M, Yoshida O: Comparison of the Effects by Obybutynin and Tolterodine on Spina Bifida Patients: A Pilot Crossover Study. LUTS: Lower Urinary Tract Symptoms. 2011 Sep;3(2):99-103.<\/li>\n
                          9. Ohno Y, Hattori A, Ueda M, Kageyama S, Yoshiki T, Kakeya H: Multiple NF-Y-binding CCAAT boxes are essential for transcriptional regulation of the human C7orf24 gene, a novel tumor-associated gene. FEBS J. 2011 Nov;278(21):4088-99.<\/li>\n
                          10. Beppu M, Araki I, Yoshiyama M, Du S, Kobayashi H, Zakoji H, Takeda M: Bladder outlet obstruction induced expression of prostaglandin E2 receptor subtype EP4 in the rat bladder: a possible counteractive mechanism against detrusor overactivity. J Urol. 2011 Dec;186(6):2463-9.<\/li>\n
                          11. Wu Y, Miyamoto T, Li K, Nakagomi H, Sawada N, Kira S, Kobayashi H, Zakohji H, Tsuchida T, Fukazawa M, Araki I, Takeda M: Decreased expression of the epithelial Ca2+ channel TRPV5 and TRPV6 in human renal cell carcinoma associated with vitamin D receptor. J Urol. 2011 Dec;186(6):2419-25.<\/li>\n
                          12. \u6210\u7530\u5145\u5f18\u3001\u5f71\u5c71\u3000\u9032\u3001\u76ca\u7530\u826f\u8ce2\u3001\u6c34\u6d41\u8f1d\u5f66\u3001\u5ca1\u7530\u88d5\u4f5c\uff1aHemi-Kock pouch\u6cd5\u306b\u3088\u308b\u81ea\u7136\u6392\u5c3f\u578b\u56de\u8178\u65b0\u8180\u80f1\u9020\u8a2d\u8853\uff0eAudio-Visual Journal of JUA\uff0e2011; 17(1): 17-6.<\/li>\n
                          13. \u5409\u826f\u3000\u8061\u3001\u8352\u6728\u52c7\u96c4\u3001\u7fbd\u6839\u7530\u7834\u3001\u5c0f\u6797\u82f1\u6a39\u3001\u6b66\u7530\u6b63\u4e4b\uff1a\u5973\u6027\u9aa8\u76e4\u81d3\u5668\u8131\u306b\u304a\u3051\u308b\u54b3\u30b9\u30c8\u30ec\u30b9\u30c6\u30b9\u30c8\u306e\u6709\u7528\u6027\uff0e\u65e5\u5973\u6027\u9aa8\u76e4\u5e95\u533b\u4f1a\u8a8c\u30002011; 8(1):18-20.<\/li>\n
                          14. \u5f71\u5c71\u3000\u9032\u3001\u5ca9\u57ce\u79c0\u51fa\u6d19\u3001\u76ca\u7530\u826f\u8ce2\u3001\u5409\u7530\u54f2\u4e5f\u3001\u6210\u7530\u5145\u5f18\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u30a8\u30b9\u30c8\u30e9\u30e0\u30b9\u30c1\u30f3\u4f75\u7528\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb\u5316\u5b66\u7642\u6cd5\u306b\u3088\u308a\u9577\u671f\u306e\u75c5\u52e2\u5b89\u5b9a\u304c\u5f97\u3089\u308c\u305f\u53bb\u52e2\u62b5\u6297\u6027\u524d\u7acb\u817a\u764c\u306e1\u4f8b\uff0e\u6ccc\u7d00\uff0e2011; 57(4): 203-7.<\/li>\n
                          15. \u5f71\u5c71\u3000\u9032\u3001\u524d\u6fa4\u5353\u4e5f\u3001\u5409\u7530\u54f2\u4e5f\u3001\u4f0a\u72e9\u3000\u4eae\u3001\u5bcc\u7530\u572d\u53f8\u3001\u82b1\u7530\u82f1\u7d00\u3001\u725b\u7530\u3000\u535a\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u6210\u7530\u5145\u5f18\u3001\u5ca1\u672c\u572d\u751f\u3001\u8352\u6728\u52c7\u96c4\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u9ad8\u30ea\u30b9\u30afT1\u8180\u80f1\u764c\u306b\u304a\u3051\u308b\u8853\u5f8c\u8180\u80f1\u5185\u6ce8\u5165\u7642\u6cd5\u306e\u691c\u8a0e\uff0e\u6ccc\u5916\uff0e2011; 24(5): 909-13.<\/li>\n
                          16. \u5bcc\u7530\u572d\u53f8\u3001\u7027\u672c\u5553\u592a\u3001\u91d1\u3000\u54f2\u5c07\uff1a\u7d4c\u5c3f\u9053\u7684\u524d\u7acb\u817a\u5207\u9664\u8853(TUR-P)\u5f8c\u306e\u767a\u71b1\u30ea\u30b9\u30af\u306e\u540c\u5b9a\u3068\u30ea\u30b9\u30af\u7fa4\u306b\u5bfe\u3059\u308b\u6297\u83cc\u85ac\u6295\u4e0e\u306e\u691c\u8a0e\uff0e\u6ccc\u5916\uff0e2011; 24(6): 1077-80.<\/li>\n
                          17. \u548c\u7530\u6643\u5178\u3001\u524d\u6fa4\u5353\u4e5f\u3001\u5f71\u5c71\u3000\u9032\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u6210\u7530\u5145\u5f18\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u8180\u80f1\u8ee2\u79fb\u3092\u6765\u305f\u3057\u305f\u814e\u7d30\u80de\u764c\u306e1\u4f8b\uff0e\u6ccc\u7d00\uff0e2011; 57(7): 381-3.<\/li>\n
                          18. \u897f\u5ddd\u4fe1\u4e4b\u3001\u9577\u8239\u3000\u5d07\u3001\u91d1\u3000\u54f2\u5c07\uff1a\u7cbe\u5de3\u9798\u819c\u56a2\u80de\u306e1\u4f8b.\u3000\u6ccc\u7d00 2011; 57(6):341-4.<\/li>\n
                          19. \u91d1\u3000\u54f2\u5c07\u3001\u4f50\u91ce\u592a\u4e00\u3001\u5bcc\u7530\u572d\u53f8\u3001\u7027\u672c\u5553\u592a\uff1a\u6839\u6cbb\u7684\u8180\u80f1\u5168\u6458\u9664\u8853\u304a\u3088\u3073\u4e00\u5074\u4e26\u5217\u5c3f\u7ba1\u76ae\u819a\u763b\u9020\u8a2d\u8853\u5f8c\u65e9\u671f\u306e\u9ebb\u75fa\u6027\u30a4\u30ec\u30a6\u30b9\u306e\u691c\u8a0e.\u3000\u6ccc\u7d002011; 57(10):535-8.<\/li>\n
                          20. \u91d1\u3000\u54f2\u5c07\u3001\u4f50\u91ce\u592a\u4e00\u3001\u5bcc\u7530\u572d\u53f8\u3001\u6751\u4e95\u4eae\u4ecb\u3001\u7027\u672c\u5553\u592a\u3001\u5ca1\u672c\u6b63\u543e\uff1a\u8180\u80f1\u764c\u306b\u5bfe\u3059\u308b\u6839\u6cbb\u7684\u8180\u80f1\u5168\u6458\u9664\u8853\u304a\u3088\u3073\u8179\u58c1\u5c3f\u7ba1\u30c8\u30f3\u30cd\u30eb\u5b89\u5b9a\u5316\u3092\u4f34\u3046\u30c1\u30e5\u30fc\u30d6\u30ec\u30b9\u5c3f\u7ba1\u76ae\u819a\u763b\u9020\u8a2d\u8853\u5f8c\u306e\u508d\u30b9\u30c8\u30fc\u30de\u30d8\u30eb\u30cb\u30a2\u306e\u983b\u5ea6\u3068\u5371\u967a\u56e0\u5b50\u306e\u691c\u8a0e. \u7532\u8cc0\u75c5\u7d002011; 14:55-61.<\/li>\n
                          21.  <\/li>\n<\/ol>\n

                            2010\u5e74<\/em><\/h2>\n
                              \n
                            1. Kageyama S, Tsuru T, Okamoto K, Narita M, Okada Y: Primary synovial sarcoma arising from a crossed ectopic kidney with fusion. Int J Urol. 2010 Jan;17(1):96-8.<\/li>\n
                            2. Minami K, Chano T, Kawakami T, Ushida H, Kushima R, Okabe H, Okada Y, Okamoto K: DNMT3L is a novel marker and is essential for the growth of human embryonal carcinoma. Clin Cancer Res. 2010 May 15;16(10):2751-9.<\/li>\n
                            3. Kim CJ, Takimoto K, Tomita K: Parastomal hernia after the construction of tubeless cutaneous ureterostomy: Report of a case. \u6ccc\u5916. 2010 23(6): 869-871.<\/li>\n
                            4. Yoshiyama M, Araki I, Kobayashi H, Zakoji H, Takeda M: Functional roles of TRPV1 channels in lower urinary tract irritated by acetic acid: in vivo evaluations of the sex difference in decerebrate unanesthetized mice. Am J Physiol Renal Physiol. 2010 Jun;298(6):F1351-9.<\/li>\n
                            5. Ikari R, Okamoto K, Yoshida T, Johnin K, Okabe H, Okada Y: A rare case of multiple schwannomas presenting with scrotal mass: a probable case of schwannomatosis. Int J Urol. 2010 Aug;17(8):734-6.<\/li>\n
                            6. Kanematsu A, Johnin K, Yoshimura K, Okubo K, Aoki K, Watanabe M, Yoshino K, Tanaka S, Tanikaze S, Ogawa O: Objective patterning of uroflowmetry curves in children with daytime and nighttime wetting. J Urol. 2010 Oct;184(4 Suppl):1674-9.<\/li>\n
                            7. \u5bcc\u7530\u572d\u53f8\u3001\u5ca9\u57ce\u79c0\u51fa\u6d19\u3001\u5f71\u5c71\u3000\u9032\u3001\u6210\u7530\u5145\u5f18\u3001\u5409\u8cb4\u9054\u5bdb\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u920d\u7684\u814e\u5916\u50b7\u306b\u3088\u308b\u814e\u52d5\u9759\u8108\u76ae\u819a\u763b\u306e1\u4f8b\uff0e\u6ccc\u7d00.\u30002010; 56(1): 25-8.<\/li>\n
                            8. \u91ce\u6751\u7167\u4e45\u3001\u8431\u6cbc\u8ce2\u53f8\u3001\u5c71\u5cb8\u3000\u656c\u3001\u9593\u5ead\u7ae0\u5149\u3001\u4e2d\u8fbc\u5b99\u53f2\u3001\u4e09\u795e\u88d5\u7d00\u3001\u5ea7\u5149\u5bfa\u79c0\u5178\u3001\u571f\u7530\u5b5d\u4e4b\u3001\u8352\u6728\u52c7\u96c4\u3001\u6b66\u7530\u6b63\u4e4b\uff1a\u814e\u816b\u760d\u306b\u5bfe\u3059\u308b\u814e\u90e8\u5206\u5207\u9664\u8853\u5f0f\u306e\u691c\u8a0e\uff1a\u30df\u30cb\u30de\u30e0\u5275\u624b\u8853\u3068\u4f53\u8154\u93e1\u4e0b\u624b\u8853\u306e\u691c\u8a0e\uff0e\u65e5\u30df\u30cb\u30de\u30e0\u5275\u6ccc\u5185\u8996\u93e1\u5916\u4f1a\u8a8c.\u30002010; 2(1): 79-84.<\/li>\n
                            9. \u5ea7\u5149\u5bfa\u79c0\u5178\u3001\u5bae\u672c\u9054\u4e5f\u3001\u795e\u5bb6\u6e80\u5b66\u3001\u72ac\u585a\u79c0\u5eb7\u3001\u571f\u7530\u5b5d\u4e4b\u3001\u8352\u6728\u52c7\u96c4\u3001\u6b66\u7530\u6b63\u4e4b\uff1a\u30ed\u30bf\u30a6\u30a3\u30eb\u30b9\u8178\u708e\u5f8c\u306b\u4e21\u5074\u5c3f\u7ba1\u7d50\u77f3\u306b\u3088\u308b\u6025\u6027\u814e\u4e0d\u5168\u3092\u5448\u3057\u305f2\u5e7c\u5150\u4f8b\uff0e\u3000\u65e5\u6ccc\u4f1a\u8a8c.\u30002010; 101(1): 29-33.<\/li>\n
                            10. \u5ea7\u5149\u5bfa\u79c0\u5178\u3001\u6fa4\u7530\u667a\u53f2\u3001\u9234\u6728\u7965\u53f8\u3001\u571f\u7530\u5b5d\u4e4b\u3001\u8352\u6728\u52c7\u96c4\u3001\u6b66\u7530\u6b63\u4e4b\uff1a\u53f3\u814e\u7d50\u77f3\u5408\u4f75\u4e0b\u5927\u9759\u8108\u5f8c\u5c3f\u7ba1\u306b\u5bfe\u3057\u3066\u5c3f\u7ba1\u5207\u65ad\u30fb\u5185\u8996\u93e1\u4e0b\u7d50\u77f3\u6458\u51fa\u30fb\u5c3f\u7ba1\u5c3f\u7ba1\u543b\u5408\u3092\u5f8c\u8179\u819c\u93e1\u4e0b\u306b\u65bd\u884c\u3057\u305f1\u4f8b\uff0e\u65e5\u5185\u8996\u93e1\u5916\u4f1a\u8a8c.\u30002010; 15(1): 111-4.<\/li>\n
                            11. \u5409\u826f\u3000\u8061\u3001\u8352\u6728\u52c7\u96c4\u3001\u4e09\u795e\u88d5\u7d00\u3001\u7fbd\u6839\u7530\u7834\u3001\u6fa4\u7530\u667a\u53f2\u3001\u6b66\u7530\u6b63\u4e4b\uff1a\u5973\u6027\u9aa8\u76e4\u81d3\u5668\u8131\u3068\u904e\u6d3b\u52d5\u8180\u80f1\uff0e\u65e5\u5973\u6027\u9aa8\u76e4\u5e95\u533b\u4f1a\u8a8c.\u30002010; 7(1): 187-90.<\/li>\n
                            12. \u5ca9\u57ce\u79c0\u51fa\u6d19\u3001\u6210\u7530\u5145\u5f18\u3001\u66fd\u6211\u5f18\u6a39\u3001\u5742\u91ce\u7950\u53f8\u3001\u5c0f\u897f\u3000\u5e73\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u524d\u7acb\u817a\u80a5\u5927\u75c7\u60a3\u8005\u306e\u591c\u9593\u983b\u5c3f\u3068\u7761\u7720\u969c\u5bb3\u306b\u5bfe\u3059\u308b\u30ca\u30d5\u30c8\u30d4\u30b8\u30eb\u306e\u6709\u7528\u6027\u306b\u3064\u3044\u3066.\u6ccc\u7d00.\u30002010; 56(4): 209-13.<\/li>\n
                            13. \u6c34\u6d41\u8f1d\u5f66\u3001\u5f71\u5c71\u3000\u9032\u3001\u6210\u7530\u5145\u5f18\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u591a\u7cbe\u5de3\u75c7\u306e1\u4f8b\uff0e\u65e5\u6ccc\u4f1a\u8a8c.\u30002010; 101(6): 738-41.<\/li>\n
                            14. \u82e5\u6749\u5409\u5ba3\u3001\u8d64\u7fbd\u7406\u4e5f\u3001\u91ce\u7530\u54f2\u53f2\u3001\u6cb3\u7530\u660e\u5f18\u3001\u524d\u6fa4\u5353\u4e5f\u3001\u5f71\u5c71\u3000\u9032\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u5343\u8449\u5e79\u592b\u3001\u84d1\u5185\u5fb3\u8535\uff1a\u5206\u5b50\u6a19\u7684\u85ac\u30bd\u30e9\u30d5\u30a7\u30cb\u30d6\u306b\u304a\u3051\u308b\u81ea\u65bd\u8a2d\u3067\u306e\u89e3\u6790\u306b\u57fa\u3065\u304f\u526f\u4f5c\u7528\u8aac\u660e\u66f8\u306e\u4f5c\u6210\uff0e\u65e5\u75c5\u85ac\u5e2b\u4f1a\u8a8c.\u30002010; 46(6): 775-9.<\/li>\n
                            15. \u6cb3\u91ce\u76f4\u660e\u3001\u90b5\u3000\u5553\u5168\u3001\u6d25\u5ddd\u62d3\u4e5f\u3001\u6751\u7530\u559c\u4ee3\u53f2\u3001\u725b\u7530\u3000\u535a\u3001\u5ca1\u672c\u572d\u751f\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u9650\u5c40\u6027\u524d\u7acb\u817a\u764c(\u9ad8\u30ea\u30b9\u30af\u7fa4)\u306b\u5bfe\u3059\u308b\u5f37\u5ea6\u5909\u8abf\u653e\u5c04\u7dda\u6cbb\u7642(IMRT)\u306e\u521d\u671f\u6cbb\u7642\u6210\u7e3e\uff0e\u6ccc\u5916.\u30002010; 23(8): 1173-4.<\/li>\n
                            16. \u5bcc\u7530\u572d\u53f8\u3001\u897f\u5ddd\u4fe1\u4e4b\u3001\u7027\u672c\u5553\u592a\u3001\u91d1\u3000\u54f2\u5c07\uff1a\u9ad8\u4f4d\u7cbe\u5de3\u6458\u9664\u8853\u5f8c\u306b\u30d2\u30c8\u7d68\u6bdb\u6027\u30b4\u30ca\u30c9\u30c8\u30ed\u30d4\u30f3\u03b2(hCG-\u03b2)\u304c\u507d\u967d\u6027\u3092\u5448\u3057\u305fStage I\u30bb\u30df\u30ce\u30fc\u30de\u306e1\u4f8b\uff0e\u6ccc\u7d00.\u30002010; 56(11): 663-5.<\/li>\n<\/ol>\n

                              2009\u5e74<\/em><\/h2>\n
                                \n
                              1. Kim CJ, Takimoto K, Tomita K, Osafune T: A comparison of management of hemorrhage following transurethral resection of the prostate between routine continuous bladder irrigation and no bladder irrigation with catheter traction: A prospective randomized study. Jpn J Endourol ESWL. 2009 22(1):88-91.<\/li>\n
                              2. Kageyama S, Isono T, Matsuda S, Ushio Y, Satomura S, Terai A, Arai Y, Kawakita M, Okada Y, Yoshiki T: Urinary calreticulin in the diagnosis of bladder urothelial carcinoma. Int J Urol. 2009 May;16(5):481-6.<\/li>\n
                              3. Isono T, Kim CJ, Ando Y, Sakurai H, Okada Y, Inoue H: Suppression of cell invasiveness by periostin via TAB1\/TAK1. Int J Oncol. 2009 Aug;35(2):425-32.<\/li>\n
                              4. Kim CJ, Nishi K, Isono T, Okuyama Y, Tambe Y, Okada Y, Inoue H: Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells. Mol Carcinog. 2009 Oct;48(10):953-64.<\/li>\n
                              5. Kim CJ, Takimoto K, Tomita K, Osafune T, Nishikawa N, Johnin K, Okada Y: Evaluation of hydronephrosis with tubeless cutaneous ureterostomy using Tc-99m MAG3 diuretic renography. Clin Nucl Med. 2009 Oct;34(10):666-9.<\/li>\n
                              6. Oda K, Makino S, Masuda C, Yoshiki T, Kitamura Y, Takata K, Yanagisawa D, Taniguchi T, Tooyama I: The mRNA distribution of C7orf24, a gamma-glutamyl cyclotransferase, in rat tissues. J Histochem Cytochem. 2009 Dec;57(12):1121-6.<\/li>\n
                              7. \u725b\u7530\u3000\u535a\u3001\u6c34\u6d41\u8f1d\u5f66\u3001\u5f71\u5c71\u3000\u9032\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u6210\u7530\u5145\u5f18\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u8457\u660e\u306a\u708e\u75c7\u6027\u30dd\u30ea\u30fc\u30d7\u3092\u5408\u4f75\u3057\u305f\u5c3f\u7ba1\u7d50\u77f3\u306b\u5bfe\u3059\u308b\u5f8c\u8179\u819c\u93e1\u4e0b\u5c3f\u7ba1\u5207\u77f3\u3001\u30dd\u30ea\u30fc\u30d7\u5207\u9664\u8853\u306e1\u4f8b\uff0e\u3000Jpn J Endourol ESWL.\u30002009; 22(1): 115-9.<\/li>\n
                              8. \u524d\u6fa4\u5353\u4e5f\u3001\u6210\u7530\u5145\u5f18\u3001\u4f50\u91ce\u592a\u4e00\u3001\u5f71\u5c71\u3000\u9032\u3001\u5ca9\u57ce\u79c0\u51fa\u6d19\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u8179\u8154\u93e1\u4e0b\u306b\u6458\u51fa\u3057\u305f\u5f8c\u8179\u819c\u795e\u7d4c\u9798\u7a2e\u306e1\u4f8b\uff0e\u3000\u6ccc\u7d00.\u30002009; 55(3): 129-31.<\/li>\n
                              9. \u91d1\u3000\u54f2\u5c07\u3001\u7027\u672c\u5553\u592a\u3001\u5bcc\u7530\u572d\u53f8\u3001\u9577\u8239\u3000\u5d07\u3001\u897f\u5ddd\u4fe1\u4e4b\uff1a\u30c1\u30e5\u30fc\u30d6\u30ec\u30b9\u5c3f\u7ba1\u76ae\u819a\u763b\u306e\u6cbb\u7642\u6210\u7e3e\uff0e\u3000\u6ccc\u7d00.\u30002009; 55(7): 385-7.<\/li>\n
                              10. \u5b89\u7530\u771f\u5b50\u3001\u4e00\u8272\u5553\u4e8c\u3001\u5742\u53e3\u6b63\u82b3\u3001\u91d1\u5d0e\u96c5\u7f8e\u3001\u52a0\u85e4\u7d00\u5b50\u3001\u5c71\u539f\u5eb7\u4f51\u3001\u9ad8\u6728\u5f69\u4e43\u3001\u5ca9\u4e95\u3000\u74b0\u3001\u4e0a\u7530\u4e45\u5df3\u3001\u8352\u6728\u4fe1\u4e00\u3001\u6749\u672c\u4fca\u90ce\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u5b87\u6d25\u3000\u8cb4\uff1aPR3-ANCA\u3001MPO-ANCA\u3068\u3082\u306b\u967d\u6027\u306e\u534a\u6708\u4f53\u5f62\u6210\u6027\u7cf8\u7403\u4f53\u814e\u708e\u306b\u80ba\u5916\u30ea\u30f3\u30d1\u7bc0\u7d50\u6838\u306e\u95a2\u4e0e\u304c\u793a\u5506\u3055\u308c\u305f\u900f\u6790\u5c0e\u5165\u60a3\u8005\u306e1\u4f8b.\u3000\u65e5\u900f\u6790\u533b\u5b66\u4f1a\u8a8c.\u30002009; 42(12): 965-972.<\/li>\n<\/ol>\n

                                2008\u5e74<\/em><\/h2>\n
                                  \n
                                1. Kim CJ, Isono T, Tambe Y, Chano T, Okabe H, Okada Y, Inoue H: Role of alternative splicing of periostin in human bladder carcinogenesis. Int J Oncol. 2008 Jan;32(1):161-9.<\/li>\n
                                2. Ushida H, Johnin K, Koizumi S, Kadowaki T, Masada T, Okada Y: Subacute adrenal hemorrhage by blunt abdominal contusion during snowboarding. \u6ecb\u8cc0\u533b\u5927\u8a8c 2008 21(1):1-3.<\/li>\n
                                3. Osawa N, Sakaguchi M, Sugimoto T, Isshiki K, Kanasaki M, Nishio T, Uzu T, Kashiwagi A, Okada Y: Does empiric treatment with fluoroquinolones delay the diagnosis of tuberculosis in patients with hemodialysis? Hemodial Int. 2008 Oct;12(4):499-500.<\/li>\n
                                4. \u725b\u7530\u3000\u535a\u3001\u76ca\u7530\u826f\u8ce2\u3001\u5c0f\u6cc9\u4fee\u4e00\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u9aa8\u76e4\u5185\u3092\u5360\u62e0\u3059\u308b\u307e\u3067\u62e1\u5f35\u3057\u305f\u5de6\u5de8\u5927\u5c3f\u7ba1\u306b\u767a\u751f\u3057\u305f\u5c3f\u7ba1\u764c\u306e1\u4f8b\uff0e\u3000\u65e5\u6ccc\u4f1a\u8a8c.\u30002008; 99(7): 733-6.<\/li>\n
                                5. \u4e00\u8272\u5553\u4e8c\u3001\u4e2d\u6fa4\u3000\u7d14\u3001\u6749\u672c\u4fca\u90ce\u3001\u5742\u53e3\u6b63\u82b3\u3001\u5c0f\u5c71\u54f2\u6717\u3001\u7530\u4e2d\u3000\u656c\u3001\u6b66\u7530\u5c1a\u5b50\u3001\u7530\u4e2d\u88d5\u7d00\u3001\u5b89\u7530\u771f\u5b50\u3001\u6d25\u7530\u5b89\u90fd\u5b50\u3001\u4e45\u7c73\u771f\u53f8\u3001\u91d1\u5d0e\u96c5\u7f8e\u3001\u8352\u6728\u4fe1\u4e00\u3001\u5ddd\u6dfb\u667a\u9053\u3001\u6642\u7530\u7531\u7f8e\u5b50\u3001\u4e2d\u6751\u7d18\u5b50\u3001\u524d\u7530\u61b2\u543e\u3001\u5bcc\u7530\u8015\u5f6c\u3001\u5b87\u6d25\u3000\u8cb4\u3001\u9ad8\u6a4b\u3000\u5fcd\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u6458\u51fa\u816b\u7624\u306e\u75c5\u7406\u7d44\u7e54\u6a19\u672c\u6240\u898b\u3088\u308a\u981a\u690e\u816b\u760d\u72b6\u77f3\u7070\u6c88\u7740\u75c7(cervical tumoral calcinosis)\u3068\u8a3a\u65ad\u3057\u5f97\u305f\u7dad\u6301\u900f\u6790\u60a3\u8005\u306e1\u4f8b\uff0e\u3000\u65e5\u900f\u6790\u533b\u5b66\u4f1a\u8a8c.\u30002008; 41(8): 483-8.<\/li>\n
                                6. \u82b1\u7530\u82f1\u7d00\u3001\u5f71\u5c71\u3000\u9032\u3001\u6210\u7530\u5145\u5f18\u3001\u91d1\u3000\u54f2\u5c06\u3001\u5409\u8cb4\u9054\u5bdb\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u6cb3\u91ce\u76f4\u660e\u3001\u53e4\u5ddd\u3000\u9855\uff1a\u5916\u50b7\u306b\u3088\u308a\u767a\u75c7\u3057\u305f\u52d5\u8108\u6d41\u5165\u904e\u5270\u578b\u6301\u7d9a\u52c3\u8d77\u75c7\u306e1\u4f8b\uff0e\u3000\u6ccc\u7d00.\u30002008; 54(9): 633-5.<\/li>\n
                                7. \u725b\u7530\u3000\u535a\u3001\u76ca\u7530\u826f\u8ce2\u3001\u5409\u7530\u54f2\u4e5f\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u56de\u8178\u65b0\u8180\u80f1\u9020\u8a2d\u8853\u5f8c\u306e\u5c3f\u9053\u518d\u767a\u306b\u5bfe\u3059\u308b\u866b\u5782\u5229\u7528\u81ea\u5df1\u5c0e\u5c3f\u578b\u5c3f\u8def\u518d\u5909\u5411\u8853\u306e\u7d4c\u9a13\uff0e\u3000\u6ccc\u7d00.\u30002008; 54(11): 749-52.<\/li>\n
                                8. \u91d1\u3000\u54f2\u5c07\u3001\u897f\u5ddd\u4fe1\u4e4b\u3001\u9577\u8239\u3000\u5d07\uff1a\u524d\u7acb\u817a\u5bb9\u7a4d20ml\u672a\u6e80\u306e\u75c7\u4f8b\u306b\u5bfe\u3059\u308b\u7d4c\u5c3f\u9053\u7684\u524d\u7acb\u817a\u5207\u9664\u8853\u306e\u81e8\u5e8a\u7684\u691c\u8a0e.\u3000Jpn J Endourol ESWL 2008; 21(2):225-9<\/li>\n
                                9. \u9577\u8239\u3000\u5d07\u3001\u7027\u672c\u5553\u592a\u3001\u91d1\u3000\u54f2\u5c07\uff1a\u6839\u6cbb\u7684\u524d\u7acb\u817a\u5168\u6458\u8853\u5f8c\u306e\u30c9\u30ec\u30ca\u30fc\u30b8\u30c1\u30e5\u30fc\u30d6\u81ea\u7136\u65ad\u88c2.\u3000\u81e8\u6ccc 2008; 62(11):893-5.<\/li>\n<\/ol>\n

                                  2007\u5e74<\/em><\/h2>\n
                                    \n
                                  1. Kato M, Takeda A, Saito S, Terai A, Taki Y, Kato S, Okada Y, Ogawa O, Arai Y; Tohoku-Kyoto Urinary Reconstruction Study Group: Long-term functional outcomes of ileal and sigmoid orthotopic neobladder procedures. Urology. 2007 Jan;69(1):74-7.<\/li>\n
                                  2. Takazakura R, Johnin K, Furukawa A, Nitta N, Takahashi M, Okada Y, Murata K: Magnetic resonance voiding cystourethrography for vesicoureteral reflux. J Magn Reson Imaging. 2007 Jan;25(1):170-4.<\/li>\n
                                  3. Kageyama S, Iwaki H, Inoue H, Isono T, Yuasa T, Nogawa M, Maekawa T, Ueda M, Kajita Y, Ogawa O, Toguchida J, Yoshiki T: A novel tumor-related protein, C7orf24, identified by proteome differential display of bladder urothelial carcinoma. Proteomics Clin Appl. 2007 Feb;1(2):192-9.<\/li>\n
                                  4. Johnin K, Narita M, Kim CJ, Wakabayashi Y, Yoshiki T, Okada Y: Bilateral single ectopic ureters with hypoplastic bladder: how should we treat these challenging entities? J Pediatr Urol. 2007 Jun;3(3):243-6.<\/li>\n
                                  5. Iwaki H, Johnin K, Kageyama S, Kim CJ, Isono T, Yoshiki T: Up-regulation of urinary UPIII mRNA levels in vesicoureteral reflux patients: potential application as a screening test for vesicoureteral reflux. Int J Urol. 2007 Oct;14(10):918-23.<\/li>\n
                                  6. Zeng Y, Wu XX, Homma Y, Yoshimura N, Iwaki H, Kageyama S, Yoshiki T, Kakehi Y: Uroplakin III-delta4 messenger RNA as a promising marker to identify nonulcerative interstitial cystitis. J Urol. 2007 Oct;178(4 Pt 1):1322-7.<\/li>\n
                                  7. \u6749\u672c\u4fca\u90ce\u3001\u5411\u702c\u3000\u7763\u3001\u91d1\u5d0e\u5553\u9020\u3001\u7267\u77f3\u5fb9\u4e5f\u3001\u9ad8\u8c37\u5b63\u7a42\u3001\u8352\u6728\u4e45\u6f84\u3001\u5b97\u6751\u4e07\u91cc\u5b50\u3001\u51fa\u8def\u5948\u7dd2\u5b50\u3001\u5e73\u7530\u90a6\u592b\u3001\u4e2d\u6ca2 \u7d14\u3001\u4e00\u8272\u5553\u4e8c\u3001\u91d1\u5d0e\u96c5\u7f8e\u3001\u5ddd\u6dfb\u667a\u9053\u3001\u5b87\u6d25\u3000\u8cb4\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u58ca\u75bd\u5207\u65ad\u80a2\u306b\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u585e\u6813\u75c7\u3092\u8a8d\u3081\u305f\u7dad\u6301\u8840\u6db2\u900f\u6790\u60a3\u8005\u306e1\u4f8b.\u3000\u65e5\u900f\u6790\u533b\u5b66\u4f1a\u8a8c.\u30002007; 40(2): 189-193.<\/li>\n
                                  8. \u52a0\u85e4\u6b63\u5178\u3001\u7af9\u7530\u7be4\u53f2\u3001\u4e26\u6728\u4fca\u4e00\u3001\u8352\u4e95\u967d\u4e00\u3001\u5409\u6751\u8015\u6cbb\u3001\u5c0f\u5ddd\u3000\u4fee\u3001\u7027\u3000\u6d0b\u4e8c\u3001\u5bfa\u4e95\u7ae0\u4eba\u3001\u52a0\u85e4\u614e\u4e4b\u4ecb\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u809b\u9580\u6e29\u5b58\u624b\u8853\u3068\u4ee3\u7528\u8180\u80f1\u306eQOL \u5c3f\u8def\u5909\u5411\u8853\u306b\u304a\u3051\u308b\u8853\u5f0f\u5225QOL\u306e\u6bd4\u8f03\u691c\u8a0e.\u3000\u65e5\u30b9\u30c8\u30fc\u30de\uff65\u6392\u6cc4\u4f1a\u8a8c.\u30002007; 23(3): 97-102.<\/li>\n
                                  9. \u897f\u5ddd\u4fe1\u4e4b\u3001\u9f4a\u85e4\u4eae\u4e00\u3001\u9577\u8239\u3000\u5d07\u3001\u91d1\u3000\u54f2\u5c07\uff1a\u7cbe\u7d22\u7d50\u6838\u306e1\u4f8b.\u3000\u6ccc\u5916 2007; 20(5):695-7.<\/li>\n<\/ol>\n

                                    2006\u5e74<\/em><\/h2>\n
                                      \n
                                    1. Yuasa T, Yoshida T, Wakabayashi Y, Kataoka A, Narita M, Yoshiki T, Okada Y: Successful treatment of disseminated extragonadal germ cell cancer with intensive conventional chemotherapy after first-line high-dose chemotherapy. Int J Clin Oncol. 2006 Feb;11(1):60-3.<\/li>\n
                                    2. Kawakami T, Chano T, Minami K, Okabe H, Okada Y, Okamoto K: Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma. Hum Mol Genet. 2006 Mar 15;15(6):821-30.<\/li>\n
                                    3. Kawakami T, Zhang C, Okada Y, Okamoto K: Erasure of methylation imprint at the promoter and CTCF-binding site upstream of H19 in human testicular germ cell tumors of adolescents indicate their fetal germ cell origin. Oncogene. 2006 Jun 1;25(23):3225-36.<\/li>\n
                                    4. Arai Y, Takeda A, Taki Y, Okada Y, Ogawa O; Tohoku-Kyoto Urinary Reconstruction Study Group: 5-year interval change in voiding function of orthotopic ileal neobladder. Int J Urol. 2006 Jun;13(6):703-6.<\/li>\n
                                    5. Kataoka A, Yuasa T, Kageyama S, Tsuchiya N, Habuchi T, Iwaki H, Narita M, Okada Y, Yoshiki T: Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen. Clin Oncol (R Coll Radiol). 2006 Aug;18(6):480-4.<\/li>\n
                                    6. \u6749\u672c\u4fca\u90ce\u3001\u5411\u702c\u3000\u7763\u3001\u91d1\u5d0e\u5553\u9020\u3001\u7267\u77f3\u5fb9\u4e5f\u3001\u9ad8\u8c37\u5b63\u7a42\u3001\u8352\u6728\u4e45\u6f84\u3001\u5b97\u6751\u4e07\u91cc\u5b50\u3001\u51fa\u8def\u5948\u7dd2\u5b50\u3001\u5e73\u7530\u90a6\u592b\u3001\u4e2d\u6fa4\u3000\u7d14\u3001\u4e00\u8272\u5553\u4e8c\u3001\u91d1\u5d0e\u96c5\u7f8e\u3001\u5ddd\u6dfb\u667a\u9053\u3001\u5b87\u6d25\u3000\u8cb4\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u58ca\u75d5\u5207\u65ad\u80a2\u306b\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u585e\u6813\u75c7\u3092\u8a8d\u3081\u305f\u7dad\u6301\u8840\u6db2\u900f\u6790\u60a3\u8005\u306e1\u4f8b\uff0e\u3000\u65e5\u900f\u6790\u533b\u5b66\u4f1a\u8a8c.\u30002006; 40(2): 189-93.<\/li>\n
                                    7. \u8d64\u7fbd\u7406\u4e5f\u3001\u5742\u91ce\u7950\u53f8\u3001\u5f71\u5c71\u3000\u9032\u3001\u6210\u7530\u5145\u5f18\u3001\u5343\u8449\u5e79\u592b\u3001\u5c71\u8def\u3000\u662d\uff1a\u30db\u30eb\u30e2\u30f3\u62b5\u6297\u6027\u524d\u7acb\u817a\u304c\u3093\u306b\u5bfe\u3059\u308b\u9069\u5fdc\u5916\u4f75\u7528\u5316\u5b66\u7642\u6cd5\uff0e\uff0d\u30bf\u30ad\u30b5\u30f3\u7cfb\u6297\u304c\u3093\u5264\uff08\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb\u3001\u30d1\u30af\u30ea\u30bf\u30ad\u30bb\u30eb\uff09\uff0b\u30a8\u30b9\u30c8\u30e9\u30e0\u30b9\u30c1\u30f3\u306e\u6cbb\u7642\u52b9\u679c\u3068\u85ac\u5264\u5e2b\u306e\u95a2\u308f\u308a\uff0d\uff0e\u3000\u65e5\u75c5\u85ac\u5e2b\u4f1a\u8a8c.\u30002006; 42(8): 1075-8.<\/li>\n
                                    8. \u5f71\u5c71\u3000\u9032\u3001\u6210\u7530\u5145\u5f18\u3001\u91d1\u3000\u54f2\u5c07\u3001\u82b1\u7530\u82f1\u7d00\u3001\u5742\u91ce\u7950\u53f8\u3001\u5ca9\u57ce\u79c0\u51fa\u6d19\u3001\u5409\u8cb4\u9054\u5bdb\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u524d\u7acb\u817a\u5c0f\u7d30\u80de\u764c\u306e3\u4f8b\uff0d\u672c\u90a6\u5831\u544a\u4f8b\u306b\u3088\u308b\u4e88\u5f8c\u89e3\u6790\uff0d\uff0e\u3000\u6ccc\u7d00.\u30002006; 52(10): 809-15.<\/li>\n<\/ol>\n

                                      2005\u5e74<\/em><\/h2>\n
                                        \n
                                      1. Wakabayashi Y, Narita M, Kim CJ, Hanada E, Yoshiki T, Okada Y: A training method for accurate suturing in laparoscopic urethrovesical anastomosis using dotted tubes. Jpn J Endourol ESWL. 2005 18(1):131-2.<\/li>\n
                                      2. Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, Yokota A, Segawa H, Toda Y, Kageyama S, Yoshiki T, Okada Y, Maekawa T: Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest. 2005 Apr;115(4):978-85.<\/li>\n
                                      3. Kataoka A, Yuasa T, Kageyama S, Iwaki H, Higuchi K, Tanaka T, Okada Y, Yoshiki T: Expression of thymidine phosphorylase correlates with microvessel density in prostate cancer. Oncol Rep. 2005 Apr;13(4):597-600.<\/li>\n
                                      4. Zhang C, Kawakami T, Okada Y, Okamoto K: Distinctive epigenetic phenotype of cancer testis antigen genes among seminomatous and nonseminomatous testicular germ-cell tumors. Genes Chromosomes Cancer. 2005 May;43(1):104-12.<\/li>\n
                                      5. Kim CJ, Wakabayashi Y, Sakano Y, Johnin K, Yoshiki T, Okada Y: Simple technique for improving tubeless cutaneous ureterostomy. Urology. 2005 Jun;65(6):1221-5.<\/li>\n
                                      6. Kim CJ, Yoshioka N, Tambe Y, Kushima R, Okada Y, Inoue H: Periostin is down-regulated in high grade human bladder cancers and suppresses in vitro cell invasiveness and in vivo metastasis of cancer cells. Int J Cancer. 2005 Oct 20;117(1):51-8.<\/li>\n
                                      7. \u6771\u3000\u7fa9\u4eba\u3001\u5c71\u7530\u3000\u4ec1\u3001\u5c0f\u5800\u3000\u8c6a\u3001\u5e73\u4e95\u614e\u4e8c\u3001\u5ddd\u6751\u58fd\u4e00\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u4e0a\u90e8\u5c3f\u8def\u7d50\u77f3\u75c7\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u30a6\u30ed\u30ab\u30eb\u30f3\u5c0f\u578b\u5316\u9320\u306e\u81e8\u5e8a\u7684\u540c\u7b49\u6027\u8a66\u9a13.\u3000\u6ccc\u7d00.\u30002005; 51(3): 215-23.<\/li>\n
                                      8. \u897f\u5ddd\u4fe1\u4e4b\u3001\u9f4a\u85e4\u4eae\u4e00\u3001\u4e0a\u7530\u670b\u5b8f\u3001\u91d1\u3000\u54f2\u5c07\u3001\u6751\u4e0a\u967d\u5b50\u3001\u4e95\u672c\u52dd\u6cbb\u3001\u5742\u672c\u3000\u529b\uff1a\u6025\u6027\u8179\u75c7\u306b\u3066\u767a\u75c7\u3057\u305f\u814e\u8840\u7ba1\u7b4b\u8102\u80aa\u816b\u81ea\u7136\u7834\u88c2\u306e2\u4f8b.\u3000\u7532\u8cc0\u75c5\u7d00 2005; 8:89-93.<\/li>\n

                                        <\/ol>\n

                                        2004\u5e74<\/em><\/h2>\n
                                          \n
                                        1. Kawakami T, Okamoto K, Ogawa O, Okada Y: XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. Lancet. 2004 Jan 3;363(9402):40-2.<\/li>\n
                                        2. Kim CJ, Wakabayashi Y, Kushima R, Sakano Y, Yoshiki T, Okada Y: Retroperitoneal lymph node dissection in patients with interaortocaval lymph node metastases of transitional cell carcinoma of the urinary tract. Int J Urol. 2004 Apr;11(4):243-7.<\/li>\n
                                        3. Wakabayashi Y, Narita M, Kim CJ, Kawakami T, Yoshiki T, Okada Y: Renal hypothermia using ice slush for retroperitoneal laparoscopic partial nephrectomy. Urology. 2004 Apr;63(4):773-5.<\/li>\n
                                        4. Kageyama S, Isono T, Iwaki H, Wakabayashi Y, Okada Y, Kontani K, Yoshimura K, Terai A, Arai Y, Yoshiki T: Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem. 2004 May;50(5):857-66.<\/li>\n
                                        5. Kawakami T, Okamoto K, Sugihara H, Hattori T, Reeve AE, Ogawa O, Okada Y: The MET proto-oncogene is not a major target for the gain of chromosome 7 in testicular germ-cell tumors of adolescents. Virchows Arch. 2004 May;444(5):480-1.<\/li>\n
                                        6. Kawakami T, Zhang C, Taniguchi T, Kim CJ, Okada Y, Sugihara H, Hattori T, Reeve AE, Ogawa O, Okamoto K: Characterization of loss-of-inactive X in Klinefelter syndrome and female-derived cancer cells. Oncogene. 2004 Aug 12;23(36):6163-9.<\/li>\n
                                        7. Iwaki H, Kageyama S, Isono T, Wakabayashi Y, Okada Y, Yoshimura K, Terai A, Arai Y, Iwamura H, Kawakita M, Yoshiki T: Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma -synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci. 2004 Dec;95(12):955-61.<\/li>\n
                                        8. \u7802\u5009\u745e\u660e\u3001\u585a\u672c\u54f2\u90ce\u3001\u7c73\u702c\u6df3\u4e8c\u3001\u4e2d\u77f3\u771f\u884c\u3001\u5927\u4e45\u4fdd\u96c4\u5e73\u3001\u524d\u6fa4\u5353\u4e5f\u3001\u7027\u672c\u5553\u592a\u3001\u798f\u4e95\u3000\u5dd6\u3001\u4e2d\u5ddd\u3000\u5065\u3001\u5965\u6751\u3000\u6804\u3001\u77f3\u5ddd\u96c4\u4e00\u3001\u9752\u6728\u3000\u671b\uff1aVIP\u3092\u7de9\u89e3\u5c0e\u5165\u7642\u6cd5\u3068\u3057\u305f\u975e\u30bb\u30df\u30ce\u30fc\u30de\u6027\u817a\u5916\u80da\u7d30\u80de\u816b\u760d6\u4f8b\u306e\u6cbb\u7642\u6210\u7e3e\uff0e\u3000\u65e5\u6ccc\u4f1a\u8a8c.\u30002004; 95(3): 634-7.<\/li>\n
                                        9. \u82b1\u7530\u82f1\u7d00\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u7247\u5ca1\u3000\u6643\u3001\u82e5\u6797\u8ce2\u5f66\u3001\u5409\u8cb4\u9054\u5bdb\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u4ed9\u5c3e\u90e8\u5947\u5f62\u816b\u306e\u8853\u5f8c\u306b\u767a\u751f\u3057\u305f\u6392\u5c3f\u969c\u5bb3\u306e1\u4f8b\uff0e\u3000\u65e5\u6ccc\u4f1a\u8a8c.\u30002004; 95(4): 692-6.<\/li>\n
                                        10. \u76ca\u7530\u826f\u8ce2\u3001\u5ddd\u4e0a\u4eab\u5f18\u3001\u91d1\u3000\u54f2\u5c07\u3001\u82e5\u6797\u8ce2\u5f66\u3001\u5409\u8cb4\u9054\u5bdb\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u5b50\u5bae\u5916\u598a\u5a20\u6cbb\u7642\u4e2d\u306b\u5076\u7136\u767a\u898b\u3055\u308c\u305f\u8180\u80f1nephrogenic adenoma\uff0e\u3000\u81e8\u6ccc.\u30002004; 58(5): 319-21.<\/li>\n
                                        11. \u725b\u7530\u3000\u535a\u3001\u5c0f\u6cc9\u4fee\u4e00\uff1a\u79fb\u884c\u4e0a\u76ae\u764c\u3068\u9451\u5225\u56f0\u96e3\u3067\u3042\u3063\u305f\u524d\u7acb\u817a\u5c0e\u7ba1\u764c\u306e1\u4f8b\uff0e\u3000\u6ccc\u7d00.\u30002004; 50(5): 535-8.<\/li>\n
                                        12. \u4e0a\u4ec1\u6570\u7fa9\u3001\u76ca\u7530\u826f\u8ce2\u3001\u82b1\u7530\u82f1\u7d00\u3001\u91d1\u3000\u54f2\u5c07\u3001\u82e5\u6797\u8ce2\u5f66\u3001\u5409\u8cb4\u9054\u5bdb\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u96e3\u6cbb\u6027\u591c\u5c3f\u75c7\u306b\u5bfe\u3059\u308b\u6f22\u65b9\u85ac\u5c11\u91cf\u4f75\u7528\u306e\u6709\u7528\u6027\u306b\u3064\u3044\u3066\uff0e\u3000\u591c\u5c3f\u75c7\u7814.\u30002004; 9: 59-65.<\/li>\n
                                        13. \u5c71\u672c\u65b0\u543e\u3001\u56fd\u5cf6\u5eb7\u6674\u3001\u91d1\u4e38\u8070\u6df3\u3001\u4f0a\u85e4\u54f2\u4e4b\u3001\u6728\u4e0b\u79c0\u6587\u3001\u8cc0\u672c\u654f\u884c\u3001\u5c0f\u5ddd\u3000\u4fee\u3001\u8352\u4e95\u967d\u4e00\u3001\u5bfa\u5730\u654f\u90ce\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u897f\u5c3e\u606d\u898f\u3001\u91d1\u4e38\u6d0b\u53f2\u3001\u4e7e\u3000\u653f\u5fd7\u3001\u6d45\u59bb\u3000\u9855\u3001\u91d1\u8c37\u3000\u52f3\u3001\u4f50\u3005\u6728\u7f8e\u6674\u3001\u897f\u5ddd\u4fe1\u4e4b\u3001\u98db\u7530\u53ce\u4e00\u3001\u91ce\u3005\u6751\u5149\u751f\u3001\u5bfa\u4e95\u7ae0\u4eba\u3001\u5c0f\u5009\u5553\u53f8\u3001\u5149\u68ee\u5065\u4e8c\u3001\u897f\u6751\u4e00\u7537\u3001\u5927\u897f\u88d5\u4e4b\u3001\u5800\u4e95\u6cf0\u6a39\u3001\u5c71\u5d0e\u4fca\u6210\uff1a\u6ccc\u5c3f\u5668\u79d1\u9818\u57df\u306b\u304a\u3051\u308b\u5468\u8853\u671f\u611f\u67d3\u75c7\u963b\u6b62\u85ac\u9069\u6b63\u4f7f\u7528\u306b\u95a2\u3059\u308b\u591a\u65bd\u8a2d\u5171\u540c\u7814\u7a76\uff0e\u3000\u6ccc\u7d00.\u30002004; 50(10): 673-83.<\/li>\n
                                        14. \u6210\u7530\u5145\u5f18\u3001\u524d\u6fa4\u5353\u4e5f\u3001\u6797\u7530\u82f1\u8cc7\u3001\u6c34\u91ce\u9686\u5143\u3001\u524d\u7530\u5eb7\u79c0\u3001\u82e5\u6797\u8ce2\u5f66\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u6839\u6cbb\u7684\u524d\u7acb\u817a\u6458\u9664\u8853\u306b\u304a\u3051\u308b\u524d\u7acb\u817a\u5c16\u90e8\u3078\u306e\u30a2\u30d7\u30ed\u30fc\u30c1\u6cd5\u306e\u6539\u826f\u3000\u8853\u5f8c\u5c3f\u5931\u7981\u306b\u95a2\u3059\u308b\u691c\u8a0e\uff0e\u3000\u6ccc\u5916.\u30002004; 17(11): 673-83.<\/li>\n
                                        15. \u82e5\u6797\u8ce2\u5f66\u3001\u91d1\u3000\u54f2\u5c07\u3001\u5742\u91ce\u7950\u53f8\u3001\u6210\u7530\u5145\u5f18\u3001\u5ca1\u7530\u88d5\u4f5c\uff1aIce slush\u3092\u7528\u3044\u305f\u814e\u51b7\u5374\u306b\u3088\u308b\u5f8c\u8179\u819c\u93e1\u4e0b\u814e\u90e8\u5206\u5207\u9664\u8853\uff0e\u3000Video Journal of JUA.\u30002004; 10: 17.<\/li>\n
                                        16. \u6749\u672c\u4fca\u90ce\u3001\u51fa\u8def\u5948\u7dd2\u5b50\u3001\u78ef\u91ce\u5143\u79c0\u3001\u4e45\u7c73\u771f\u53f8\u3001\u5927\u6fa4\u7d00\u4e4b\u3001\u91d1\u5d0e\u5553\u9020\u3001\u8352\u6728\u4fe1\u4e00\u3001\u4e00\u8272\u5553\u4e8c\u3001\u5ddd\u6dfb\u667a\u9053\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u53e4\u5bb6\u5927\u7950\uff1a\u305f\u3053\u3064\u307c\u578b\u5fc3\u7b4b\u969c\u5bb3\u3092\u5408\u4f75\u3057\u96c6\u5b66\u7684\u6cbb\u7642\u306b\u3066\u6551\u547d\u3057\u3048\u305f\u6025\u6027\u814e\u4e0d\u5168\u306e1\u4f8b.\u3000\u65e5\u900f\u6790\u533b\u5b66\u4f1a\u8a8c.\u30002004; 37(12): 2093-8.<\/li>\n<\/ol>\n

                                          2003\u5e74<\/em><\/h2>\n
                                            \n
                                          1. Kawakami T, Okamoto K, Ogawa O, Okada Y: Multipoint methylation and expression analysis of tumor suppressor genes in human renal cancer cells. Urology. 2003 Jan;61(1):226-30.<\/li>\n
                                          2. Kawakami T, Wakabayashi Y, Aimi Y, Isono T, Okada Y: Developmental expression of glial cell-line derived neurotrophic factor, neurturin, and their receptor mRNA in the rat urinary bladder. Neurourol Urodyn. 2003;22(1):83-8.<\/li>\n
                                          3. Wakabayashi Y, Kataoka A, Johnin K, Yoshiki T, Okada Y: Simple techniques for atraumatic peritoneal dissection from the abdominal wall and for preventing peritoneal injury during trocar placement under retroperitoneoscopy. J Urol. 2003 Jan;169(1):256-7.<\/li>\n
                                          4. Johnin K, Kadowaki T, Kushima M, Ushida H, Koizumi S, Okada Y: Primary heterologous carcinosarcoma of the ureter with necrotic malignant polyps. Report of a case and review of the literature. Urol Int. 2003;70(3):232-5.<\/li>\n
                                          5. Wakabayashi Y, Kataoka A, Koizumi S, Sakano Y, Johnin K, Narita M, Kim CJ, Yoshiki T, Okada Y: Complications of retroperitoneal laparoscopic nephrectomy. Jpn J Endourol ESWL. 2003 16(3):263-7.<\/li>\n
                                          6. Wakabayashi Y, Kataoka A, Koizumi S, Sakano Y, Johnin K, Yoshiki T, Okada Y: A simple technique for facilitating kidney entrapment using a laparoscopic sack during retroperitoneal laparoscopic radical nephrectomy. Urology. 2003 Apr;61(4):828-9.<\/li>\n
                                          7. Kawakami T, Okamoto K, Sugihara H, Hattori T, Reeve AE, Ogawa O, Okada Y: The roles of supernumerical X chromosomes and XIST expression in testicular germ cell tumors. J Urol. 2003 Apr;169(4):1546-52.<\/li>\n
                                          8. Kim CJ, Shimakage M, Kushima R, Mukaisho K, Shinka T, Okada Y, Inoue H: Down-regulation of drs mRNA in human prostate carcinomas. Hum Pathol. 2003 Jul;34(7):654-7.<\/li>\n
                                          9. Kawakami T, Okamoto K, Kataoka A, Koizumi S, Iwaki H, Sugihara H, Reeve AE, Ogawa O, Okada Y: Multipoint methylation analysis indicates a distinctive epigenetic phenotype among testicular germ cell tumors and testicular malignant lymphomas. Genes Chromosomes Cancer. 2003 Sep;38(1):97-101.<\/li>\n
                                          10. \u7247\u5ca1\u3000\u6643\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u7027\u672c\u5553\u592a\u3001\u82e5\u6797\u8ce2\u5f66\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a10\u30f6\u6708\u306e\u4e73\u5150\u306b\u767a\u751f\u3057\u305f\u814e\u7d50\u77f3\u306b\u5bfe\u3057\u4f53\u5916\u885d\u6483\u6ce2\u7d50\u77f3\u7834\u7815\u8853\uff08ESWL)\u3092\u65bd\u884c\u3057\u305f1\u4f8b\uff0e\u3000Jpn J Endourol ESWL.\u30002003; 16(1): 159-62.<\/li>\n
                                          11. \u6751\u4e0a\u967d\u5b50\u3001\u5c71\u5d0e\u9053\u592b\u3001\u4e0a\u7530\u4fee\u4e09\u3001\u53e4\u5ddd\u3000\u9855\u3001\u6751\u7530\u559c\u4ee3\u53f2\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u5ca1\u90e8\u82f1\u4fca\uff1a\u814e\u76c2\u764c\u306b\u5408\u4f75\u3057\u305f\u813e\u904e\u8aa4\u816b\u306e\u4e00\u4f8b.\u3000\u81e8MRI.\u30002003; 14(1): 17-22.<\/li>\n
                                          12. \u4e0a\u7530\u4fee\u4e09\u3001\u5c71\u5d0e\u9053\u592b\u3001\u9580\u3000\u967d\u5b50\u3001\u5bae\u672c\u826f\u7f8e\u3001\u4e0a\u7530\u4f9d\u5b50\u3001\u53e4\u5ddd\u3000\u9855\u3001\u9ad8\u7530\u653f\u5f66\u3001\u9ad8\u6a4b\u96c5\u58eb\u3001\u6751\u7530\u559c\u4ee3\u53f2\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u82e5\u5bae\u3000\u8aa0\u3001\u5927\u7530\u4fe1\u4e00\uff1a\u814e\u816b\u760d(collecting duct carcinoma)\u306e\u4e00\u4f8b.\u3000\u81e8MRI.\u30002002; 13(2): 69-73.<\/li>\n
                                          13. \u65b0\u4e95\u3000\u8c4a\u3001\u897f\u5ddd\u5168\u6d77\u3001\u6c60\u7530\u6d69\u6a39\u3001\u5ddd\u4e0a\u4eab\u5f18\u3001\u7247\u5ca1\u3000\u6643\u3001\u91d1\u3000\u54f2\u5c07\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u814e\u76c2\u814e\u676f\u306e\u62e1\u5f35\u3092\u4f34\u308f\u306a\u3044\u814e\u5f8c\u6027\u814e\u4e0d\u5168\u3092\u304d\u305f\u3057\u305f\u8180\u80f1\u764c\u306e1\u4f8b\uff0e\u3000\u814e\u3068\u900f\u6790.\u30002003; 52(3): 346-9.<\/li>\n
                                          14. \u7802\u5009\u745e\u660e\u3001\u585a\u672c\u54f2\u90ce\u3001\u7c73\u702c\u6df3\u4e8c\u3001\u4e2d\u77f3\u771f\u884c\u3001\u524d\u6fa4\u5353\u4e5f\u3001\u7027\u672c\u5553\u592a\u3001\u798f\u4e95\u3000\u5dd6\uff1a\u7537\u6027\u30db\u30eb\u30e2\u30f3\u5264\u5185\u670d\u4e2d\u306b\u767a\u898b\u3055\u308c\u305f\u30db\u30eb\u30e2\u30f3\u7642\u6cd5\u304c\u8457\u52b9\u3092\u793a\u3057\u305f\u524d\u7acb\u817a\u764c\u306e1\u4f8b\uff0e\u3000\u65e5\u6ccc\u4f1a\u8a8c.\u30002003; 94(4) : 529-32.<\/li>\n
                                          15. \u661f\u91ce\u771f\u4ecb\u3001\u99ac\u5834\u5178\u5b50\u3001\u52a0\u85e4\u535a\u6587\u3001\u591a\u8cc0\u3000\u5d07\u3001\u592a\u7530\u3000\u8302\u3001\u7af9\u5185\u7fa9\u535a\u3001\u77f3\u5ddd\u3000\u5065\u3001\u76ee\u65b9\u82f1\u6cbb\u3001\u8c37\u3000\u5fb9\u3001\u4e0a\u4ec1\u6570\u7fa9\uff1a\u9aa8\u76e4\u8154\u5185\u816b\u760d\u306b\u3088\u308b\u3068\u601d\u308f\u308c\u308b\u53f3\u6c34\u814e\u75c7\u3092\u5408\u4f75\u3057\u305f\u30de\u30b9\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u767a\u898b\u795e\u7d4c\u82bd\u816b\u75c7\u4f8b\u306b\u3064\u3044\u3066.\u3000\u5c0f\u5150\u304c\u3093.\u30002003; 40(4): 620-2.<\/li>\n
                                          16. \u725b\u7530\u3000\u535a\u3001\u5c0f\u5800\u3000\u8c6a\u3001\u524d\u5ddd\u6b63\u4fe1\u3001\u524d\u5ddd\u4fe1\u4e5f\u3001\u91d1\u5b50\u5609\u5fd7\u3001\u5927\u68ee\u5b5d\u5e73\u3001\u897f\u6751\u4e00\u7537\uff1a\u814e\u4e0d\u5168\u3092\u5951\u6a5f\u306b\u767a\u898b\u3055\u308c\u305f\u5c3f\u8def\u7d50\u6838\u3001\u7c9f\u7c92\u7d50\u6838\u306e1\u4f8b\uff0e\u3000\u6ccc\u7d00.<\/li>\n
                                          17. \u91d1\u3000\u54f2\u5c07\u3001\u52a0\u85e4\u7814\u6b21\u90ce\u3001\u5409\u8cb4\u9054\u5bdb\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u8c37\u3000\u5fb9\uff1a\u81bf\u814e\u75c7\u306b\u5bfe\u3059\u308b\u814e\u6458\u9664\u8853\u5f8c\u306b\u767a\u75c7\u3057\u305f\u96e3\u6cbb\u6027\u5341\u4e8c\u6307\u8178\u76ae\u819a\u763b\u306e1\u4f8b.\u3000\u6ccc\u7d00 2003; 49(9):547-50.<\/li>\n
                                          18. \u82e5\u6797\u8ce2\u5f66\u3001\u91d1\u3000\u54f2\u5c07\u3001\u7247\u5ca1\u3000\u6643\u3001\u5742\u91ce\u7950\u53f8\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u5409\u8cb4\u9054\u5bdb\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u53e4\u5ddd\u3000\u9855\u3001\u6751\u7530\u559c\u4ee3\u53f2\uff1a\u6839\u6cbb\u7684\u524d\u7acb\u817a\u6458\u9664\u8853\u5f8c\u306e\u5c3f\u5931\u7981\u306b\u95a2\u3059\u308b\u691c\u8a0e:\u524d\u7acb\u817a\u5c16\u90e8\u306e\u51e6\u7406\u30fb\u543b\u5408\u6cd5\u306e\u6539\u826f.\u3000\u6ccc\u7d00 2003; 49(9):503-7.<\/li>\n<\/ol>\n

                                            2002\u5e74<\/em><\/h2>\n
                                              \n
                                            1. Kamoto T, Satomura S, Yoshiki T, Okada Y, Henmi F, Nishiyama H, Kobayashi T, Terai A, Habuchi T, Ogawa O: Lectin-reactive alpha-Fetoprotein (AFP-L3%) curability and prediction of clinical course after treatment of non-seminomatous germ cell tumors. Jpn J Clin Oncol 32:472-476, 2002.<\/li>\n
                                            2. Isono T, Tanaka T, Kageyama S, Yoshiki T: Structural diversity of cancer-related and non-cancer-related prostate-specific antigen. Clin Chem 48:2187-2194, 2002.<\/li>\n
                                            3. Takimoto K, Okamoto K, Wakabayashi Y, Okada Y: Torsion of spermatocele: a rare manifestation. Urol Int 69:164-165, 2002.<\/li>\n
                                            4. Nishikawa Z, Okamoto K, Kataoka A, Soga H, Wakabayashi Y, Kushima R, Okada Y: Transitional cell carcinoma in a single ectopic ureter opening into the ejaculatory duct. Urology 60:912, 2002.<\/li>\n
                                            5. Kawakami T, Wakabayashi Y, Isono T, Aimi Y, Okada Y: Expression of neurotrophin messenger RNAs during rat urinary bladder development. Neurosci Lett 329:77-80, 2002.<\/li>\n
                                            6. Kageyama S, Yoshiki T, Isono T, Tanaka T, Kim CJ, Yuasa T, Okada Y: High expression of human Uroplakin Ia in urinary bladder transitional cell carcinoma. Jpn J Cancer Res 93:523-531, 2002.<\/li>\n
                                            7. Wakabayashi Y, Kawakami T, Aimi Y, Okada Y: Development of growth-associated protein-43 and neurotrophin receptor immuoreactivities in the rat urinary bladder. Anat Embryol 205:255-261, 2002.<\/li>\n
                                            8. Ozaki Y, Konntani K, Hanaoka J, Chano T, Tearmoto K, Texuka N, Sawai S, Fujino S, Yoshiki T, Okabe H, Okubo I: Expression and immunology of a tumor-associated antigen, 90K\/Mac-2 binding protein in lung carcinoma: The possibility of its clinical use as a tumor marker and a target antigen in cancer immunotherapy. Cancer 95:1954-1962, 2002.<\/li>\n
                                            9. Usida H, Shintaku M, Maegawa M, Maekawa S, Inoue K, Kaneko Y, Ohmori K, Babaya K, Nishimura K: Mixed tumor of paratesticular rhabdomyosarcoma and an adenomatoid tumor in an elderly patient. Urology 59:773viii-773x, 2002.<\/li>\n
                                            10. Takimoto K, Okamoto K, Wakabayashi Y, Okada Y: Torsion of spermatocele: a rare manifestation. Urol Int. 2002;69(2):164-5.<\/li>\n
                                            11. Kageyama S, Yoshiki T, Isono T, Tanaka T, Kim CJ, Yuasa T, Okada Y: High expression of human uroplakin Ia in urinary bladder transitional cell carcinoma. Jpn J Cancer Res. 2002 May;93(5):523-31.<\/li>\n
                                            12. Ushida H, Shintaku M, Maegawa M, Maekawa S, Inoue K, Kaneko Y, Ohmori K, Babaya K, Nishimura K: Mixed tumor of paratesticular rhabdomyosarcoma and an adenomatoid tumor in an elderly patient. Urology. 2002 May;59(5):773.<\/li>\n
                                            13. Wakabayashi Y, Kawakami T, Aimi Y, Okada Y: Development of growth-associated protein-43 and neurotrophin receptor immunoreactivities in the rat urinary bladder. Anat Embryol (Berl). 2002 Jun;205(3):255-61.<\/li>\n
                                            14. Kawakami T, Wakabayashi Y, Isono T, Aimi Y, Okada Y: Expression of neurotrophin messenger RNAs during rat urinary bladder development. Neurosci Lett. 2002 Aug 23;329(1):77-80.<\/li>\n
                                            15. Ozaki Y, Kontani K, Hanaoka J, Chano T, Teramoto K, Tezuka N, Sawai S, Fujino S, Yoshiki T, Okabe H, Ohkubo I: Expression and immunogenicity of a tumor-associated antigen, 90K\/Mac-2 binding protein, in lung carcinoma. Cancer. 2002 Nov 1;95(9):1954-62.<\/li>\n
                                            16. Nishikawa Z, Okamoto K, Kataoka A, Soga H, Wakabayashi Y, Kushima R, Okada Y: Transitional cell carcinoma in a single ectopic ureter opening into the ejaculatory duct. Urology. 2002 Nov;60(5):912.<\/li>\n
                                            17. Kamoto T, Satomura S, Yoshiki T, Okada Y, Henmi F, Nishiyama H, Kobayashi T, Terai A, Habuchi T, Ogawa O: Lectin-reactive alpha-fetoprotein (AFP-L3%) curability and prediction of clinical course after treatment of non-seminomatous germ cell tumors. Jpn J Clin Oncol. 2002 Nov;32(11):472-6.<\/li>\n
                                            18. Isono T, Tanaka T, Kageyama S, Yoshiki T: Structural diversity of cancer-related and non-cancer-related prostate-specific antigen. Clin Chem. 2002 Dec;48(12):2187-94.<\/li>\n
                                            19. \u725b\u7530\u3000\u535a\u3001\u524d\u5ddd\u6b63\u4fe1\u3001\u524d\u5ddd\u4fe1\u4e5f\u3001\u4e95\u4e0a\u5e78\u6cbb\u3001\u91d1\u5b50\u5609\u5fd7\u3001\u5927\u68ee\u5b5d\u5e73\u3001\u897f\u6751\u4e00\u7537\uff1a\u7cbe\u5de3\u9798\u819c\u7531\u6765\u306e\u7dda\u7dad\u6027\u507d\u816b\u760d\u306e1\u4f8b\uff0e\u3000\u6ccc\u7d00.\u30002002; 48(2): 101-3.<\/li>\n
                                            20. \u4e0a\u4ec1\u6570\u7fa9\u3001\u82e5\u6797\u8ce2\u5f66\u3001\u7247\u5ca1\u3000\u6643\u3001\u7027\u672c\u5553\u592a\u3001\u5409\u8cb4\u9054\u5bdb\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u4e5d\u5d8b\u4eae\u6cbb\uff1aVanishing testis\u306e\u81e8\u5e8a\u7684\u691c\u8a0e\uff0e\u3000\u65e5\u5c0f\u5150\u6ccc\u4f1a\u8a8c.\u30002002; 11(2): 113-21.<\/li>\n
                                            21. \u65b0\u4e95\u3000\u8c4a\u3001\u897f\u5ddd\u5168\u6d77\u3001\u6c60\u7530\u6d69\u6a39\u3001\u5ddd\u4e0a\u4eab\u5f18\u3001\u7247\u5ca1\u3000\u6643\u3001\u91d1\u3000\u54f2\u5c07\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u814e\u76c2\u814e\u676f\u306e\u62e1\u5f35\u3092\u4f34\u308f\u306a\u3044\u814e\u5f8c\u6027\u814e\u4e0d\u5168\u3092\u304d\u305f\u3057\u305f\u8180\u80f1\u764c\u306e1\u4f8b\uff0e\u3000\u814e\u3068\u900f\u6790.\u30002002; 52(3): 346-9.<\/li>\n
                                            22. \u524d\u5ddd\u6b63\u4fe1\u3001\u5317\u6751\u3000\u5065\u3001\u725b\u7530\u3000\u535a\u3001\u524d\u5ddd\u4fe1\u4e5f\u3001\u4e95\u4e0a\u5e78\u6cbb\u3001\u91d1\u5b50\u5609\u5fd7\u3001\u5927\u68ee\u5b5d\u5e73\u3001\u897f\u6751\u4e00\u7537\uff1a\u7d50\u77f3\u3092\u4f34\u3063\u305f\u907a\u6b8b\u5c3f\u7ba1\u5185\u84c4\u81bf\u75c7\u306e1\u4f8b.\u3000\u6ccc\u7d00.\u30002002; 48(3): 167-9.<\/li>\n
                                            23. \u77f3\u4e95\u4fe1\u884c\u3001\u7c73\u702c\u6df3\u4e8c\u3001\u585a\u672c\u54f2\u90ce\u3001\u524d\u6fa4\u5353\u4e5f\u3001\u798f\u4e95\u3000\u5dd6\u3001\u77f3\u5ddd\u96c4\u4e00\u3001\u9752\u6728\u3000\u671b\uff1a\u7dda\u7dad\u8089\u816b\u3068\u6241\u5e73\u4e0a\u76ae\u764c\u306e\u539f\u767a\u6027\u540c\u6642\u6027\u91cd\u8907\u8180\u80f1\u60aa\u6027\u816b\u760d\u306e1\u4f8b\uff0e\u3000\u65e5\u6ccc\u4f1a\u8a8c.\u30002002; 93(5): 642-7.<\/li>\n
                                            24. \u585a\u672c\u54f2\u90ce\u3001\u7c73\u702c\u6df3\u4e8c\u3001\u77f3\u4e95\u4fe1\u884c\u3001\u524d\u6fa4\u5353\u4e5f\u3001\u798f\u4e95\u3000\u5dd6\uff1a\u30b5\u30eb\u30d9\u30fc\u30b8\u5316\u5b66\u7642\u6cd5\u3068\u3057\u3066gemcitabine, etoposide, cisplatin\u306e3\u8005\u4f75\u7528\u5316\u5b66\u7642\u6cd5\u304c\u594f\u52b9\u3057\u305f\u8ee2\u79fb\u6027\u5c3f\u7ba1\u764c\u306e1\u4f8b\uff0e\u3000\u6ccc\u7d00.\u30002002; 48(7): 427-30.<\/li>\n
                                            25. \u524d\u6fa4\u5353\u4e5f\u3001\u7c73\u702c\u6df3\u4e8c\u3001\u585a\u672c\u54f2\u90ce\u3001\u77f3\u4e95\u4fe1\u884c\u3001\u798f\u4e95\u3000\u5dd6\uff1a\u9032\u884c\u6027\u5c3f\u8def\u4e0a\u76ae\u764c\u306b\u5bfe\u3059\u308bIFEP\u5316\u5b66\u7642\u6cd5\u3000\u305d\u306e\u6cbb\u7642\u6210\u7e3e\u306a\u3089\u3073\u306b\u52b9\u679c\u5224\u5b9a\u306b\u304a\u3051\u308b\u816b\u760d\u30de\u30fc\u30ab\u30fc\u6e2c\u5b9a\u306e\u6709\u7528\u6027\u306e\u691c\u8a0e\uff0e\u3000\u65e5\u6ccc\u4f1a\u8a8c.\u30002002; 93(7): 727-35.<\/li>\n
                                            26. \u5c0f\u5800\u3000\u8c6a\u3001\u524d\u5ddd\u6b63\u4fe1\u3001\u725b\u7530\u3000\u535a\u3001\u524d\u5ddd\u4fe1\u4e5f\u3001\u91d1\u5b50\u5609\u53f2\u3001\u5927\u68ee\u5b5d\u5e73\u3001\u897f\u6751\u4e00\u7537\uff1a\u814e\u88ab\u819c\u539f\u767a\u8102\u80aa\u8089\u816b\u306e1\u4f8b.\u3000\u6ccc\u7d00.\u30002002; 48(7): 451-4.<\/li>\n
                                            27. \u5c0f\u5800\u3000\u8c6a\u3001\u524d\u5ddd\u6b63\u4fe1\u3001\u725b\u7530\u3000\u535a\u3001\u524d\u5ddd\u4fe1\u4e5f\u3001\u4e95\u4e0a\u5e78\u6cbb\u3001\u91d1\u5b50\u5609\u5fd7\u3001\u5927\u68ee\u5b5d\u5e73\u3001\u897f\u6751\u4e00\u7537\uff1aInterleukin(IL-2)\u6295\u4e0e\u5f8c\u306b\u8179\u6c34\u8caf\u7559\u3092\u8a8d\u3081\u305f\u814e\u7d30\u80de\u764c\u306e2\u4f8b.\u3000\u6ccc\u7d00.\u30002002; 48(7): 455-7.<\/li>\n
                                            28. \u82e5\u6797\u8ce2\u5f66\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u7247\u5ca1\u3000\u6643\u3001\u91d1\u3000\u54f2\u5c07\u3001\u5409\u8cb4\u9054\u5bdb\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u814e\u76c2\u5c3f\u7ba1\u79fb\u884c\u90e8\u72ed\u7a84\u75c7\u624b\u8853\u306b\u304a\u3051\u308b\u521d\u56de\u4e0d\u6210\u529f\u4f8b\u306e\u691c\u8a0e\uff0e\u3000\u6ccc\u7d00.\u30002002; 48(8): 475-7.<\/li>\n<\/ol>\n

                                              2001\u5e74<\/em><\/h2>\n
                                                \n
                                              1. Dok An C, Yoshiki T, Lee G, Okada Y: Evaluation of a rapid qualitative prostate specific antigen assay, the One Step PSA(TM) test. Cancer Lett. 2001 Jan 26;162(2):135-9.<\/li>\n
                                              2. Ushida H, Park KI, Kim CJ, Okada Y: Living renal transplantation in a child with branchio-oto-renal syndrome. J Jpn Soc Dial Ther. 2001 34(3):207-9.<\/li>\n
                                              3. Johnin K, Nakai O, Kataoka A, Koizumi S, Dok An C, Okada Y, Makuuchi M: Surgical management of renal cell carcinoma invading into the liver: radical nephrectomy en bloc with right hepatic lateral sector. Urology. 2001 May;57(5):975.<\/li>\n
                                              4. Yuasa T, Okamoto K, Kawakami T, Mishina M, Ogawa O, Okada Y: Expression patterns of cancer testis antigens in testicular germ cell tumors and adjacent testicular tissue. J Urol. 2001 May;165(5):1790-4.<\/li>\n
                                              5. Shimada K, Hosokawa S, Matsumoto F, Johnin K, Naitoh Y, Harada Y: Urological management of cloacal anomalies. Int J Urol. 2001 Jun;8(6):282-9.<\/li>\n
                                              6. Yuasa T, Kageyama S, Yoshiki T, Okada Y: Preputial calculi: a case report. Hinyokika Kiyo. 2001 Jul;47(7):513-5.<\/li>\n
                                              7. \u68b6\u7530\u6d0b\u4e00\u90ce\u3001\u6e05\u6c34\u6d0b\u7950\u3001\u9ad8\u5c3e\u5178\u606d\u3001\u5ca9\u57ce\u79c0\u51fa\u6d19\u3001\u5c71\u5185\u6c11\u7537\uff1a\u540c\u5074\u814e\u7121\u5f62\u6210\u3092\u4f34\u3063\u305f\u7cbe\u56a2\u56a2\u80de\u306e1\u4f8b\uff0e\u3000\u6ccc\u7d00. 2001; 47(3): 203-206.<\/li>\n
                                              8. \u725b\u7530\u3000\u535a\u3001\u5c0f\u6cc9\u4fee\u4e00\u3001\u52a0\u85e4\u7814\u6b21\u90ce\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u5f8c\u8179\u819c\u81bf\u760d\u6cbb\u7642\u4e2d\u306b\u8133\u5e79\u90e8\u6897\u585e\u3001\u51fa\u8840\u3092\u304d\u305f\u3057\u305fSLE\u60a3\u8005\u306e1\u4f8b\uff0e\u3000\u65e5\u6ccc\u4f1a\u8a8c. 2001; 92(5): 579-82.<\/li>\n
                                              9. \u725b\u7530\u3000\u535a\u3001\u5c0f\u6cc9\u4fee\u4e00\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u52a0\u85e4\u7814\u6b21\u90ce\uff1aUrosepsis\u306b\u3088\u308b\u30a8\u30f3\u30c9\u30c8\u30ad\u30b7\u30f3\u30b7\u30e7\u30c3\u30af\u306b\u5bfe\u3059\u308b\u30a8\u30f3\u30c9\u30c8\u30ad\u30b7\u30f3\u5438\u7740\u7642\u6cd5\uff08PMX\uff09\u306e\u7d4c\u9a13\uff0e\u3000\u6ccc\u7d00. 2001; 47(5): 329-31.<\/li>\n
                                              10. \u524d\u6fa4\u5353\u4e5f\u3001\u7c73\u702c\u6df3\u4e8c\u3001\u585a\u672c\u54f2\u90ce\u3001\u77f3\u4e95\u4fe1\u884c\u3001\u9577\u8c37\u5ddd\u96c4\u4e00\u3001\u798f\u4e95\u5dd6\u3001\u77f3\u5ddd\u96c4\u4e00\uff1a\u4f4e\u7528\u91cfCVD\u5316\u5b66\u7642\u6cd5\u304ctumor dormancy therapy\u3068\u3057\u3066\u6709\u52b9\u3067\u3042\u3063\u305f\u526f\u814e\u5916\u60aa\u6027\u8910\u8272\u7d30\u80de\u816b\u306e1\u4f8b\uff0e\u3000\u65e5\u6ccc\u4f1a\u8a8c. 2001; 92(5): 593-6.<\/li>\n
                                              11. \u677e\u672c\u5bcc\u7f8e\u3001\u5cf6\u7530\u61b2\u6b21\u3001\u7d30\u5ddd\u5c1a\u4e09\u3001\u4e0a\u4ec1\u6570\u7fa9\uff1a\u51fa\u751f\u524d\u304a\u3088\u3073\u65b0\u751f\u5150\u671f\u306b\u8a3a\u65ad\u3055\u308c\u305f\u4e00\u5074\u6027\u591a\u56a2\u814e\u75c7\u4f8b\u306e\u81e8\u5e8a\u7d4c\u904e\uff0e\u3000\u65e5\u6ccc\u4f1a\u8a8c. 2001; 92(6): 615-8.<\/li>\n
                                              12. \u524d\u5ddd\u4fe1\u4e5f\u3001\u524d\u5ddd\u6b63\u4fe1\u3001\u725b\u7530\u3000\u535a\u3001\u4e95\u4e0a\u5e78\u6cbb\u3001\u5927\u68ee\u5b5d\u5e73\u3001\u897f\u6751\u4e00\u7537\uff1a\u5de8\u5927\u306a\u51fa\u8840\u6027\u56a2\u80de\u3092\u4f34\u3063\u305f\u8910\u8272\u7d30\u80de\u816b.\u3000\u81e8\u6ccc. 2001; 55(8): 667-9.<\/li>\n
                                              13. \u524d\u5ddd\u4fe1\u4e5f\u3001\u524d\u5ddd\u6b63\u4fe1\u3001\u725b\u7530\u3000\u535a\u3001\u4e95\u4e0a\u5e78\u6cbb\u3001\u91d1\u5b50\u5609\u5fd7\u3001\u5927\u68ee\u5b5d\u5e73\u3001\u897f\u6751\u4e00\u7537\uff1a\u524d\u7acb\u817a\u764c\u306b\u5bfe\u3059\u308bPSA\u4f4e\u5024\u3067\u518d\u958b\u3059\u308b\u9593\u6b20\u7684\u5185\u5206\u6ccc\u7642\u6cd5\u306e\u6210\u7e3e\u3000\u521d\u56de\u4f11\u85ac\u671f\u9593\u306e\u691c\u8a0e\u3092\u4e2d\u5fc3\u306b.\u3000\u6ccc\u7d00. 2001; 47(8): 553-5.<\/li>\n
                                              14. \u725b\u7530\u3000\u535a\u3001\u524d\u5ddd\u6b63\u4fe1\u3001\u524d\u5ddd\u4fe1\u4e5f\u3001\u4e95\u4e0a\u5e78\u6cbb\u3001\u91d1\u5b50\u5609\u5fd7\u3001\u5927\u68ee\u516c\u5e73\u3001\u897f\u6751\u4e00\u7537\uff1a\u5727\u96fb\u5f0f\u4f53\u5916\u885d\u6483\u6ce2\u7d50\u77f3\u7834\u7815\u88c5\u7f6e\u306b\u3088\u308b\u4e0a\u90e8\u5c3f\u8def\u7d50\u77f3\u306e\u6cbb\u7642\u6210\u7e3e\uff0e\u3000\u6ccc\u7d00.\u30002001; 47(10): 709-13.<\/li>\n<\/ol>\n

                                                2000\u5e74<\/em><\/h2>\n
                                                  \n
                                                1. Tanaka T, Isono T, Yoshiki T, Yuasa T, Okada Y: A novel form of prostate-specific antigen transcript produced by alternative splicing. Cancer Res. 2000 Jan 1;60(1):56-9.<\/li>\n
                                                2. Ueda T, Tamaki M, Kageyama S, Yoshimura N, Yoshida O: Urinary incontinence among community-dwelling people aged 40 years or older in Japan: prevalence, risk factors, knowledge and self-perception. Int J Urol. 2000 Mar;7(3):95-103.<\/li>\n
                                                3. Kim CJ, Kushima R, Okada Y, Seto A: Establishment and characterization of a prostatic small-cell carcinoma cell line (PSK-1) derived from a patient with Klinefelter syndrome. Prostate. 2000 Mar 1;42(4):287-94.<\/li>\n
                                                4. Ushida H, Johnin K, Koizumi S, Okada Y: Idiopathic retroperitoneal hematoma mimicking cystic tumor associated with hemorrhagic renal cyst. J Urol. 2000 Apr;163(4):1247-8.<\/li>\n
                                                5. Shimada K, Hosokawa S, Tohda A, Matsumoto F, and Johnin K: Histology of the fetal prune belly syndrome with reference to the efficacy of prenatal decompression. Int J Urol. 2000 May;7(5):161-6.<\/li>\n
                                                6. Johnin K, Nakatoh M, Kadowaki T, Kushima M, Koizumi S, Okada Y: Fournier’s gangrene caused by Candida species as the primary organism. Urology. 2000 Jul 1;56(1):153.<\/li>\n
                                                7. Lu JJ, Kakehi Y, Takahashi T, Wu XX, Yuasa T, Yoshiki T, Okada Y, Terachi T, Ogawa O: Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer. Clin Cancer Res. 2000 Aug;6(8):3166-71.<\/li>\n
                                                8. Johnin K, Kadowaki T, Kushima M, Koizumi S, Ushida H, Konishi T, Yoshiki T, Okada Y: Congenital ureteral diverticulum coexistent with hydronephrosis caused by vascular compression involving the uterine artery and umbilical ligament: report of a case. J Pediatr Surg. 2000 Sep;35(9):1350-2.<\/li>\n
                                                9. \u4e0a\u4ec1\u6570\u7fa9\u3001\u5cf6\u7530\u61b2\u6b21\u3001\u7d30\u5ddd\u5c1a\u4e09\u3001\u677e\u672c\u5bcc\u7f8e\uff1a\u5973\u5150\u3068\u3057\u30661\u6b73\u307e\u3067\u80b2\u3066\u3089\u308c\u305fambiguous genitalia\u306e1\u4f8b.\u3000\u5927\u962a\u6bcd\u5b50\u4fdd\u5065\u7dcf\u5408\u533b\u7642\u30bb\u8a8c.\u30002000; 16(1): 65-8.<\/li>\n
                                                10. \u677e\u672c\u5bcc\u7f8e\u3001\u5cf6\u7530\u61b2\u6b21\u3001\u7d30\u5ddd\u5c1a\u4e09\u3001\u4e0a\u4ec1\u6570\u7fa9\uff1a\u65b0\u751f\u5150\u671f\u30fb\u4e73\u5150\u671f\u306eUTI\u306b\u3064\u3044\u3066\u3000\u539f\u767a\u6027VUR\u75c7\u4f8b\u306b\u304a\u3051\u308b\u691c\u8a0e.\u65e5\u5c0f\u5150\u6ccc\u4f1a\u8a8c.\u30002000; 9(2): 111-4.<\/li>\n
                                                11. \u5409\u7530\u54f2\u4e5f\u3001\u7c73\u702c\u6df3\u4e8c\u3001\u585a\u672c\u54f2\u90ce\u3001\u5409\u5ddd\u614e\u4e00\u3001\u91d1\u3000\u6cf0\u6b63\u3001\u524d\u7530\u5eb7\u79c0\u3001\u798f\u4e95\u3000\u5dd6\uff1aVIP\u3092\u5c0e\u5165\u7642\u6cd5\u3068\u3057\u305f\u9032\u884c\u6027\u80da\u7d30\u80de\u816b\u760d\u306e\u6cbb\u7642\u6210\u7e3e\uff0e\u3000\u65e5\u6ccc\u4f1a\u8a8c.\u30002000; 91(2): 55-61.<\/li>\n
                                                12. \u66fd\u6211\u5f18\u6a39\u3001\u6797\u7530\u82f1\u8cc7\u3001\u5409\u8cb4\u9054\u5bdb\u3001\u6a0b\u53e3\u4f73\u4ee3\u5b50\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a5′-DFUR\u6295\u4e0e\u5f8c\u306b\u816b\u5927\u30ea\u30f3\u30d1\u7bc0\u304c\u7e2e\u5c0f\u3057\u305f\u6d78\u6f64\u6027\u8180\u80f1\u764c\u306e1\u4f8b\uff0e\u3000\u764c\u3068\u5316\u7642.\u30002000; 27(2): 311-4.<\/li>\n
                                                13. \u725b\u7530\u3000\u535a\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u5c0f\u6cc9\u4fee\u4e00\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u53f3\u6025\u6027\u9670\u56a2\u75c7\u3092\u5448\u3057\u305f\u7cbe\u5de3\u533a\u57df\u6897\u585e\u306e1\u4f8b\uff0e\u3000\u65e5\u6ccc\u4f1a\u8a8c.\u30002000; 91(2): 79-82.<\/li>\n
                                                14. \u677e\u672c\u5bcc\u7f8e\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u7d30\u5ddd\u5c1a\u4e09\u3001\u5cf6\u7530\u61b2\u6b21\u3001\u91cc\u6751\u61b2\u4e00\uff1a\u591c\u5c3f\u75c7\u3092\u4e3b\u8a34\u3068\u3057\u305f\u4e2d\u67a2\u6027\u5c3f\u5d29\u75c7\u306e1\u4f8b.\u3000\u5927\u962a\u6bcd\u5b50\u4fdd\u5065\u7dcf\u5408\u533b\u7642\u30bb\u8a8c. 2000; 15(2): 128-30.<\/li>\n
                                                15. \u5409\u7530\u3000\u5fb9\u3001\u68b6\u7530\u6d0b\u4e00\u90ce\u3001\u5ca9\u57ce\u79c0\u51fa\u6d19\u3001\u68ee\u3000\u5553\u9ad8\u3001\u5c71\u5185\u6c11\u7537\uff1a\u814e\u76c2\u5c3f\u7ba1\u764c\u306e\u81e8\u5e8a\u7684\u691c\u8a0e\uff0e\u6ccc\u7d00. 2000; 46(2): 77-81.<\/li>\n
                                                16. \u5bae\u5ddd\u660e\u5b50\u3001\u5742\u90e8\u79c0\u660e\u3001\u4e2d\u5cf6\u6ecb\u7f8e\u3001\u6839\u672c\u3000\u6b63\u3001\u6210\u7530\u5145\u5f18\u3001\u5c71\u672c\u9f8d\u7bc4\uff1a\u8d64\u767d\u8840\u75c5\u3092\u5408\u4f75\u3057\u305f\u7e26\u9694\u539f\u767a\u80da\u7d30\u80de\u816b\u760d\u306e1\u75c7\u4f8b.\u3000\u5185\u79d1\u533b\u4f1a\u8a8c.\u30002000; 12(3): 501-5.<\/li>\n
                                                17. \u897f\u6751\u548c\u660e\u3001\u85e4\u6751\u660c\u6a39\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u82e5\u6797\u8ce2\u5f66\u3001\u7247\u5ca1\u3000\u6643\u3001\u5e73\u91ce\u6b63\u6e80\u3001\u6728\u4e0b\u3000\u9686\u3001\u5c71\u672c\u80b2\u7537\u3001\u5c0f\u6c60\u88d5\u4e4b\u3001\u5c0f\u6c60\u96c5\u4eba\u3001\u5143\u77f3\u3000\u5145\u3001\u677e\u7530\u516c\u5fd7\uff1a\u814e\u7d30\u80de\u764c\u306b\u5bfe\u3059\u308b\u8179\u8154\u93e1\u4e0b\u6839\u6cbb\u7684\u814e\u6458\u9664\u8853\u306e\u7d4c\u9a13.\u3000\u65e5\u5916\u5b9d.\u30002000; 68(3-4): 137-143.<\/li>\n
                                                18. \u5cf6\u7530\u61b2\u6b21\u3001\u7d30\u5ddd\u5c1a\u4e09\u3001\u677e\u672c\u5bcc\u7f8e\u3001\u6771\u7530\u3000\u7ae0\u3001\u68ee\u672c\u5eb7\u88d5\u3001\u4e0a\u4ec1\u6570\u7fa9\uff1a\u51fa\u751f\u524d\u8a3a\u65ad\u3055\u308c\u305f\u5148\u5929\u6027\u6c34\u814e\u75c7\u3000\u814e\u6a5f\u80fd\u306b\u5bfe\u3059\u308b\u814e\u76c2\u5f62\u6210\u8853\u306e\u52b9\u679c.\u3000\u65e5\u6ccc\u4f1a\u8a8c.\u30002000; 91(4):473-8.<\/li>\n
                                                19. \u725b\u7530\u3000\u535a\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u5c0f\u6cc9\u4fee\u4e00\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u5de6\u9670\u56a2\u5185\u53ca\u3073\u9f20\u5f84\u90e8\u306b\u767a\u751f\u3057\u305f\u7cbe\u7d22\u8102\u80aa\u8089\u816b\u306e1\u4f8b\uff0e\u3000\u6ccc\u7d00.\u30002000; 46(5): 349-51.<\/li>\n
                                                20. \u5cf6\u7530\u61b2\u6b21\u3001\u7d30\u5ddd\u5c1a\u4e09\u3001\u677e\u672c\u5bcc\u7f8e\u3001\u4e0a\u4ec1\u6570\u7fa9\uff1a\u3010\u611f\u67d3\u75c7\u3000\u4eca,\u3069\u3046\u8003\u3048\u308b\u304b\u3011\u3000\u57fa\u790e\u75be\u60a3\u306e\u3042\u308b\u60a3\u8005\u306b\u304a\u3051\u308b\u611f\u67d3\u75c7\u3000\u5c3f\u8def\u5947\u5f62.\u3000\u5c0f\u5150\u79d1.\u30002000; 41(6):1011-6.<\/li>\n
                                                21. \u5f71\u5c71\u3000\u9032\u3001\u5e73\u4e95\u614e\u4e8c\u3001\u6771\u3000\u7fa9\u4eba\uff1a\u5c3f\u7ba1\u7d50\u77f3\u306b\u5bfe\u3059\u308b\u4f53\u5916\u885d\u6483\u6ce2\u7d50\u77f3\u7834\u7815\u8853\u4e0d\u6210\u529f\u4f8b\u306e\u691c\u8a0e\uff0e\u3000\u6ccc\u7d00.\u30002000; 46(6): 371-6.<\/li>\n
                                                22. \u4e0a\u4ec1\u6570\u7fa9\u3001\u5cf6\u7530\u61b2\u6b21\u3001\u7d30\u5ddd\u5c1a\u4e09\u3001\u677e\u672c\u5bcc\u7f8e\uff1a\u5973\u5150\u3068\u3057\u30661\u6b73\u307e\u3067\u80b2\u3066\u3089\u308c\u305fambiguous genitalia\u306e1\u4f8b.\u3000 Pharm Med.\u30002000; 18(8): 154-6.<\/li>\n
                                                23. \u897f\u5ddd\u5168\u6d77\u3001\u7247\u5ca1\u3000\u6643\u3001\u6e6f\u6d45\u3000\u5065\u3001\u5ca1\u672c\u572d\u751f\u3001\u82e5\u6797\u8ce2\u5f66\u3001\u5409\u8cb4\u9054\u5bdb\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u81ea\u7136\u814e\u51fa\u8840\u3092\u5951\u6a5f\u306b\u767a\u898b\u3055\u308c\u305f\u5f8c\u5929\u6027\u814e\u56a2\u80de\u6027\u75be\u60a3\u306b\u5408\u4f75\u3057\u305f\u814e\u7d30\u80de\u764c\u306e1\u4f8b.\u3000\u65e5\u6ccc\u4f1a\u8a8c. 2000; 91(12): 727-30.<\/li>\n<\/ol>\n

                                                  1999\u5e74<\/em><\/h2>\n
                                                    \n
                                                  1. Tanaka T, Hamaguchi A, Kushima R, Okada Y: A case of renal pseudotumor associated with chronic pachymeningitis. Int J Urol. 1999 Feb;6(2):107-10.<\/li>\n
                                                  2. Johnin K, Kushima M, Koizumi S, Okada Y: Percutaneous transvesical retrieval of foreign bodies penetrating the urethra. J Urol. 1999 Mar;161(3):915-6.<\/li>\n
                                                  3. Yuasa T, Isono T, Tooyama I, Seto A: Overproduction of gamma interferon in B\/Jas inbred rabbits with herpes simplex virus encephalitis. Microbiol Immunol. 1999;43(4):365-71.<\/li>\n
                                                  4. Arai Y, Kawakami T, Soga H, Okada Y: Psoas abscess associated with iliac vein thrombosis and piriformis and gluteal abscesses. Int J Urol. 1999 May;6(5):257-9.<\/li>\n
                                                  5. Yuasa T, Yoshiki T, Ogawa O, Tanaka T, Isono T, Mishina M, Higuchi K, Okada Y, Yoshida O: Detection of alpha-fetoprotein mRNA in seminoma. J Androl. 1999 May-Jun;20(3):336-40.<\/li>\n
                                                  6. Yuasa T, Yoshiki T, Isono T, Tanaka T, Hayashida H, Okada Y: Expression of transitional cell-specific genes, uroplakin Ia and II, in bladder cancer: detection of circulating cancer cells in the peripheral blood of metastatic patients. Int J Urol. 1999 Jun;6(6):286-92.<\/li>\n
                                                  7. Arai Y, Okubo K, Konami T, Kin S, Kanba T, Okabe T, Hamaguchi A, Okada Y: Voiding function of orthotopic ileal neobladder in women. Urology. 1999 Jul;54(1):44-9.<\/li>\n
                                                  8. Arai Y, Taki Y, Kawase N, Terachi T, Kakehi Y, Okada T, Okabe T, Kanba T, Konami T, Kin S, Oishi K, Miyakawa M, Takeuchi H, Ueda T, Hamaguchi A, Okada Y: Orthotopic ileal neobladder in male patients: functional outcomes of 66 cases. Int J Urol. 1999 Aug;6(8):388-92.<\/li>\n
                                                  9. Yuasa T, Yoshiki T, Tanaka T, Isono T, Okada Y: Detection of circulating testicular cancer cells in peripheral blood. Cancer Lett. 1999 Aug 23;143(1):57-62.<\/li>\n
                                                  10. Yoshida O, Terai A, Ohkawa T, Okada Y: National trend of the incidence of urolithiasis in Japan from 1965 to 1995. Kidney Int. 1999 Nov;56(5):1899-904.<\/li>\n
                                                  11. Tanaka T, Yoshiki T, Arai Y, Higuchi K, Kageyama S, Ogawa Y, Isono T, Okada Y: Expression of platelet-derived endothelial cell growth factor\/thymidine phosphorylase in human bladder cancer. Jpn J Cancer Res. 1999 Dec;90(12):1344-50.<\/li>\n
                                                  12. \u6734\u3000\u52fa\u3001\u91d1\u3000\u54f2\u5c07\u3001\u65b0\u4e95\u3000\u8c4a\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u8840\u6db2\u4e2d\u306e\u764c\u7d30\u80de\u306b\u5bfe\u3059\u308b\u653e\u5c04\u7dda\u7167\u5c04\u3000\u7167\u5c04\u7dda\u91cf\u306b\u95a2\u3059\u308b\u5b9f\u9a13\u7684\u691c\u8a0e.\u3000\u81ea\u5df1\u8f38\u8840.\u30001999; 12(2): 169-72.<\/li>\n
                                                  13. \u68ee\u672c\u3000\u6df3\u3001\u829d\u7530\u4fe1\u4eba\u3001\u661f\u91ce\u4f38\u592b\u3001\u84d1\u5185\u5fb3\u8535\u3001\u5c71\u8def\u3000\u662d\u3001\u91d1\u3000\u54f2\u5c06\u3001\u6734\u3000\u52fa\u3001\u6728\u66fd\u826f\u660e\uff1a\u751f\u4f53\u814e\u79fb\u690d\u5f8c\u306b\u814e\u6a5f\u80fd\u304c\u5f90\u3005\u306b\u60aa\u5316\u3057\u3001\u30b7\u30af\u30ed\u30b9\u30dd\u30ea\u30f3\u304b\u3089\u30bf\u30af\u30ed\u30ea\u30e0\u30b9\u30d8\u5909\u66f4\u3059\u308b\u3053\u3068\u306b\u3088\u308a\u826f\u597d\u306a\u814e\u6a5f\u80fd\u304c\u5f97\u3089\u308c\u305f1\u75c7\u4f8b.\u3000TDM\u7814\u7a76.\u30001999, 16(2): 135-6.<\/li>\n
                                                  14. \u5409\u7530\u54f2\u4e5f\u3001\u7c73\u702c\u6df3\u4e8c\u3001\u5409\u5ddd\u614e\u4e00\u3001\u91d1\u3000\u6cf0\u6b63\u3001\u585a\u672c\u54f2\u90ce\u3001\u798f\u4e95\u3000\u5dcc\u3001\u77f3\u5ddd\u96c4\u4e00\u3001\u5ca9\u4e95\u6b66\u5c1a\uff1a\u4e0b\u5927\u9759\u8108\u90e8\u5206\u5207\u9664\u306a\u3089\u3073\u306b\u4eba\u5de5\u8840\u7ba1\u7f6e\u63db\u8853\u3092\u884c\u3063\u305f\u7cbe\u5de3\u816b\u760d\u5f8c\u8179\u819c\u30ea\u30f3\u30d1\u7bc0\u8ee2\u79fb\u306e1\u4f8b.\u3000\u65e5\u6ccc\u4f1a\u8a8c.\u30001999; 90(6): 643-6.<\/li>\n
                                                  15. \u725b\u7530\u3000\u535a\u3001\u6797\u7530\u82f1\u8cc7\u3001\u91d1\u3000\u54f2\u5c07\u3001\u6734\u3000\u52fa\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u4e21\u5074\u540c\u6642\u767a\u751f\u591a\u623f\u6027\u7cbe\u5de3\u4e0a\u4f53\u56a2\u80de\u306e1\u4f8b.\u3000\u65e5\u6ccc\u4f1a\u8a8c.\u30001999; 90(7): 692-5.<\/li>\n
                                                  16. \u91d1\u3000\u54f2\u5c07\u3001\u65b0\u4e95\u3000\u8c4a\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u753b\u50cf\u8a3a\u65ad\u3000\u7d50\u6838\u75c5\u5909\u304c\u793a\u5506\u3055\u308c\u305f\u7cbe\u5de3\u4e0a\u4f53\u77f3\u7070\u5316\u75c7.\u3000\u81e8\u6ccc.\u30001999; 53(9): 729-31.<\/li>\n
                                                  17. \u725b\u7530\u3000\u535a\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u5c0f\u6cc9\u4fee\u4e00\u3001\u7af9\u7530\u5f6c\u4e00\u3001\u91d1\u5150\u3000\u6f54\u3001\u9060\u85e4\u3000\u6e05\u3001\u4ef2\u4e95\u3000\u7406\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u53f3\u6c34\u814e\u75c7\u306b\u3088\u308b\u53f3\u80cc\u90e8\u75db\u304c\u521d\u767a\u75c7\u72b6\u3067\u3042\u3063\u305f\u80c3\u764c (Borrmann IV\u578b)\u306e3\u75c7\u4f8b.\u3000\u6ccc\u7d00.\u30001999; 45(10): 729-32.<\/li>\n
                                                  18. \u7389\u7f6e\u96c5\u5f18\u3001\u4e0a\u7530\u670b\u5b8f\u3001\u5f71\u5c71\u3000\u9032\uff1a\u5869\u9178\u30c6\u30e9\u30be\u30b7\u30f3\u5358\u72ec\u6295\u4e0e\u306b\u3088\u308b\u524d\u7acb\u817a\u80a5\u5927\u75c7\u60a3\u8005\u306e\u8840\u6e05\u8102\u8cea\u306e\u5909\u52d5\u306b\u3064\u3044\u3066.\u3000\u6ccc\u7d00.\u30001999; 45(12): 827-30.<\/li>\n
                                                  19. \u5ca9\u57ce\u79c0\u51fa\u6d19\u3001\u68ee\u3000\u5553\u9ad8\u3001\u68b6\u7530\u6d0b\u4e00\u90ce\u3001\u5409\u7530\u3000\u5fb9\u3001\u5c71\u5185\u6c11\u7537\uff1a\u5de8\u5927\u306a\u8178\u8170\u7b4b\u81bf\u760d\u306e1\u4f8b\uff0e\u6ccc\u7d00.\u30001999; 45(12): 835-837.<\/li>\n<\/ol>\n

                                                    1998\u5e74<\/em><\/h2>\n
                                                      \n
                                                    1. Okada T, Terai A, Terachi T, Okada Y, and Yoshida O: Transurethral electrovaporization of the prostate: preliminary clinical results with pressure-flow analysis. Int J Urol. 1998 Jan; 5(1):55-9.<\/li>\n
                                                    2. Kim CJ, Park KI, Inoue H, Yoshida T, Yoshiki T, Tomoyoshi T, Abe H, Kodama M, Sako H, Nakane Y: Azathioprine-induced megaloblastic anemia with pancytopenia 22 years after living-related renal transplantation. Int J Urol. 1998 Jan; 5(1):100-2.<\/li>\n
                                                    3. Wakabayashi Y, Maeda T, Tomoyoshi T, and Kwok YN: Increase of growth-associated protein-43 immunoreactivity following cyclophosphamide-induced cystitis in rats. Neurosci Lett. 1998 Jan 9; 240(2):89-92.<\/li>\n
                                                    4. Kim CJ, Yuasa T, Kushima R, Tomoyoshi T, Seto A: Antitumor killer lymphocytes in the peripheral blood of a patient with transitional cell carcinoma of the bladder. Int J Urol. 1998 May;5(3):230-6.<\/li>\n
                                                    5. Yoshimura N, Takami N, Ogawa O, Kakehi Y, Okada Y, Fukui T, Yoshida O: Decision analysis for treatment of early stage prostate cancer. Jpn J Cancer Res. 1998 Jun;89(6):681-9.<\/li>\n
                                                    6. Studer UE, Hautmann RE, Hohenfellner M, Mills RD, Okada Y, Rowland RG, Tobisu K, Tsukamoto T: Indications for continent diversion after cystectomy and factors affecting long-term results. Urol Oncol. 1998 Jul-Oct;4(4-5):172-82.<\/li>\n
                                                    7. Yuasa T, Yoshiki T, Tanaka T, Kim CJ, Isono T, Okada Y: Expression of uroplakin Ib and uroplakin III genes in tissues and peripheral blood of patients with transitional cell carcinoma. Jpn J Cancer Res. 1998 Sep;89(9):879-82.<\/li>\n
                                                    8. Wakabayashi Y, Maeda T, Aimi Y, Kwok YN: Increase of low-affinity neurotrophin receptor p75 and growth-associated protein-43 immunoreactivities in the rat urinary bladder during experimentally induced nerve regeneration. J Urol. 1998 Oct;160(4):1513-7.<\/li>\n
                                                    9. Shibata N, Ohmae T, Hoshino N, Minouchi T, Yamaji A, Park KI, Tomoyoshi T, Abe H, Kodama M: Correlation between plasma glucocorticoids and clinical outcomes in living-related renal transplant recipients. Transplant Proc. 1998 Nov;30(7):3053-6.<\/li>\n
                                                    10. \u5c0f\u5cf6\u3000\u4fee\u3001\u6734\u3000\u52fa\u3001\u6ff1\u53e3\u6643\u4e00\uff1a\u5b97\u6559\u7684\u7406\u7531\u306b\u3088\u308a\u8f38\u8840\u3092\u62d2\u5426\u3057\u305f\u8180\u80f1\u764c\u60a3\u8005\u306b\u5bfe\u3059\u308b\u6839\u6cbb\u7684\u8180\u80f1\u6458\u51fa\u8853\u306e\u4e00\u4f8b.\u3000\u81ea\u5df1\u8f38\u8840.\u30001998; 11(1): 145-8.<\/li>\n
                                                    11. \u5409\u7530\u54f2\u4e5f\u3001\u91d1\u3000\u54f2\u5c07\u3001\u5c0f\u897f\u3000\u5e73\u3001\u5409\u8cb4\u9054\u5bdb\u3001\u6734\u3000\u52fa\u3001\u53cb\u5409\u552f\u592b\uff1a\u56de\u8178\u5229\u7528\u8180\u80f1\u62e1\u5927\u8853\u5f8c19\u5e74\u7d4c\u904e\u306e\u56de\u8178\u8180\u80f1\u543b\u5408\u90e8\u817a\u764c\u306e1\u4f8b.\u3000\u65e5\u6ccc\u4f1a\u8a8c.\u30001998; 89(1): 54-7.<\/li>\n
                                                    12. \u5c0f \u6cc9\u4fee\u4e00\u3001\u68b6\u539f\u6b63\u7ae0\u3001\u4f50\u3005\u6728\u5eb7\u6210\u3001\u53e4\u5ddd\u6cf0\u4e09\u3001\u91d1\u5150\u3000\u6f54\u3001\u9060\u85e4\u3000\u6e05\u3001\u5cf6\u888b\u76db\u4e00\u3001\u85e4\u6c5f\u7d14\u4e8c\u3001\u95a2\u5ca1\u654f\u592b\u3001\u4ef2\u4e95\u3000\u7406\u3001\u5897\u7530\u9053\u5f66\u3001\u725b\u7530\u3000\u535a\u3001\u4e0a\u4ec1\u6570\u7fa9\u3001\u9580\u8107\u3000\u5d69\uff1a\u91cd\u75c7 \u8179\u819c\u708e\u306b\u5bfe\u3059\u308b\u30a8\u30f3\u30c9\u30c8\u30ad\u30b7\u30f3\u5438\u7740\u9664\u53bb\u7642\u6cd5\u306e\u73fe\u6cc1\u3068\u65bd\u884c\u6642\u671f\u306b\u3064\u3044\u3066.\u3000\u4eac\u90fd\u533b\u4f1a\u8a8c.\u30001998; 45(2): 45-7.<\/li>\n
                                                    13. \u65b0\u4e95\u3000\u8c4a\u3001\u91d1\u3000\u54f2\u5c07\u3001\u6734\u3000\u52fa\u3001\u53cb\u5409\u552f\u592b\u3001\u963f\u500d\u3000\u5143\u3001\u53e4\u5c4b\u5927\u7950\uff1a\u8840\u6db2\u900f\u6790\u60a3\u8005\u306e\u5168\u8eab\u9ebb\u9154\u4e0b\u624b\u8853\u75c7\u4f8b\u306e\u691c\u8a0e.\u3000\u814e\u3068\u900f\u6790.\u30001998; 45(2): 233-7.<\/li>\n
                                                    14. \u91d1\u3000\u54f2\u5c07\u3001\u6734\u3000\u52fa\u3001\u7247\u5ca1\u3000\u6643\u3001\u6ff1\u53e3\u6643\u4e00\u3001\u6797\u7530\u82f1\u8cc7\u3001\u65b0\u4e95\u3000\u8c4a\u3001\u5409\u8cb4\u9054\u5bdb\u3001\u5c0f\u897f\u3000\u5e73\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u963f\u90e8\u3000\u5143\u3001\u5c0f\u7389\u6b63\u667a\u3001\u8feb\u3000\u88d5\u5b5d\u3001\u4e2d\u6839\u4f73\u5b8f\u3001\u4e95\u4e0a\u3000\u5747\u3001\u53cb\u5409\u552f\u592b\uff1a\u514d\u75ab\u6291\u5236\u6cd5\u5225\u306b\u307f\u305f\u751f\u4f53\u814e\u79fb\u690d38\u4f8b\u306e\u79fb\u690d\u6210\u7e3e\u306e\u691c\u8a0e.\u3000\u814e\u3068\u900f\u6790.\u30001998; 45(3): 367-71.<\/li>\n
                                                    15. \u65b0\u4e95\u3000\u8c4a\u3001\u66fd\u6211\u5f18\u6a39\u3001\u68b6\u539f\u4fe1\u4e4b\u3001\u307b\u304b\uff1a\u91cd\u66f9\u6295\u4e0e\u306b\u3088\u308b\u8840\u6db2\u900f\u6790\u60a3\u8005\u306e\u9178\u5869\u57fa\u7de9\u885d\u80fd\u529b\u306e\u6539\u5584.\u3000\u5927\u962a\u900f\u6790\u7814\u4f1a\u8a8c. 1998, 16(1): 41-4.<\/li>\n
                                                    16. \u65b0\u4e95\u3000\u8c4a\u3001\u66fd\u6211\u5f18\u6a39\u3001\u5c0f\u897f\u3000\u5e73\u3001\u53cb\u5409\u552f\u592b\uff1a\u8edf\u6027\u5c3f\u7ba1\u93e1\u306b\u3088\u308a\u78ba\u8a8d\u3055\u308c\u305f\u56a2\u80de\u6027\u814e\u76c2\u708e\u306e1\u4f8b.\u3000\u65e5\u6ccc\u4f1a\u8a8c.\u30001998; 89(4): 499-502.<\/li>\n
                                                    17. \u6c34\u8c37\u967d\u4e00\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u5409\u7530\u3000\u4fee\u3001\u6238\u4e95\u7530\u4e00\u90ce\u3001\u9ed2\u7530\u4fca\u5409\uff1a\u6297\u764c\u5264\u306eBCG\u306b\u5bfe\u3059\u308b\u6297\u83cc\u4f5c\u7528.\u3000Biotherapy.\u30001998; 12(5): 748-50.<\/li>\n
                                                    18. \u6734\u3000\u52fa\uff1a\u30f4\u30a7\u30c8\u30ca\u30e0\u306e\u6ccc\u5c3f\u5668\u79d1\u533b.\u3000\u81e8\u6ccc.\u30001998; 52(6): 451-3.<\/li>\n
                                                    19. \u5742\u91ce\u7950\u53f8\u3001\u6210\u7530\u5145\u5f18\u3001\u5c0f\u897f\u3000\u5e73\u3001\u6734\u3000\u52fa\u3001\u53cb\u5409\u552f\u592b\uff1a\u30e1\u30c3\u30b7\u30e5\u3092\u7528\u3044\u3066\u4fee\u5fa9\u3057\u305f\u5973\u6027\u8180\u80f1\u30d8\u30eb\u30cb\u30a2\u306e1\u4f8b.\u3000\u6ccc\u5916.\u30001998; 11(7): 833-5.<\/li>\n
                                                    20. \u5f71\u5c71\u3000\u9032\u3001\u4e0a\u7530\u670b\u5b8f\uff1aGrowing teratoma syndrome\u306e1\u4f8b.\u3000\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u96d1\u8a8c. 89(8): 730-733, 1998.<\/li>\n
                                                    21. \u65b0\u4e95\u3000\u8c4a\u3001\u6734\u3000\u52fa\u3001\u5409\u8cb4\u9054\u5bdb\u3001\u4f50\u4e95\u7fa9\u548c\uff1a\u6ccc\u5c3f\u5668\u79d1\u624b\u8853\u306b\u304a\u3051\u308b\u5e0c\u91c8\u5f0f\u81ea\u5df1\u8840\u8f38\u8840\u306e\u7d4c\u9a13.\u3000\u81e8\u6ccc. 1998; 52(9): 663-6.<\/li>\n
                                                    22. \u5449\u3000\u79c0\u8ce2\u3001\u6c34\u8c37\u967d\u4e00\u3001\u7b67\u3000\u5584\u884c\u3001\u4e2d\u6751\u82f1\u4e8c\u90ce\u3001\u5149\u68ee\u5065\u4e8c\u3001\u9ad8\u6a4b\u3000\u6bc5\u3001\u5bfa\u5730\u654f\u90ce\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u5409\u7530\u3000\u4fee\uff1a\u814e\u764c\u7d30\u80de\u306b\u304a\u3051\u308b\u4e3b\u8981\u7d44\u7e54\u9069\u5408\u6297\u539f\u3001\u63a5\u7740\u5206\u5b50\u306e\u767a\u73fe\u3068Interferon-\u03b1\uff0cCimetidine\u306b\u3088\u308b\u4fee\u98fe.\u3000\u6ccc\u7d00.\u30001998; 44(9): 621-6.<\/li>\n
                                                    23. \u725b\u7530\u3000\u535a\u3001\u91d1\u3000\u54f2\u5c07\u3001\u6797\u7530\u82f1\u8cc7\u3001\u5c0f\u897f\u3000\u5e73\u3001\u6734\u3000\u52fa\u3001\u53cb\u5409\u552f\u592b\u3001\u5ca1\u7530\u88d5\u4f5c\uff1a\u7d50\u7bc0\u6027\u786c\u5316\u75c7\u306b\u814e\u8840\u7ba1\u7b4b\u8102\u80aa\u816b\u3001\u80ba\u30ea\u30f3\u30d1\u7ba1\u7b4b\u816b\u75c7\u3001\u722a\u4e0b\u7dda\u7dad\u816b\u3092\u5408\u4f75\u3057\u305f1\u4f8b.\u3000\u65e5\u6ccc\u4f1a\u8a8c.\u30001998\uff1b89(10): 850-3.<\/li>\n
                                                    24. \u91d1\u8c37\u3000\u52f2\u3001\u5965\u6751\u548c\u5f18\u3001\u6d45\u59bb\u3000\u9855\u3001\u5965\u91ce\u3000\u535a\u3001\u5ddd\u559c\u7530\u7766\u53f8\u3001\u7b67\u3000\u5584\u884c\u3001\u5bfa\u5730\u654f\u90ce\u3001\u5ca1\u7530\u88d5\u4f5c\u3001\u5409\u7530\u3000\u4fee\uff1a\u9577\u671f\u8840\u6db2\u900f\u6790\u60a3\u8005\u306e\u5c3f\u8def\u306b\u540c\u6642\u6027\u591a\u767a\u6027\u306b\u767a\u751f\u3057\u305f\u6d78\u6f64\u6027\u79fb\u884c\u4e0a\u76ae\u764c\u306e1\u4f8b.\u3000\u6ccc\u7d00.\u30001998; 44(11): 821-4.<\/li>\n
                                                    25. \u4e0a\u4ec1\u6570\u7fa9\u3001\u5c0f\u6cc9\u4fee\u4e00\u3001\u5ca1\u7530\u88d5\u4f5c\uff1aMRI\u304c\u8a3a\u65ad\u306b\u6709\u7528\u3067\u3042\u3063\u305fS\u72b6\u7d50\u8178\u8180\u80f1\u763b\u306e1\u4f8b.\u3000\u6ccc\u7d00.\u30001998; 44(12): 879-882.<\/li>\n
                                                    26. \u5c71\u5185\u6c11\u7537\u3001\u5409\u7530\u3000\u5fb9\u3001\u5ca9\u57ce\u79c0\u51fa\u6d19\u3001\u68ee\u3000\u5553\u9ad8\uff1a\u518d\u767a\u6027\u8180\u80f1\u764c\u306b\u5bfe\u3059\u308bBCG\u8180\u80f1\u5185\u6ce8\u5165\u7642\u6cd5\u306e\u518d\u767a\u4e88\u9632\u52b9\u679c\u4e88\u6e2c\u306e\u305f\u3081\u306e\u6cbb\u7642\u524d\u672b\u68a2\u8840\u30ea\u30f3\u30d1\u7403\u30b5\u30d6\u30bb\u30c3\u30c8\u53ca\u3073\u5358\u7403\u6570\u306b\u3088\u308b\u5224\u5225\u95a2\u6570\u5f0f\uff0eBCG\uff65BRM\u7642\u7814\u4f1a\u8a8c. 1998; 22; 53-60.<\/li>\n<\/ol>\n<\/div>\n","protected":false},"excerpt":{"rendered":"2022\u5e74 \u03b3-Glutamylcyclotransferase, a novel regulator of HIF-1\u03b1 expression, triggers aerobic glycolysis. Taniguc […]","protected":false},"author":1,"featured_media":0,"parent":433,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/sumsuro.jp\/wp_sumsuro\/wp-json\/wp\/v2\/pages\/435"}],"collection":[{"href":"https:\/\/sumsuro.jp\/wp_sumsuro\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sumsuro.jp\/wp_sumsuro\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sumsuro.jp\/wp_sumsuro\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sumsuro.jp\/wp_sumsuro\/wp-json\/wp\/v2\/comments?post=435"}],"version-history":[{"count":5,"href":"https:\/\/sumsuro.jp\/wp_sumsuro\/wp-json\/wp\/v2\/pages\/435\/revisions"}],"predecessor-version":[{"id":840,"href":"https:\/\/sumsuro.jp\/wp_sumsuro\/wp-json\/wp\/v2\/pages\/435\/revisions\/840"}],"up":[{"embeddable":true,"href":"https:\/\/sumsuro.jp\/wp_sumsuro\/wp-json\/wp\/v2\/pages\/433"}],"wp:attachment":[{"href":"https:\/\/sumsuro.jp\/wp_sumsuro\/wp-json\/wp\/v2\/media?parent=435"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}